PROTOCOL AMENDMENT APPROVA L
CONFIDENTIA L
This clinical study is being sponsored globally by F. Hoffmann -La [COMPANY_002] Ltd of Basel, 
Switzerland. However, it may be implemented in individual countries by [CONTACT_26702]’s local affiliates, 
including Genentech, Inc. in the [LOCATION_002].  The information contained in this document, especially 
any unpublished data, is the property of F. Hoffmann -La [COMPANY_002] Ltd (or under its control) and therefore 
is provided to you in confidence as an investigator, potential investigator, or consultant, for review by 
[CONTACT_10825], your staff, and an applicable Ethics Committee or Institutional Review Board.  It is understood that 
this information wil l not be disclosed to others without written authorization from [COMPANY_002] except to the 
extent necessary to obtain informed consent from persons to whom the drug may  be administered.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
Protocol GO29438 , Version 7PROTOCOL
TITLE: A PHA SE III, OPEN -LABEL, RA NDOMIZED 
STUDY OF ATEZOLIZUMA B (MPD L3280A , 
ANTI–PD-L1ANTIBODY) IN COMBINA TION WITH 
CARBOPLA TIN OR CISPL ATINPEMETREXED
COMPA RED WITH CARBOPLA TIN OR 
CISPLA TINPEMETREXED IN PATIENTS WHO 
ARE CHEMOTHERA PY-NAIVE A ND HA VE 
STAGEIV NON -SQUAMOUS NON –SMA LLCELL 
LUNG CA NCER
PROTOCOL NUMBER: GO29438
VERSION NUMBER: [ADDRESS_76274] NUMBER: 2015 -003605 -42
IND NUMBER: [ADDRESS_76275] NUMBER: [STUDY_ID_REMOVED]
TEST PRODUCT: Atezolizumab (RO5541267)
MEDICA L MONITOR: , M.D.
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
DATE FINA L: Version 1:  19 September 2015
DATESAMENDED: Version 2:  24 November 2015
Version 3:  9 June 2016
Version 4:  10 October 2016
Version 5:  9 October 2017
Version 6:  2November 2018
Version 7:  See electronic date stamp below.
 
11-Feb-2020 00:33:32
Title
Approver's Name
[CONTACT_26862] (UTC)

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
2/Protocol GO29438, Version 7PROTOCOL A MENDMENT, VERSION 7:
RATIONA LE
Proto col GO29438 has been amended to reflect a change in the definition for the end of 
study and to align with curren t atezolizumab risk language . Changes to the protocol, 
along with a rationale for each change, are summarized below .
Background information on atezolizumab has been updated to account for additional 
approved indications (Section 1.2).
Language has been added to clarify that, after withdrawal of consent for 
participation in the [COMPANY_002] Clinical Repository (RCR), remaining RCR samples will 
be destroyed or will no longer be linked to the patient (Section [IP_ADDRESS]).
The list of atezolizumab risks has been updated to include myositis for consistency 
with the list of identified risks in the Atezolizumab Investigator's Brochure 
(Section 5.1.1).
To align with the Atezolizumab Investigator 's Brochure, Version 15 , 
"immune -related" has been changed to "immune -mediated" when describing events 
associated with atezolizumab (Section s [IP_ADDRESS] , 4.4.2, 4.6.2, 5.1.1, [IP_ADDRESS], 5.1.9, 
andAppendix 15).
To address a request by [CONTACT_70080] (ANSM) , systemic immune activation has been replaced by 
[CONTACT_70081] (Section 5.1. 1) and the management 
guidelines for systemic immune activation have been replaced with management 
guidelines for hemophagocytic lymphohistiocytosis and macrop hage activation 
syndrome ( Section 5.1.7 has been deleted; management guidelines have been 
added to Appendix 15 ).  In addition, systemic immune activation has been removed 
from the list of adverse events of special interest (Section 5.2.3 ).
Language has been updated to indicate that therapeutic or elective abortions are 
not considered adverse events unless performed because of an underlying maternal 
or embryofetal toxicity.  In such cases, the underlying toxicity should be reported as 
a serio us adverse event.  Language has also been added to clarify that all abortions 
are to be reported on the paper Clinical Trial Pregnancy Reporting Form
(Section [IP_ADDRESS]).
Language has been added to indicate that the study will comply with applicable local, 
regional, and national laws (Section 8.1).
The Appendix 11 (Anaphylaxis Precautions) has been modified to remove the 
requirement for use of a tourniquet.  The application of a tourniquet is no longer 
recommended due to the limited therapeutic benefit and ri sk of losing time for more 
important measures (Ring J, Beyer K, Biedermann T, et al. Allergo J Int. 
2014;23:96 112).
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
3/Protocol GO29438 , Version 7To address a request by [CONTACT_70082], the atezolizumab adverse event 
management guidelines have been revised to add laboratory (e.g., B -type natriuretic 
peptide) and cardiac imaging abnormalities as signs or symptoms that are 
suggestive of myocarditis (Appendix 15).
Guidelines for managing patients who experience atezolizumab -associated adverse 
events have been revised to include myositis (Appendix 15) .
The management guidelines for infusion -related reactions associated with 
atezolizumab have been updated to include guidelines for cytokine -release 
syndrome (CRS) to align with the definition, grading, and management of CRS 
reflected in a rec ent publication (Lee et al. 2019) (Appendix 15).
Additional minor changes have been made to improve clarity and consistency.  
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol.
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
4/Protocol GO29438, Version 7TABLE OF CONTENTS
PROTOCOL AMENDMENT A CCEPTANCE FORM .......................................... [ADDRESS_76276]-Line Treatment for Advanced Non Small 
Cell Lung Cancer with an EGFR Mutation or ALK 
Rearrangement ...................................................................... [ADDRESS_76277] -Line NSCLC .................... 31
1.1.4 Pemetrexed ........................................................................... 31
[IP_ADDRESS] Pemetrexed plus Platinum Compounds in 
First-Line NSCLC .................................................................. 31
[IP_ADDRESS] Pemetrexed Maintenance Therapy in NSCLC ....................... 32
1.1.5 Targeted Therapy for NSCLC ................................................ 33
1.2 Background on Atezolizumab ................................................ 33
1.2.1 Summary of Nonclinical Studies ............................................ 34
1.3 Clinical Experience with Atezolizumab .................................. 34
1.3.1 Ongoing Clinical Studies ........................................................ 34
1.3.2 Clinical Safety ........................................................................ 35
[IP_ADDRESS] Single -Agent Clinical Safety in Patients with 
NSCLC in Study PCD4989g .................................................. 35
[IP_ADDRESS] Single -Agent Clinical Safety in Patients with 
NSCLC in the POPLAR Study ............................................... 37
[IP_ADDRESS] Clinical Safety in Combination Platinum- Based 
Doublet Chemotherapy .......................................................... 39
1.3.3 Clinical Activity ....................................................................... 41
[IP_ADDRESS] Single -Agent Clinical Activity in Patients with 
NSCLC in Study PCD4989g .................................................. 41
[IP_ADDRESS] Single -Agent Clinical Activity in Patients with 
NSCLC in the POPLAR Study ............................................... 42

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
5/Protocol GO29438 , Version [IP_ADDRESS] Clinical Efficacy in Combination with 
Platinum -Based Doublet Chemotherapy in 
Patients with NSCLC ............................................................. 44
1.3.4 Clinical Pharmacokinetics and Immunogenicity ..................... 44
1.3.5 Rationale for Atezolizumab Dosage ...................................... 44
1.4 Study Rationale and Benefit -Risk Assessment ...................... 45
1.4.1 Rationale for Testing Atezolizumab in 
Combination with Carboplatin or Cisplatin and 
Pemetrexed ........................................................................... 46
2. OBJECTIVES .............................................................................................. 48
2.1 Efficacy Objecti ves................................................................ 48
2.1.1 Co-Primary Efficacy Objectives ............................................. 48
2.1.2 Secondary Efficacy Objectives .............................................. 48
2.2 Safety Objectives ................................................................... 48
2.3 Pharmaco kinetic Objectives .................................................. 49
2.4 Exploratory Objectives ........................................................... 49
3. STUDY DESIGN ......................................................................................... 50
3.1 Description of Study .............................................................. 50
3.1.1 Independent Data Monitoring Committee .............................. 52
3.2 End of Study and Length of Study ......................................... 53
3.3 Rationale for Study Design .................................................... 53
3.3.1 Rationale for Testing Atezolizumab in Patients 
with PD -L1Unselected NSCLC ............................................ 53
3.3.2 Rationale for Control Arm ...................................................... 54
3.3.3 Rationale for Open -Label Study ............................................ 54
3.3.4 Rationale for Progression -Free Survival and 
Overall Survival as Co -Primary Endpoints ............................. 55
3.3.5 Rationale for Allowing Patie nts to Continue 
Atezolizumab Treatment until Loss of Clinical 
Benefit ................................................................................... 55
3.3.6 Rationale for Patient -Reported Outcome 
Assessments ......................................................................... 56
3.3.7 Rationale for Collection of Archival and/or Fresh 
Tumor Specimens ................................................................ .56
3.3.8 Rationale for Blood Sampling for Biomarkers ........................ 57

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
6/Protocol GO29438 , Version 73.4 Outcome Measures ............................................................... 57
3.4.1 Efficacy Outcome Measures .................................................. 57
[IP_ADDRESS] Co-Primary Efficacy Outcome Measures ............................... 57
[IP_ADDRESS] Secondary Efficacy Outcome Measures ................................ 57
3.4.2 Safety Outcome Measures .................................................... 58
3.4.3 Pharmacokinetic Outcome Measures .................................... 58
3.4.4 Exploratory Outcome Measures ............................................ 58
4. MATERIALS AND MET HODS .................................................................... 59
4.1 Patients.................................................................................. 59
4.1.1 Inclusion Criteria .................................................................... 59
4.1.2 Exclusion Criteria ................................................................... 62
[IP_ADDRESS] Cancer -Specific Exclusions ................................................... 62
[IP_ADDRESS] General Medical Exclusions .................................................. 63
[IP_ADDRESS] Exclusion Criteria Related to Medications ............................. 64
[IP_ADDRESS] Exclusion Criteria Related to Chemotherapy ......................... 65
4.2 Method of Treatment Assignment and Blinding ..................... 65
4.3 Study Treatment .................................................................... 66
4.3.1 Formulation, Packaging, an d Handling .................................. 66
[IP_ADDRESS] Atezolizumab ......................................................................... 66
[IP_ADDRESS] Carboplatin or Cisplatin Pemetrexed .................................. 66
4.3.2 Dosage, Administration, and Compliance .............................. 67
[IP_ADDRESS] Atezolizumab ......................................................................... 68
[IP_ADDRESS] Pemetrexed Carboplatin or Cisplatin .................................. [ADDRESS_76278]- Study Access to Atezolizumab ...................................... 71
4.4 Concomitant Therapy ............................................................ 72
4.4.1 Permitted Therapy ................................................................ .72
4.4.2 Cautionary Therapy for Atezolizumab -Treated 
Patients.................................................................................. 73
4.4.3 Prohibited Therapy ................................................................ 73
4.5 Study Assessments ............................................................... 74
4.5.1 Informed Consent Forms and Screening Log ........................ 74
4.5.2 Medical History and Demographic Data ................................ 74

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
7/Protocol GO29438 , Version 74.5.3 Physical Examinations ........................................................... 75
4.5.4 Vital Signs .............................................................................. 75
4.5.5 Tumor and Response Evaluations ......................................... 76
4.5.6 Laboratory Assessments and Biomarker 
Samples ................................................................................. 77
4.5.7 Tumor Tissue Samples .......................................................... 79
[IP_ADDRESS] Archival or Freshly Collected Tumor Tissue 
Samples at Screening ............................................................ 79
[IP_ADDRESS] Optional Tumor Samples at the Time of 
Radiographic Progression ..................................................... 79
[IP_ADDRESS] Tumor Samples at Other Timepoints ..................................... 80
[IP_ADDRESS] Use and Storage of Remaining Samples from 
Study -Related Procedures ..................................................... 80
4.5.8 Anti-Therapeutic Antibody Testing ......................................... 80
4.5.9 Electrocardiograms ................................................................ 81
4.5.10 Patient -Reported Outcomes .................................................. 81
4.5.11 Samples for [COMPANY_002] Clinical Repository .................................. 83
[IP_ADDRESS] Overview of the [COMPANY_002] Clinical Repository ............................ 83
[IP_ADDRESS] Approval by [CONTACT_33427] .................................................................. 83
[IP_ADDRESS] Sample Collection .................................................................. 83
[IP_ADDRESS] Confidentiality ........................................................................ 84
[IP_ADDRESS] Consent to Participate in the [COMPANY_002] Clinical 
Repository ............................................................................. 85
[IP_ADDRESS] Withdrawal from the [COMPANY_002] Clinical Repository ..................... 85
[IP_ADDRESS] Monitoring and Oversight ....................................................... 85
4.5.12 Timing of Assessments .......................................................... 86
[IP_ADDRESS] Screening and Baseline Assessments .................................. 86
[IP_ADDRESS] Assessments during Treatment ............................................. 86
[IP_ADDRESS] Assessments at Study Drug Discontinuation Visit ................. 87
[IP_ADDRESS] Follow -Up Assessments ........................................................ 87
[IP_ADDRESS] Assessments at Unplanned Visits ......................................... 88
4.6 Patient, Treatment, Study, and Site 
Discontinuation ...................................................................... 88
4.6.1 Patient Discontinuation .......................................................... 88

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
8/Protocol GO29438 , Version 74.6.2 Study Treatment Discontinuation ........................................... 89
4.6.3 Study and Site Discontinuation .............................................. 91
5. ASSESSMENT OF SAF ETY....................................................................... 91
5.1 Safety Plan ............................................................................ 91
5.1.1 Risks Associated with Atezolizumab ..................................... 92
5.1.2 Risks Associated with Pemetrexed 
Administration ........................................................................ 92
5.1.3 Risks Associated with Carboplatin ......................................... 92
5.1.4 Risks Associated with Cisplatin Chemotherapy ..................... 93
5.1.5 General Plan to Manage Safety Concerns ............................ 93
[IP_ADDRESS] Monitoring .............................................................................. 93
5.1.6 Dose Modification .................................................................. 93
[IP_ADDRESS] General Notes Regarding Dose Modification ......................... 93
[IP_ADDRESS] Atezolizumab Dose Modification and 
Management of Specific Adverse Events .............................. 94
5.1.7 Pemetrexed Dose Modification and Management 
of Specific Adverse Events .................................................... 95
5.1.8 Platinum Chemotherapy Dose Modification and 
Management of Specific Adverse Events .............................. 97
[IP_ADDRESS] Cisplatin ................................................................................. 97
[IP_ADDRESS] Carboplatin ............................................................................ 99
5.1.9 Potentia l Overlappi[INVESTIGATOR_70034] .......................................... 100
5.2 Safety Parameters and Definitions ...................................... 101
5.2.1 Adverse Events ................................................................... 101
5.2.2 Seriou s Adverse Events (Immediately Reportable 
to the Sponsor) .................................................................... [ADDRESS_76279] (Immediately 
Reportable to the Sponsor) .................................................. 103
5.3 Methods and Timing for Capturing and 
Assessing Safety Parameters .............................................. 103
5.3.1 Adverse Event Reporting Period ......................................... 104
5.3.2 Eliciting Adverse Event Information ..................................... 104
5.3.3 Assessment of Severity of Adverse Events ......................... 104
5.3.4 Assessment of Causality of Adverse Events ....................... 105
5.3.5 Procedures for Recording Adverse Events .......................... 106

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
9/Protocol GO29438 , Version [IP_ADDRESS] Diagnosis versus Signs and Symptoms ............................... 106
[IP_ADDRESS] Adverse Events That are Secondary to Other 
Events.................................................................................. 106
[IP_ADDRESS] Persistent or Recurrent Adverse Events .............................. 107
[IP_ADDRESS] Abnormal Laboratory Values ............................................... 107
[IP_ADDRESS] Abnormal Vital Sign Values ................................................. 108
[IP_ADDRESS] Abnormal Liver Function Tests ............................................ 108
[IP_ADDRESS] Deaths ................................................................................. 109
[IP_ADDRESS] Preexisting Medical Conditions ............................................ 109
[IP_ADDRESS] Worsening of NSCLC .......................................................... 110
[IP_ADDRESS] Hospi[INVESTIGATOR_26589] ........................ 110
[IP_ADDRESS] Adverse Events Associated with an Overdose or 
Error in Drug Administration ................................................ 110
[IP_ADDRESS] Patient -Reported Outcome Data ......................................... [ADDRESS_76280] ................... 112
[IP_ADDRESS] Events That Occur prior to Study Drug Initiation .................. 112
[IP_ADDRESS] Events That Occur after Study Drug Initiation ...................... 112
5.4.3 Reporting Requirements for Pregnancies ............................ 113
[IP_ADDRESS] Pregnancies in Female Patients .......................................... 113
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients ............... 113
[IP_ADDRESS] Abortions ............................................................................. 114
[IP_ADDRESS] Congenital Anomalies and Birth Defects ............................. 114
5.5 Follow -Up of Patients after Adverse Events ........................ 114
5.5.1 Investigator Follow -Up......................................................... 114
5.5.2 Sponsor Follow -Up.............................................................. 115
5.6 Adverse Events That Occur after the Adverse 
Event Reporting Period ........................................................ 115
5.7 Expedited Reporting to Health Authorities, 
Investigators, Institutional Review Boards, and 
Ethics Committees ............................................................... 115

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
10/Protocol GO29438 , Version 76. STATISTICAL CONSI DERATIONS AND ANALYS IS PLAN ..................... [ADDRESS_76281] of Study .......................................... 118
6.3 Summaries of Treatment Group Comparability ................... 118
6.4 Efficacy Analyses ................................................................ 118
6.4.1 Co-Primary Efficacy Endpoints ............................................ 118
6.4.2 Secondary Efficacy Endpoints ............................................. 120
[IP_ADDRESS] Objective Response Rate .................................................... 120
[IP_ADDRESS] Duration of Response .......................................................... 120
[IP_ADDRESS] Overall Survival Rate at Landmark Timepoints .................... 120
[IP_ADDRESS] Patient -Reported Outcomes ................................................ 120
6.4.3 Handling of Missing Data ..................................................... 121
6.5 Safety Analyses ................................................................... 121
6.6 Pharmacokinetic Analyses ................................................... 122
6.7 Exploratory Analyses ........................................................... 122
6.7.1 Exploratory Analyses of Progression -Free 
Survival ................................................................................ 122
[IP_ADDRESS] Progression-Free Survival Rate at Landmark 
Timepoints ........................................................................... 122
[IP_ADDRESS] NonProtocol -Specified Anti -Cancer Therapy ..................... 122
[IP_ADDRESS] Subgroup Analysis ............................................................... 123
[IP_ADDRESS] Sensitivity Analyses ............................................................. 123
6.7.2 Exploratory Analyses of Overall Survival ............................. 123
[IP_ADDRESS] Loss to Follow -Up................................................................ 123
[IP_ADDRESS] Subgroup Analysis ............................................................... 123
[IP_ADDRESS] Overall Survival Rate at 3 -Year Landmark .......................... 124
[IP_ADDRESS] Milestone Overall Survival Analysis ..................................... 124
[IP_ADDRESS] NonProtocol -Specified Anti -Cancer Therapy ..................... 124
6.7.3 Exploratory Biomarker Analysis ........................................... 124
6.7.4 EQ-5D-5L Health Status Data ............................................. 124
6.7.5 Exploratory Patient -Reported Outcome Analyses ............... 125
6.8 Interim Analyses .................................................................. 125
6.8.1 Planned Interim Analyses .................................................... 125
6.8.2 Optional Interim Analysis ..................................................... 126

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
11/Protocol GO29438 , Version 76.[ADDRESS_76282] or Ethics Committee .................. 131
8.4 Confidentiality ...................................................................... 131
8.5 Financial Disclosure ............................................................ 132
9. STUDY DOCUMENTATION, MONI TORING, AND 
ADMINISTRATION ................................................................................... 132
9.1 Study Documentation .......................................................... 132
9.2 Protocol Deviations .............................................................. 132
9.3 SiteInspections ................................................................... 133
9.4 Administrative Structure ....................................................... 133
9.5 Publication of Data and Protection of 
Trade Secrets ...................................................................... 133
9.6 Protocol Amendments ......................................................... 134
10. REFERENCES ......................................................................................... 135

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
12/Protocol GO29438 , Version 7LIST OF TA BLES
Table 1 Randomized Phase III Studies in Patients with Previously 
Untreated NSCLC ....................................................................... 29
Table 2 Study PCD4 989g:  Adverse Events with Frequency 10% of 
Patients for All Grades ................................................................ [ADDRESS_76283] 10% of Patients in 
thePOPLAR Study ..................................................................... 38
Table 4 Study GP28328:  All Reported Adverse Events .......................... 40
Table 5 Patients with NSCLC in Study PCD4989g:  Investigator-
Assessed Confirmed Objective Response Rate by [CONTACT_70083]-L1 Expression, Duration of Response, and 6 -Month 
Progression- Free Survival Rates (per RECIST Version 1.1) ....... 42
Table 6 Efficacy Results in the POPLAR Study:  Intent -to-Treat 
Popul ation ................................................................................... 43
Table 7 Study GO29438 Treatment Arms ................................................ 51
Table 8 Premedication for Pemetrexed .................................................... 67
Table 9 Treatment Regimen for Pemetrexed Platinum -Based 
Chemotherapy ............................................................................ [ADDRESS_76284] and Subsequent Infusions 
ofAtezolizumab .......................................................................... 69
Table 11 Vital Sign Measurements at Cycle 1 and All Subsequent 
Cycles ......................................................................................... 75
Table 12 Pemetrexed Dose Modification for Hematologic Toxicities ......... 95
Table 13 Pemetrexed Dose Modification for Non -Hematologic 
Toxicities ..................................................................................... 96
Table 14 Cisplatin Dose Modification for Hematologic Toxicities ............... 97
Table 15 Cisplatin Dose Modification for Non -Hematologic Toxicities 
(Excluding Neurotoxicity) ............................................................ 98
Table 16 Cisplatin Dose Modification for Associated Neurotoxicity ........... 98
Table 17 Carboplatin Dose Modification for Hematologic Toxicities .......... 99
Table 18 Carboplatin Dose Modification on the Basis of 
Non-Hematologic Toxicities in the Preceding Cycle .................. 100
Table 19 Adverse Event Severity Grading Scale for Events Not 
Specifically Listed in NCI CTCAE ............................................. 105
Table 20 Analysis Timing and Stoppi[INVESTIGATOR_70035] .....126

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
13/Protocol GO29438 , Version 7LIST OF FIGURES
Figure 1 Study Schema ............................................................................. 50
Figure 2 Criteria for Continuing A tezolizumab in Presence of 
Increased Radiographic Tumor Size (Atezolizumab Arms) ......... [ADDRESS_76285] OF A PPEN DICES
Appendix 1 Schedule of Assessments ......................................................... 143
Append ix2 Schedule of Pharmacokinetic, Biomarker, and Anti -
Therapeutic Antibody Assessments .......................................... 149
Appendix 3 American Joint Committee on Cancer Non Small Cell Lung 
Cancer Staging, 7th Edition ...................................................... 152
Appendix 4 Response Evaluation Criteria in Solid Tumors:  
Modified Excerpt from Original Publication ............................... 154
Appendix 5 Modified Response Evaluation Criteria in Solid Tumors ........... 166
Appendix 6 AntiPD-L1 Immunohistochemistry ........................................... 173
Appendix 7 EORTC QLQ -C30..................................................................... 174
Appendix 8 EORTC QLQ -LC13 ................................................................... 176
Appendix 9 EQ-5D-5L.................................................................................. 177
Appendix 10 Eastern Cooperat ive Oncology Group Performance Status 
Scale ......................................................................................... 180
Appendix 11 Anaphylaxis Precautions ........................................................... 181
Appendix 12 Preexisting Autoimmune Diseases ........................................... 182
Appendix 13 Symptoms in Lung Cancer ........................................................ 183
Appendix 14 Additional Guidance on Chemotherapy Administration ............. 186
Appendix 15 Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with 
Atezolizumab ............................................................................ 188

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
14/Protocol GO29438 , Version 7PROTOCOL AMENDMENT ACCEPTA NCE FORM
TITLE: A PHA SE III, OPEN -LABEL, RA NDOMIZED 
STUDY OF ATEZOLIZUMA B (MPD L3280A , 
ANTI–PD-L1ANTIBODY) IN COMBINA TION WITH
CARBOPLA TIN OR CISPL ATINPEMETREXED
COMPA RED WITH CARBOPLA TIN OR 
CISPLA TINPEMETREXED IN PATIENTS WHO 
ARE CHEMOTHERA PY-NAIVE A ND HA VE 
STAGEIV NON -SQUAMOUS NON –SMA LLCELL 
LUNG CA NCER
PROTOCOL NUMBER: GO29438
VERSION NUMBER: [ADDRESS_76286] NUMBER: 2015 -003605 -42
IND NUMBER: [ADDRESS_76287]: Atezolizumab (RO5541267)
MEDICA L MONITOR: , M.D.
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
I agree to conduct the study in accordance with the current protocol.
Principal Investigator’s Name (print)
Principal Investigator’s Signature [CONTACT_33505].  Please return a copy to 
the Sponsor or their designee.  Contact [CONTACT_70084].

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
15/Protocol GO29438 , Version 7PROTOCOL SYNOPSIS
TITLE: A PHA SE III, OPEN -LABEL, RA NDOMIZED STUD Y 
OFATEZOLIZUM AB (MPDL32 80A, ANTI–PD-L1 ANTIBODY) 
INCOMBINA TION WITH CA RBOPLA TIN OR 
CISPL ATINPEM ETREXED COMPA RED WITH CARBOPL ATIN 
OR CISPL ATINPEM ETREXED IN PATIENTS WHO A RE 
CHEMOTHERA PY-NAIVE A ND HA VE ST AGEIV 
NON -SQU AMOUS NON– SMALL CELL LUNG CA NCER
PROTOCOL NUMBER: GO29438
VERSION NUMBER: [ADDRESS_76288] NUMBER: 2015- 003605 -42
IND NUMBER: [ADDRESS_76289]: Atezolizumab (RO5541267)
PHASE: III
INDIC ATION: Non-squamous non small cell lung cancer
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
Objectives and Endpoints
This study will evaluate the efficacy , safety, and pharmacokinetics of atezolizumab in 
combination with carboplatin or cisplatin pemetrexed compared with carboplatin or 
cisplatin pemetrexed in patients who are chemotherapy -naive and have Stage IV 
non-squamous non small cell lung cancer (NSCLC).  Specific objectives and corresponding 
endpoints for the study are outlined below.
Efficacy Objectives
The co -primary objectives of this study are:
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_1697] -assessed 
progression -free survival (PFS) according to Response Evaluation Criteria in Solid Tumors 
Version 1.1 (RECIST v1.1)
To eva luate the efficacy  of atezolizumab as measured by [CONTACT_70085] (OS)
The secondary efficacy  objectives for this study are:
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_1697] -assessed objective 
response rate (ORR) according to RECIST v1 .1
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_1697] -assessed duration of 
response (DOR) according to RECIST v1.1
To evaluate the OS rate at 1 and 2 years
To determine the impact of atezolizumab as measured by [CONTACT_70086] -reported lung cancer sy mptoms of cough, dy spnea (single -item and multi -item 
subscales), chest pain, or arm/shoulder pain, using the European Organization for 
theResearch and Treatment of Cancer (EORTC) Quality -of-Life Questionnaire Core 30 
(QLQ -C30) and the supplemental lung cancer module (QLQ -LC13)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
16/Protocol GO29438 , Version 7To determine the impact of atezolizumab as measured by [CONTACT_70087] -reported lung cancer symptoms (chest pain, dyspnea, and cough) scores using the 
Symptoms in Lung Cancer (SILC) scale sy mptom s everity scores
Safety Objectives
The safety  objectives for this study are:
To evaluate the safety and tolerability of atezolizumab when given in combination with 
carboplatin or cisplatin pemetrexed or as maintenance therapy with pemetrex ed alone
To evaluate the incidence and titers of anti -therapeutic antibody against atezolizumab and 
to explore the potential relationship of the immunogenicity response with pharmacokinetics, 
safety, and efficacy
Pharmacokinetic Objectives
The PK objectiv es for this study are:
To characterize the pharmacokinetics of atezolizumab when given in combination with 
carboplatin or cisplatin pemetrexed or pemetrexed alone
To characterize the pharmacokinetics of carboplatin when given in combination with 
atezoliz umab and pemetrexed
To characterize the pharmacokinetics of cisplatin when given in combination with 
atezolizumab pemetrexed
To characterize the pharmacokinetics of pemetrexed when given in combination with 
atezolizumab carboplatin or cisplatin
Exploratory Objectives
The exploratory objectives for this study are:
To evaluate the PFS rate at 6 -month and 1- year landmark timepoints
To evaluate the OS rate at 3 years in each treatment arm
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_70088] -assessed 
PFS according to RECIST v1.1 in subgroups based on demographic and baseline 
characteristics
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_70089]
To evaluate the relationship between biomarkers in tumors and bloo d (including but not 
limited to programmed death ligand 1 (PD- L1), programmed death 1 (PD-1), somatic 
mutations and others), as defined by [CONTACT_9064] (IHC), quantitative reverse 
transcriptase polymerase chain reaction (qRT -PCR), next -generation sequencing, and/or 
other methods and measures of efficacy
To assess predictive, prognostic, and pharmacodynamic exploratory biomarkers in archival 
and/or fresh tumor tissue and blood and their association with dis ease status, mechanisms 
of resistance, and/or response to study treatment
To evaluate and compare patient’s health status as assessed by [CONTACT_70090] 
5Dimensions 5 -Level questionnaire to generate utility scores for use in economic models 
for reimbursement
To determine the impact of atezolizumab in each of the treatment comparisons as 
measured by [CONTACT_70091] -reported outcomes (PROs) of health -related 
qualit y of li fe, lung c ancer related s ymptoms, and health status as assessed by [CONTACT_70092] -C30 and QLQ -LC13
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
17/Protocol GO29438 , Version 7Study Design
Description of Study
This is a randomized, Phase III, multicenter, open -label study (IMpower 132) designed to 
evaluate the safety and efficacy of atezolizumab in combination with cisplatin or 
carboplatin pemetrexed com pared with treatment with cisplatin or carboplatin pemetrexed in 
patients who are chemotherapy -naive and have Stage IV non -squamous NSCLC.
Eligible patients will be stratified by [CONTACT_4321] (male vs. female), smoking status (never vs. current 
and/or former), Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1) and 
chemotherapy regimen (carboplatin vs. cisplatin) and randomized by a 1:1 ratio to receive one 
of the following treatment regimens:
Induction phase (four or six 21 -day cycles):
Arm A: atezolizumab carboplatin or cisplatin pemetrexed
Arm B:  carboplatin or cisplatin pemetrexed
Maintenance phase (21 -day c ycles):
Arm A:  atezolizumab pemetrexed
Arm B:  pemetrexed
Treatment with chemotherapy (both in Arm A and B) should be discontinued in all patients who 
exhibit evidence of progressive disease by [CONTACT_393] 1.1.  During induction or maintenance 
treatment, patients randomized to Arm A may  continue treatment with atezoli zumab be yond 
progressive disease by [CONTACT_393] v1.1, provided they are experiencing clinical benefit as 
assessed by [CONTACT_093].
Patients will undergo tumor assessments at baseline and every [ADDRESS_76290] v1.1 or loss of clinical benefit 
(for ate zolizumab -treated only patients who continue treatment after radiographic disease 
progression according to RECIST v1.1), withdrawal of consent, study termination by [CONTACT_2728], 
or death, whichever occurs first.  Patients who discontinue treatment for reasons other than 
radiographic disease progression (e.g., toxicity) will continue scheduled tumor assessments 
until radiographic disease progression per RECIST v1.1 or loss of clinical benefit (for 
atezolizumab -treated patients who continue treatment after radiog raphic disease progression 
according to RECIST v1.1), withdrawal of consent, study termination by [CONTACT_2728], or death, 
whichever occurs first, regardless of whether patients start a new anti- cancer therapy.
All primary imaging data used for tumor assessment will be collected by [CONTACT_70093], independent review of response endpoints. The independent reviews of the stored 
scans will be performed when requested.
Number of Patients
Approximately [ADDRESS_76291] meet all of the following criteria to be eligible for study entry:
Signed Informed Consent Form
Male or female, 18 years of age or older
ECOG perform ance status of 0 or 1
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
18/Protocol GO29438 , Version 7Histologically or cytologically confirmed, Stage IV non -squamous NSCLC (per the Union 
Internationale contre le Cancer/American Joint Committee on Cancer staging s ystem, 
7thedition; Detterbeck et al. 2009)
Patients with tumors of mixe d non -small cell histology (i.e., squamous and 
non-squamous) are eligible if the major histological component appears to be 
non-squamous.
No prior treatment for Stage IV non -squamous NSCLC
Patients with a sensitizing mutation in the epi[INVESTIGATOR_3506] ( EGFR ) 
gene are excluded given that erlotinib, gefitinib, or another EGFR tyrosine kinase 
inhibitor is the appropriate initial treatment of EGFR -mutant NSCLC.
Patients with an anaplastic ly mphoma kinase ( ALK) fusion oncogene are excluded 
given that crizotinib or other ALK inhibitors is the appropriate initial treatment of 
NSCLC in patients having an ALK fusion oncogene.
Patients with unknown EGFR and ALK status require test results at screening. ALK
and/or EGFRmay be assessed at a local or central laborator y.
Patients who have received prior neo- adjuvant, adjuvant chemotherapy, radiotherapy or 
chemoradiotherapy with curative intent for non- metastatic disease must have experienced a 
treatment -free interval of at least [ADDRESS_76292] dose of 
chemotherapy and/or radiotherapy.
Patients with a histor y of treated asy mptomatic CNS metastases are eligible, provided they 
meet all of the following criteria:
Only supratentorial and cerebellar metastases allowed (i.e., no metastases to midbrain, 
pons, medulla or spi[INVESTIGATOR_1831])
No ongoing requirement for corticosteroids as therapy for CNS disease
No stereotactic radiation within 7 days or whole -brain radiation within 14 days prior to 
randomization
No evidence of interim progression between the completion of CNS -directed therapy 
and the screening radiographic study
Patients with new asy mptomatic CNS metastases detected at the screening scan must 
receive radiation therapy and/or surgery for CNS metastases.  Following treatment, these 
patients may then be eligible without the need for an additional brain scan prior to 
randomization, if all other criteria are met.
Patients should submit a pre -treatment tumor tissue sample (if available).  If tumor tissue is 
not available (e.g., depleted for prior diagnostic testing), patients are still eligible.
If tumor tissue is available, a representative formalin -fixed paraffin -embedded (FFPE) 
tumor specimen in paraffin block or unstained, freshly cut, serial sections (preferably at 
least 10) from an FFPE tumor specimen, are preferred.  If 10 sections are not available, 
fewer can be submitted.
If FFPE specimens described above are not available, any type of specimens 
(including fine- needle aspi[INVESTIGATOR_1516], cell pellet speci mens [e.g., from pleural effusion], and 
lavage samples) are also acceptable.
This specimen should be accompanied by [CONTACT_40869].
Any available tumor tissue sample should be submitted before or within 4 weeks 
after enrollment.
Measurable disease, as defined by [CONTACT_393] v1.1
Previously irradiated lesions can only be considered as measurable disease if disease 
progression has been unequivocally documented at that site since radiation and the 
previously irradiated lesion is not the only site o f disease.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
19/Protocol GO29438 , Version 7Adequate hematologic and end organ function, defined by [CONTACT_40843] 14 days prior to randomization:
ANC  1500 cells/ L without granuloc yte colony -stimulating factor support
Lymphocyte count 500/L
Platelet count 100,000/ L without transfusion
Hemoglobin  9.0 g/dL
Patients may be transfused to meet this criterion.
INR or aPTT 1.5upper limit of normal (ULN)
This applies only to patients who are not receiving therapeutic anticoagulation; 
patients receiving therapeutic anticoagulation should be on a stable dose.
AST, ALT, and alkaline phosphatase 2.5ULN, with the following exceptions:
Patients with documented liver metastases:  AST and/or ALT 5ULN
Patients with documented liver or bone met astases:  alkaline phosphatase 
5ULN.
Serum bilirubin 1.25ULN
Patients with known Gilbert disease who have serum bilirubin level 3ULN may 
be enrolled.
Calculated creatinine clearance (CRCL) 45 mL/min or, if using cisplatin, 
calculated CRCL must be 60 mL/min
For patients enrolled in the extended China enrollment phase: current resident of mainland 
China, Hong Kong, or Taiwan and of Chinese ancestr y
For women of childbearing potential:  agree ment to remain abstinent (refrain from 
heterosexual intercourse) or use contraceptive methods that result in a failure rate of 1% 
per year during the treatment period and for at least [ADDRESS_76293] refrain from donating eggs during this same period.
A woman is considered to be of childbearing potential if she is postmenarcheal, has 
not reached a postmenopausal state ( 12continuous months of amenorrhea with no 
identified cause other than menopause), and has not undergone surgical sterilization 
(removal of ovaries and/or uterus).
Examples of non -hormonal contraceptive methods with a failure rate of 1%per year 
include bilateral tubal ligat ion, male sterilization, established, proper use of hormonal 
contraceptives that inhibit ovulation, hormone -releasing intrauterine devices, and 
copper intrauterine devices.
The reliability of sexual abstinence should be evaluated in relation to the duratio n of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and withdrawal 
are not acceptable methods of contraception.
For men:  agreement to remai n abstinent (refrain from heterosexual intercourse) or use 
contraceptive measures and agreement to refrain from donating sperm, as defined below:
With female partners of childbearing potential, men must remain abstinent or use a 
condom plus an additional c ontraceptive method that together result in a failure rate 
of1% per year during the chemotherapy treatment period and for at least [ADDRESS_76294] dose of 
chemotherapy.
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the pat ient.  Periodic abstinence 
(e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and withdrawal 
are not acceptable methods of contraception.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
20/Protocol GO29438 , Version 7Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entr y:
Cancer -Specific Exclusions
Patients with a sensitizing mutation in the EGFR gene or an ALK fusion oncogene
Active or untreated CNS metastases as determined by [CONTACT_70094]
Spi[INVESTIGATOR_33373]/or radiation or previously 
diagnosed and treated spi[INVESTIGATOR_70036] 2weeks prior to randomization
Leptomening eal disease
Uncontrolled tumor -related pain
Patients requiring pain medication must be receiving a stable regimen at study entry.
Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or 
metastases causing nerve impi[INVESTIGATOR_20804]) should be treated prior to randomization.  
Patients should be recovered from the effects of radiation.  There is no required 
minimum recovery period.
Asymptomatic metastatic lesions whose further growth would likely cause functional 
deficits or intractable pain (e.g., epi[INVESTIGATOR_70037]) should be considered for loco-regional therapy, if 
appropriate, prior to randomization.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recu rrent drainage 
procedures (once monthly or more frequently)
Patients with indwelling catheters (e.g., PleurX®) are allowed.
Uncontrolled or s ymptomatic hypercalcemia ( 1.5 mmol/L ionized calcium or 
calcium 12mg/dL or corrected serum calcium  ULN)
Patients who are receiving denosumab prior to randomization must be willing and 
eligible to discontinue its use and replace it with a bisphosphonate instead while in 
thestudy .
Malignancies other than NSCLC within 5 years prior to randomization, with the e xception of 
those with a negligible risk of metastasis or death (e.g., expected 5 -year OS90%) treated 
with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, 
basal or squamous -cell skin cancer, localized prostate canc er treated surgically with 
curative intent, ductal carcinoma in situ treated surgically with curative intent)
Known tumor PD -L1 expression status as determined by [CONTACT_70095] (e.g., patients whose PD -L1 expression status was de termined during screening for 
entry into a study with anti -PD-1 or anti PD-L1 antibodies but were not eligible are excluded)
General Medical Exclusions
Women who are pregnant, lactating, or intending to become pregnant during the study
History of severe a llergic, anaphylactic, or other hypersensitivity reactions to chimeric or 
humanized antibodies or fusion proteins
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovar y 
cells or any component of the atezolizumab formulati on
History of autoimmune disease, including but not limited to m yasthenia gravis, m yositis, 
autoimmune hepatitis, sy stemic lupus erythematosus, rheumatoid arthritis, inflammatory  
bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener 
granulomatosis, Sjögren’s syndrome, Guillain- Barré syndrome, multiple sclerosis, vasculitis, 
or glomerulonephritis
Patients with a histor y of autoimmune -related hypothy roidism on a stable dose of 
thyroid replacement hormone are eligible for this s tudy.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
21/Protocol GO29438 , Version 7Patients with controlled T ype I diabetes mellitus who are receiving a stable dose of 
insulin regimen are eligible for this study.
Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic 
manifestations only (e.g., patie nts with psoriatic arthritis would be excluded) are 
permitted provided that they meet the following conditions: 
Rash must cover less than 10% of body surface area
Disease is well controlled at baseline and only requiring low potenc y topi[INVESTIGATOR_33396] 12 months 
(notrequiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, 
biologic agents, oral calcineurin inhibitors, high potency or oral steroids)
History of idiopathic p ulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), 
drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on 
screening chest CT scan
History of radiation pneumonitis in the radiation field (fibrosis) is p ermitted.
Positive test for HIV
All patients will be tested for HIV prior to the inclusion into the study and 
HIV-positive patients will be excluded from the clinical study.
Patients with active hepatitis B (chronic or acute; defined as having a positive h epatitis B 
surface antigen [HBsAg] test at screening )or hepatitis C
Patients with past hepatitis B virus (HBV) infection or resolved HBV infection 
(defined as the presence of hepatitis B core antibody and absence of HBsAg) are 
eligible only if they are ne gative for HBV DNA.
Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is 
negative for HCV RNA.
Active tuberculosis
Severe infections within [ADDRESS_76295] ications of infection, bacteremia, or severe pneumonia
Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to 
randomization
Patients receiving prophylactic antibiotics (e.g., for prevention of a urinar y tract 
infection or to prevent chronic obstructive pulmonary disease exacerbation) 
areeligible.
Significant cardiovascular disease, such as [LOCATION_001] Heart Association cardiac disease 
(Class II or greater), m yocardial infarction or cerebrovascular accident within 3 months prior 
to randomization, unstable arrhythmias, or unstable angina
Patients with known coronary arter y disease, congestive heart failure not meeting 
the above criteria, or left ventricular ejection fraction 50% must be receiving a 
stable medical regimen that is opti mized in the opi[INVESTIGATOR_021], in 
consultation with a cardiologist if appropriate.
Major surgical procedure other than for diagnosis within 28 day s prior to randomization or 
anticipation of need for a major surgical procedure during the co urse of the study
Prior allogeneic bone marrow transplantation or solid organ transplant
Administration of a live attenuated vaccine within 4 weeks before randomization or 
anticipation that such a live attenuated vaccine will be required during the study
Any other diseases, metabolic dysfunction, physical examination finding, or clinical 
laborator y finding giving reasonable suspi[INVESTIGATOR_1884] a disease or condition that contraindicates 
the use of an investigational drug or that may affect the interpretation of th e results or 
render the patient at high risk from treatment complications
Illness or condition that may interfere with a patient’s capacity to understand, follow, and/or 
comply with study procedures
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
22/Protocol GO29438 , Version 7Exclusion Criteria Related to Medications
Prior treatment with EGFR inhibitors or ALK inhibitors
Any approved anti -cancer therapy, including hormonal therapy within 21 day s prior to 
initiation of study treatment.
Treatment with any other investigational agent with therapeutic intent within 28 days prior to 
randomization
Prior treatment with CD137 agonists or immune checkpoint blockade therapi[INVESTIGATOR_014], anti PD-1, 
and anti PD-L1 therapeutic antibodies
Patients who have had prior anti cytotoxic T -lymphocyte associated antigen 4 
(CTLA -4) treatment may be enrolled, provided the following requirements are met:
Last dose of anti -CTLA -[ADDRESS_76296] 6 weeks prior to randomization
No history of severe immune -mediated adverse effects from anti -CTLA -4 
(National Cancer Institute Common Terminology Criteria for Adverse Events 
[NCI CTCAE] Grade 3 and 4)
Treatment with s ystemic immunostimulatory agents (including but not limited to interferons, 
interleukin [IL]- 2) within 4 weeks or 5 half -lives of the drug, whichever is longer, prior to 
randomization
Prior treatme nt with cancer vaccines is allowed.
Treatment with s ystemic immunosuppressive medications (including but not limited to 
corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti tumor 
necrosis factor agents) within [ADDRESS_76297] received acute, low -dose ( 10 mg oral prednisone or 
equivalent), systemic immunosuppressant medications may  be enrolled in the 
study.
The use of corticosteroids ( 10 mg oral prednisone or equivalent), for chronic 
obstru ctive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for 
patients with orthostatic hypotension, and low -dose supplemental corticosteroids 
for adrenocortical insufficiency are allowed.
Exclusion Criteria Related to Chemotherapy
History of al lergic reactions to cisplatin, carboplatin, or other platinum -containing 
compounds
Patients with hearing impairment (cisplatin)
Grade 2peripheral neuropathy as defined by [CONTACT_4652] v4.0 (cisplatin)
CRCL  60 mL/min for cisplatin or  45 mL/min for carbo platin
End of Study and Length of Study
The end of study is defined as the date of the last follow -up visit of the last patient or when all 
patients have been enrolled into an extension study.   The Sponsor may decide to terminate the 
study at any time.  If the Sponsor decides to end the study, patients who are still receiving study 
treatment or are in survival follow -up may  be offered enrollment in an extension study or a 
non-interventional stu dy.
Investigational Medicinal Products
The investigational medicinal products for this study are atezolizumab and pemetrexed.  
Depending on local classification, in this study, cisplatin and carboplatin may  either be 
considered a non- investigational medici nal product or an investigational medicinal product.
Test Product (Investigational Drug)
Patients randomized to atezolizumab will receive 1200 mg of atezolizumab administered by [CONTACT_33458] 21 day s in a monitored setting where there is immediate acce ss to trained 
personnel and adequate equipment/medicine to manage potentially serious reactions.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
23/Protocol GO29438 , Version 7Comparator
Institutions should follow their standard administration procedures for pemetrexed.  
Thepremedication doses administered should be in compliance with the prescribing information.  
All patients eligible for pemetrexed therapy should avoid taking non -steroidal anti -inflammatory 
drugs with long elimination half -lives for at least [ADDRESS_76298] 
2days following pemetrexed administration.
Non-Investigational Medicinal Products
Cisplatin should be administered by [CONTACT_70096] 30 minutes after completion of 
the pemetrexed infusion at a dose of 75 mg/m² over 1 –2hours or per standard of care at the 
institution.  P atients must receive adequate anti -emetic treatment and appropriate hydration 
prior to and/or after receiving cisplatin.
Carboplatin should be administered 30 minutes after completion of pemetrexed administration 
by [CONTACT_12781] 30 60minutes to achiev e an initial target area under the concentration time 
curve of 6 mg/mL/min (Calvert formula dosing) with standard anti -emetics per local practice 
guidelines.
Statistical Methods
Primary and Secondary Efficacy A nalyses
The primary  efficacy  analy ses for PFS and OS will include randomized patients in the ITT 
population.   ORR will be analyzed using all randomized patients.  DO R will be assessed in 
patients who have an objective response.  PRO measures will be conducted on all patients with 
a non -missing baselin e PRO assessment.  Change from baseline analysis for PRO measures 
will be performed using the patients who have both a non -missing baseline assessment and at 
least one non -missing post -baseline assessment.
Determination of Sample Size
Determination of samp le size is based on patients enrolled in the global enrollment phase.  
This study will randomize approximately [ADDRESS_76299] one patient 
is enrolled in China during the global enrollment phase.
Interim A nalyses
There are no interim analy ses planned for PFS in this study.  An external independent Data 
Monitoring Committee (iDMC) will be set up to evaluate safety data on an ongoing basis.  
Allsummaries and analyses by [CONTACT_70097]’s review will be prepared by [CONTACT_70098].  Members of the iDMC will be external to the Sponsor 
and will follow a charter that outlines their roles and responsibilities.  Any outcomes of these 
safety reviews that affect study conduct will be communicated in a timely manner to the 
investigators for notification of the Institutional Review Boards and Ethics Committees.  
Adetailed plan will be included in the iDMC Charter. 
One interim efficacy analy sis of OS isplanned and will be performed by [CONTACT_1034].  The first 
interim OS analysis will be conducted at the time of the final PFS analysis.  It is expected that 
there will be approximately 312OS events in the ITT population bu t the exact timing of this 
analysis will depend on the actual number and timing of PFS events.   If there are significantly 
fewer than the expected 312 OS events at the time of the final PFS analysis, a nominal 
two-sided of 0.01% (negligible impact on overall type I error rate) will be spent on the OS 
analysis at the time of the final PFS analysis and a second interim OS analysis will then be 
conducted after approximately [ADDRESS_76300] occurred.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
24/Protocol GO29438 , Version 7LIST OF A BBREVI ATIONS AND DEFINITIONS OF TERMS
Abbrevia tion Definition
ALK anaplastic ly mphoma kinase
ASCO American Society of Clinical Oncology
ATA anti-therapeutic antibody
AUC area under the concentration time curve
BSC best supportive care
Cmax maximum observed serum concentration
Cmin minimum observed serum concentration
CR complete response
CRC colorectal cancer
CRCL creatinine clearance
CT computed tomography
ctDNA circulating tumor DNA
Ctrough trough concentration
CTLA-[ADDRESS_76301] ratio
HRQoL health- related quality of life
IC tumor- infiltrating immune cell
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
25/Protocol GO29438 , Version 7Abbrevia tion Definition
ICH International Conference forHarmonisation
iDCC independent Data Coordinating Center
iDMC independent Data Monitoring Committee
IHC immunohistochemistry
IMP Investigational Medicinal Product
IND Investigational New Drug
IRB Institutional Review Board
IRF Independent Review Facility
ITT intent to treat
IV intravenous
IxRS interactive voice/ Web response system
KRAS GTPase Krase
MRI magnetic resonance imaging
MTD maximum tolerated dose
NCCN National Comprehensive Cancer Network
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
NGS next-generation sequencing
NSCLC non small cell lung cancer
ORR objective response rate
OS overall survival
PacCbBev paclitaxel carboplatin bevacizumab
PD-1 programmed death 1
PD-L1 programmed death ligand 1
PemCb pemetrexed carboplatin
PET positron emission tomography
PFS progression -free survival
PK pharmacokinetic
PR partial response
PRO patient -reported outcome
q3w every 3 weeks
QLQ -C30 Quality -of-Life Questionnaire Core 30
QLQ -LC13 Quality -of-Life Questionnaire Lung Cancer Module
qRT-PCR quantitative reverse transcriptase polymerase chain reaction
RCC renal cell carcinoma
RCR [COMPANY_002] Clinical Repository
RECIST Response Evaluation Criteria in Solid Tumors
SAP Statistical Analysis Plan
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
26/Protocol GO29438 , Version 7Abbrevia tion Definition
SILC Symptoms in Lung Cancer
TC tumor cell
TKI tyrosine kinase inhibitor
TNF tumor necrosis factor
TTD time to deterioration
UBC urothelial bladder cancer
ULN upper limit of normal
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
27/Protocol GO29438 , Version 71. BACKGROUND
1.1 BACKGROUND ON LUNG C ANCER
Lung cancer remains the leading cause of cancer deaths worldwide; it is the most 
common cancer in both men and women and accounted for approximately 13% of all 
new cancers in 2008 ( Jemal et al. 2011).  In 2012, it was estimated that there would be 
226,160 new cases of lung cancer and 160,340 lung cancer deaths in the [LOCATION_002] 
alone (Siegel et al. 2012 ).  Similar data from Europe estimate that there were 
288,000 new cases of lung cancer and 253,000 deaths in 2008 ( GLOBOCAN 2008 ).
Nonsmall cell lung cancer ( NSCLC) is the predominant subtype of lung cancer, 
accounting for approximately 85% of all cases ( Molina et al. 2008 ; Howlader et al. 2011 ).  
NSCLC can be divided into two major histologic types:  adenocarcinoma and squamous 
cell carcinoma ( Travis et al. 2011 ).  Adenocarcinoma histology accounts for more than 
half of all NSCLC, while squamous cell histology accounts for approximately 25% 
(Langer et al. 2010 ).  The remaining cases of NSCLC are represented by [CONTACT_70099], neuroendocrine tumors, sarcomatoid carcinoma, and poorly differentiated 
histology.
Theoverall 5 -year survival rate for advanced disease is 2% 4%, depending on 
geographic location (Cetin et al. 2011 ).  Poor prognostic factors for survival in patients 
with NSCLC include advanced stage of disease at the time of initial diagnosis, poor 
performance status, and a history of unintentional weight loss.  More than half of the 
patients with NSCLC are diagnosed with distant disease, which directly contributes to 
poor survival prospects.
There are r ecognized differences in disease characteristics between adenocarcinoma and 
squamous NSCLC.  First, squamous tumors commonly present in the central airways and 
typi[INVESTIGATOR_70038] ( Hirsch et al. 2008 ), whereas 
non-squamou s tumors are more commonly located in the lung parenchyma distal to the 
central airways.  Evaluation of NSCLC tumor tissue will reveal cytological differences 
between the squamous cell type (keratinization, intracellular bridges, and central necrosis) 
andadenocarcinoma (glandular architecture).  In cases where the tumor sample is poorly 
differentiated or there is limited tissue available, immunohistochemical markers may 
support the histologic diagnosis.  Thyroid transcription factor [ADDRESS_76302], p63, CK5/6, 
and 34 E12 are strongly expressed in squamous cell carcinoma and less frequently in 
adenocarcinoma ( Travis et al. 2011 ).
Genetic changes that have prognostic and/or predictive significance in NSCLC include 
mutations in the epi[INVESTIGATOR_3506] ( EGFR ), the rearrangement in the 
anaplastic lymphoma kinase ( ALK) genes, and mutations in the GTPase Kras ( KRAS)
gene.  The rates of these mutations differ between s quamous cell carcinoma and 
adenocarcinoma.  For example, EGFR kinase domain mutations have been reported 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
28/Protocol GO29438 , Version 7in10%40% of patients with adenocarcinoma NSCLC but are infrequently observed in 
patients with squamous NSCLC ( Herbst et al. 2008).  Similarly, the ALKfusion oncogene, 
recognized as a driver of lung tumorigenesis, is observed in approximately 7% of patients 
with adenocarcinoma but is very rare in the squamous histology ( Herbst et al. 2008 ; 
Langer et al. 2010).  In addition, KRAS mutations are very rare in squamous NSCLC, 
while they can be observed in up to 30% of cases of adenocarcinoma NSCLC 
(Travis etal. 2011 ).
1.1.[ADDRESS_76303] -Line Treatment for A dvanced Non Small Cell Lung 
Cancer with an EGFR Mutation or ALK Rearrangement
Genotype- directed therapy has the potential to dramatically improve the balance of 
benefit and toxicity for selected patients with NSCLC characterized by [CONTACT_70100], including sensitizing EGFR mutations and ALK rearrangements.  
However, these mutat ions are more prevalent in adenocarcinoma NSCLC and are very 
rare in squamous NSCLC.  Randomized Phase III studies of gefitinib (IPASS), erloti nib 
(EURTAC), and afatinib (L UX-Lung 3) showed significant improvement of 
progression -free survi val (PFS) and obj ective response rate (ORR) compared with 
platinum doublet chemotherapy ( Fukuoka etal.2011 ; Rosell et al. 2012 ; 
Yang etal.2012 ;respectively).  Similarly, the ALK inhibitor crizotinib has demonstrated 
efficacy in patients with NSCLC that is positive for ALK rearrangement as defined by 
[CONTACT_26707] ( Crino et al. 2011; Camidge et al. 2012; 
Shaw etal.2012 ; XALKORI®U.S. Package Insert [USPI]).  Both EGFR tyrosine kinase 
inhibitors (TKIs) and crizotinib have been shown to be generally well tolerated.
1.1.[ADDRESS_76304] -Line Treatment for A dvanced NSCLC without an 
EGFR Mutation or ALK Rearrangement
Patients with previously untreated NSCLC that does not harbor a driver m utation that 
confers sensitivity to a targeted agent are typi[INVESTIGATOR_70039].  
Thefirstevidence that chemotherapy produced a significant survival benefit in patients 
with advanced NSCLC came in 1995; a meta -analysis showed that platinum -based 
doublet chemotherapy conferred a [ADDRESS_76305] 
supportive care (BSC) ( NSCLC Collaborative Group 1995 ).  More recently, the 
European Big Lung Trial demonstrated the potential benefits of chemotherapy.  In this 
study, 725patients with advanced NSCLC were randomly assigned to BSC plus 
cisplatin -based chemotherapy or BSC alone ( Spi[INVESTIGATOR_70040]. 2004 ).  Patients who were 
allocated to chemotherapy had a significantly longer median survival than did those who 
were managed with BSC (8 vs. 5.7months; hazard ratio [HR] 0.77, 95% CI: 0.66, 0.89).
The benefit conferred by [CONTACT_70101] -based chemotherapy regimens appears to have 
reached a plateau in ORR (approximately 15% 22%) and median survival 
(710months).  More recently, the addition of bevacizumab to carboplatin and paclitaxel 
resulted in an increase in response rate from 15% to 35% and an increase in median 
overall survival (OS) from 10 to 12 months (see Table 1 ).

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
29/Protocol GO29438 , Version 7Table 1Randomized Phase III Studies in Patients with Previously  Untreated NSCLC
First-Line Therapy RegimenORR
(%)Median PFS
(months)Median OS
(months)OS HR
(95% CI)
Chemotherapy a
Cisplatin and paclitaxel (n 288) 21 3.4 7.8
Cisplatin and gemcitabine (n 288) 22 4.2 8.1
Cisplatin and docetaxel (n 289) 17 3.7 7.4
Carboplatin and paclitaxel (n 290) 17 3.1 8.1
Chemotherapy biologic b
Carboplatin and paclitaxel (n 444) 15 4.5 10.3 0.79
0.67 0.92Carboplatin, paclitaxel, and bevacizumab (n 434) 35 6.5 12.3
Chemotherapy c 
Cisplatin and pemetrexed, overall (n 839) 31 4.8 10.3 0.94
0.84 1.05Cisplatin and gemcitabine, overall ( n830) 28 5.1 10.3
Cisplatin and pemetrexed, non -squamous NR 5.3 11.8 0.81
0.70 0.94Cisplatin and gemcitabine, non -squamous NR 4.7 10.4
Cisplatin and pemetrexed, squamous NR 4.4 9.4 1.23
1.00 1.51Cisplatin and gemcitabine, squamous NR 5.5 10.8
Chemotherapy d
Carboplatin and nab -paclitaxel, overall ( n521) 33 6.3 12.1 0.922
0.797 1.066Carboplatin and paclitaxel, overall ( n531) 25 5.8 11.2
Carboplatin and nab -paclitaxel, non -squamous ( n221) 26 6.9 13.1 0.950
NRCarboplatin and paclitaxel, non -squamous ( n292) 25 6.5 13.0
Carboplatin and nab -paclitaxel, squamous ( n300) 41 5.6 10.7 0.890
0.719 1.101Carboplatin and paclitaxel, squamous ( n229) 24 5.7 9.5
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
30/Protocol GO29438 , Version 7Table 1Randomized Phase III Studies in Patients with Previously  Untreated NSCLC (cont.)
First-Line Therapy RegimenORR
(%)Median PFS
(months)Median OS
(months)OS HR
(95% CI)
Phase III studies e
Cisplatin and vinorelbine (n 568) 29 4.8 10.1 0.871
0.762 0.996Cisplatin, vinorelbine, and cetuximab (n 557) 36 4.8 11.3
HRhazard ratio; NR not reported; ORR objective response rate; OS overall survival; PFS progression -free survival.
aSchiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for
advanced non –small-cell lung cancer. N Engl J Med 2002;346:92 8.
bSandler A, Gray R, Perr y MC, et al. Paclitaxel –carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med 
2006;355:2542 50.
cScagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in 
chemotherapy -naive patients with advanced -stage nonsmallcell lung cancer. J Clin Oncol 2008;26:3543 51.
dSocinski MA, Bondarenki I, Karaseva NA, et al. Weekly nab- paclitaxel in combination with carboplatin versus solvent -based paclitaxel 
plus carboplatin as first -line therapy in patients with advanced non -small -cell lung cancer: final res ults of a Phase III trial. J Clin Oncol 
2012;30:2055 62.
ePi[INVESTIGATOR_70041] R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non -small -cell lung cancer (FLEX): an 
open- label randomised Phase III trial. Lancet 2009;373:1525 31.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
31/Protocol GO29438 , Version 7Despi[INVESTIGATOR_70042], platinum -based 
regimens remain the standard first -line option for most patients with locally advanced 
and metastatic NSCLC that was not harboring an activating EGFR mutation or ALK gene 
rearrangement.  In particular, for newly diagnosed advanced sta ge non -squamous 
NSCLC, the standard of care is a platinum doublet with either cisplatin or carboplatin 
and a taxane or pemetrexed, with or without bevacizumab.   However, these regimens 
are associated with substantial t oxicities (such as febrile neutropenia, myelosuppression, 
nausea, alopecia, nephropathy, and neuropathy) and are generally poorly tolerated 
by[CONTACT_33437] -performance -status patients.  Therefore, novel therapi[INVESTIGATOR_70043]-squamous NSCLC .
1.1.[ADDRESS_76306] -generation chemotherapy, 
cisplatin may result in longer survival than carboplatin (overall response of 
30% vs.24%,respectiv ely; Hotta et al. 2004 ; Ardizzoni et al. 2007 ), but overall benefit 
was quite marginal, and subgroup analyses including additional, more recent studies 
indicate that there may be no difference between the two agents ( Jiang et al. 2007; 
Azzoli et al. 2009 ).
As to safety, cisplatin -based chemotherapy has been associated with more severe 
nausea and vomiting and nephrotoxicity, while severe thrombocytopenia has been 
more frequent during carboplatin- based chemotherapy ( Hotta et al. 2004 ; 
Ardizzoni etal.2007 ). The risk of treatment -related deaths was greater in the cisplatin 
arm, but this increase was not statistically significant ( Jiang et al. 2007).
Currently, the standard of care for newly diagnosed advanced stage non- squamous 
NSCLC is a platinum doublet wit h either cisplatin orcarboplatin and a taxane or
pemetrexed, with or without bevacizumab.  In particular, the combination of platinum 
doublet with pemetrexed has been used more widely because of a better tolerability 
and safety profile.
1.1.4 Pemetrexed
Pemetre xed disodium ( ALIMTA®,pemetrexed) is a novel pyrrolo[2,3 d]pyrimidine based
folic acid analogue.  In vitro studies, pemetrexed inhibited multiple folate -dependent 
enzymes (thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide 
formyl- transferase) crucial in the de novo biosynthesis of thymidine and purine 
nucleotides (Shih et al. 1997).
[IP_ADDRESS] Pemetrexed plus Platinum Compounds in First -Line NSCLC
Two Phase II studies demonstrated that the combination of pemetrexed and carboplatin 
is tolerable and that its activity in first -line treatment of advanced- stage NSCLC is 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
32/Protocol GO29438 , Version 7comparable with other standard platinum doublets commonly used in clinical practice 
(Kelly et al. 2001 ; Scagliotti et al. 2002 ; Fossella etal. 2003 ; Reck et al. 2010) .  
Thetoxicity profile of the pemetrexed/carboplatin combination appears to be more 
favorable than that seen with other standard regimens in first -line NSCLC.
A Phase III non -inferiority study comparing the efficacy of cisplatin/pemetrexed ( n862) 
versus cisp latin/gemcitabine ( n863) in patients with incurable Stage IIIB or IV NSCLC 
who had received no prior chemotherapy.  Median OS, PFS, and time to progression 
were comparable between the two treatment groups.  However, among patients who 
had adenocarcinoma or large -cell carcinoma, patients treated with cisplatin/pemetrexed 
had significantly better median OS than patients treated with cisplatin/gemcitabine 
(12.6 vs. 10.9 months for adenocarcinoma [HR 0.84; 95% CI: 0.71, 0.99; p0.03]); 
10.4 vs.6.7months for large- cell carcinoma [ HR0.67; 95% CI: 0.48, 0.96; p0.03]).  
Inaddition, cisplatin/pemetrexed was associated with better tolerability and safety and 
necessitated less supportive care ( Scagliotti et al. 2008 ).
In addition, a supportive study nam ed PRONOUNCE was designed to assess the 
efficacy and safety of pemetrexed carboplatin (Pem Cb) followed by [CONTACT_70102] carboplatin bevacizumab followed by [CONTACT_70103] (Pac CbBev) in patients with advanced non- squamous NSCLC.  The 
median PFS was 4.44 months for Pem Cb versus 5.49 months for Pac CbBev 
(HR1.06; 95% CI: 0.84, 1.35; p0.610).  The median OS for Pem Cb was 10.5 
months versus 11.7 months for Pac CbBev (HR 1.07; 95% CI: 0.83, 1.36; p 0.615).  
One-and 2 -year survival rates were not significantly different between the arms and 
were 43.7% and 18.0% for Pem Cb and 48.8% and 17.6% for Pac CbBev.  
Response rate and disease control rate (DCR) were 23.6% and 59.9% f or Pem Cb and 
27.4% and 57.0% for Pac CbBev ( p0.414 and 0.575, respectively).
[IP_ADDRESS] Pemetrexed Maintenance Therapy  in NSCLC
A Phase III, randomized, double- blind, placebo -controlled, study that explored the use of 
pemetrexed as switch maintenance in fi rst-line patients with NSCLC after four cycles of 
induction therapy using one of six standard platinum doublets (gemcitabine, paclitaxel, or 
docetaxel with either carboplatin or cisplatin).  Patients who achieved a complete 
response (CR), partial response (PR), or stable disease were then randomized to 
maintenance therapy with pemetrexed plus BSC or placebo plus BSC until progression 
(Ciuleanu etal.2009 ).  A significant improvement in PFS was reported for patients who
received pemetrexed maintenance thera py compared with those who received placebo 
(4.04 vs. 1.97 months; unadjusted HR ,0.50; 95% CI: 0.42, 0.61; p0.[ZIP_CODE]).  In patients 
with non -squamous histology, the median PFS for patients receiving pemetrexed versus 
placebo was 4.5 months versus 2.6 months (unadjusted HR ,0.44; 95% CI: 0.36, 0.55; 
p0.[ZIP_CODE]).  The median follow -up for OS was 11.2 months for patients in the 
pemetrexed group and 10.2 months for those receiving placebo.  The median OS 
following induction chemotherapy in the overall stu dy population was 13.4 months 
withpemetrexed and 10.6 months with placebo (unadjusted HR ,0.798; 95% CI: 0.65, 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
33/Protocol GO29438 , Version 70.95; p0.012).  In the non- squamous population, the median OS was 15.5 months 
forpemetrexed -treated patients and 10.3 months for patients on placebo (unadjusted 
HR,0.70; 95% CI: 0.56 to 0.88; p0.002).
A second study also explored the value of pemetrexed in the continuous maintenance 
setting.  In this study, patients who had not received prior treatment for lung cancer 
received four cycles of pemetrexed cisplatin .  Maintenance therapy was continued if 
stable disease, a PR, or a CR was documented.  Patients were then randomized in a 
2:1fashion to either pemetrexed BSC or placebo BSC.  The median PFS in patients 
who received pemetrexed was 4.1 months (range :3.2–4.6 months) compared with the 
median PFS of 2.8 months (range: 2.6–3.1 months) in patients who received placebo.  
The HR for PFS as assessed by [CONTACT_70104] 0.62 (95% CI:0.49, 0.79; 
p0.[ZIP_CODE]).  The PFS benefit was internally consistent, and benefit was seen 
across allclinically important subgroups.  OS data from this study are pending 
(Paz-Ares etal.2012 ).
1.1.5 Targeted Therapy  for NSCLC
Genotype- directed therapy has the potential to dram atically improve the balance of 
benefit and toxicity for selected patients with NSCLC (mainly non -squamous histology) 
characterized by [CONTACT_70105], including sensitizing EGFR mutations 
and ALK rearrangement.  However, these mutations ar e more prevalent in 
adenocarcinoma NSCLC and are very rare in squamous NSCLC.  Randomized Phase III 
studies of gefitinib (IPASS), erlotinib (EURTAC), and afatinib (L UX-Lung 3) showed 
significant improvement of PFS and ORR compared with platinum -doublet 
chemotherapy (Fukuoka etal.2011; Rosell etal.2012; Yang etal.2012).  Similarly, the 
ALK inhibitors crizotinib and ceritinib have demonstrated efficacy in patients with NSCLC 
positive for ALK rearrangement as defined by [CONTACT_26707] 
(Crino etal.2011; Camidge etal.2012; Shaw etal.2012; Shaw andEngelman 2014; 
XALKORI®USPI; ZYKADIA USPI).
Despi[INVESTIGATOR_70044], 
survival rates for advanced disease remain low and acquired resistance to targeted 
agents is a major clinical problem.  Therefore, alternative treatment options that yield 
durable responses and enhance OS remain an important focus of research .  Against this 
background, immunotherapeutic agents, such as cancer vaccines and antibodies that 
modulate immune cell activity, offer an alternative treatment approach that could 
potentially improve the prognosis of patients with this disease.
1.2 BACKGROUND ON ATEZOLIZUMA B
Atezolizumab (MPDL3280A) is a h uman ized immunoglobulin G1 monoclonal antibody 
consisting of two heavy chains (448 amino acids) and two light chains (214 amino acids) 
and is produced in Chinese hamster ovary cells.  Atezolizumab was engineer ed to 
eliminate Fc -effector function via a single amino acid substitution at position 298 on the 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
34/Protocol GO29438 , Version 7heavy chain, which results in a non -glycosylated antibody that has minimal binding to 
Fcreceptors and prevents Fc -effector function at expected concentrations in humans.  
Atezolizumab targets human programmed death ligand 1 (PD-L1) and inhibits its 
interaction with its receptors, programmed death 1 (PD -1) and B7.1 (CD80, B7- 1).  
Both of these interactions are reported to provide inhibitory signals to T cells.
Atezolizumab is being investigated as a potential therapy against solid tumors and 
hematologic malignancies in huma ns.  Atezolizumab is approved for the treatment of 
urothelial carcinoma, NSCLC, small -cell lung cancer, and triple -negative breast cancer.
1.2.1 Summary  of Nonclinical Studies
The nonclinical strategy of the atezolizumab program was to demonstrate in vitro and 
invivo activity, to determine in vivo pharmacokinetic (PK) behavior, to demonstrate an 
acceptable safety profile, and to identify a Phase I s tarting dose.  Comprehensive 
pharmacology, PK, and toxicology evaluations were thus undertaken with atezolizumab.
The safety, pharmacokinetics, and toxicokinetics of atezolizumab were investigated in 
mice and cynomolgus monkeys to support intravenous (IV) administration and toaid 
inprojecting the appropriate starting dose in humans.  Given the similar binding of 
atezolizumab for cynomolgus monkey and human PD -L1, the cynomolgus monkey was 
selected as the primary and relevant nonclinical model for understa nding the safety, 
pharmacokinetics, and toxicokinetics of atezolizumab.
Overall, the nonclinical pharmacokinetics and toxicokinetics observed for atezolizumab 
supported entry into clinical studies, including providing adequate safety factors for the 
propos ed Phase I starting doses.  The results of the toxicology program were consistent 
with the anticipated pharmacologic activity of downmodulating the PD -L1/PD -[ADDRESS_76307] 
and supported entry into clinical studies in patients.
Refer to the Atezolizumab Investig ator’s Brochure for details on the nonclinical studies.
1.3 CLINICA L EXPERIENCE WITH A TEZOLIZUMA B
1.3.1 Ongoing Clinical Studies
Atezolizumab is currently being tested in multiple Phase I, II, and III studies, both as 
monotherapy and in combination with several anti- cancer therapi[INVESTIGATOR_014] (see the 
Atezolizumab Investigator’s Brochure for study descriptions).  Safety and efficacy data 
are summarized below from the following studies:
Study PCD4989g (GO27831) :  A Phase Ia, multicenter, first -in-human, open -label,
dose- escalation study evaluating the safety, tolerability, immunogenicity,
pharmacokinetics, exploratory pharmacodynamics, and preliminary evidence of
biologic activity of atezolizumab administered as a single agent by [CONTACT_70106] 3 weeks (q3w) to patient s with locally advanced or metastatic solid
malignancies or hematologic malignancies
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
35/Protocol GO29438 , Version 7Study GO28753 (hereinafter POPLAR):  A randomized, Phase II, open -label study 
assessing the clinical benefit of atezolizumab as a single agent versus docetaxel in 
PD-L1 un selected patients with locally advanced or metastatic NSCLC that has 
progressed during or following treatment with a platinum -containing regimen
Study GP28328:  A Phase Ib study of the safety and pharmacology of atezolizumab 
(antiPD-L1 antibody) administered with bevacizumab and/or with chemotherapy in 
patients with advanced solid tumors
Study GO28915 (OAK): A randomized, Phase III, open- label study assessing the 
efficacy and safety of atezolizumab as a single agent versus docetaxel in patients 
with local ly advanced or metastatic NSCLC that has progressed during or following 
treatment wit h a platinum -containing regimen
1.3.2 Clinical Safety
[IP_ADDRESS] Single -Agent Clinical Safety  in Patients with NSCLC in 
Study PCD4989g
Study PCD4989g, in which atezolizumab is being used as a single agent in patients with 
locally advanced or metastatic solid tumors or hematologic malignancies, provides the 
majority of data (with 558 safety-evaluable patients as of the data extraction date of 
11May2015) for the safety profile of atezolizu mab as monotherapy.
Currently, no maximum tolerated dos e (MTD), no dose -limiting toxicities (DLTs), and no 
clear dose -related trends in the incidence of adverse events have been determined.
The safety profile of atezolizumab as a single agent is observed t o be consistent across 
different indications.  The most common cancer types for these patients include NSCLC, 
urothelial bladder cancer (UBC), melanoma, and renal cell carcinoma (RCC).   Safety 
data for NSCLC are also derived from Studies GO28625 (FIR) and the POPLAR study .
Adverse Events
Of the 558 patients, 520 patients (93.2%) experienced at least one adverse event, 
including 376 patients (67.4%) who experienced one treatment -related adverse event.  
Commonly reported events (reported in 10% of all patients) included fatigue, 
decreased appetite, nausea, pyrexia, constipation, and cough (see Table 2 ).

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
36/Protocol GO29438 , Version 7Table 2Study PCD4989g:  A dverse Ev ents with Frequency  10% of 
Patients for A ll Grades
Preferred TermAll Grades
n (%)All Grades 
Related
n (%)Grade 3 4
n (%)Grades 34 
Related
n (%)
Any adverse event 520 (93.2) 376 (67.4) 239 (42.8) 66 (11.8)
Fatigue 192 (34.4) 115 (20.6) 13 (2.3) 6 (1.1)
Decreased appetite 142 (25.4) 62 (11.1) 4 (0.7) 0 (0.0)
Nausea 136 (24.4) 65 (11.6) 5 (0.9) 2 (0.4)
Pyrexia 117 (21.0) 63 (11.3) 2 (0.4) 0 (0.0)
Constipation 116 (20.8) 8 (1.4) 2 (0.4) 0 (0.0)
Cough 113 (20.3) 11 (2.0) 1 (0.2) 1 (0.2)
Dyspnea 112 (20.1) 18 (3.2) 18 (3.2) 4 (0.7)
Diarrhea 110 (19.7) 53 (9.5) 2 (0.4) 1 (0.2)
Anem ia 104 (18.6) 26 (4.7) 23 (4.1) 5 (0.9)
Vomiting 96 (17.2) 28 (5.0) 3 (0.5) 2 (0.4)
Asthenia 88 (15.8) 53 (9.5) 8 (1.4) 4 (0.7)
Back pain 85 (15.2) 9 (1.6) 8 (1.4) 1 (0.2)
Headache 83 (14.9) 32 (5.7) 2 (0.4) 1 (0.2)
Arthralgia 79 (14.2) 35 (6.3) 2 (0.4) 0 (0.0)
Pruritus 75 (13.4) 55 (9.9) 0 (0.0) 0 (0.0)
Rash 73 (13.1) 53 (9.5) 0 (0.0) 0 (0.0)
Abdominal p ain 63 (11.3) 12 (2.2) 8 (1.4) 0 (0.0)
Insomnia 62 (11.1) 7 (1.3) 1 (0.2) 0 (0.0)
Peripheral edema 59 (10.6) 7 (1.3)  
Chills 57 (10.2) 31 (5.6) 0 (0.0) 0 (0.0)
Note:  “ ” refers to missing Common Terminology Criteria grade.
Grade 3 4 adverse events (on the basis of National Cancer Institute Common 
Terminology Criteria for Adverse Events, Version 4. 0 [NCI CTCAE v4.0]) were reported 
in 239 patients (42.8%), of which 66 (11.8%) were considered related.  Grade [ADDRESS_76308], increased gamma -glutamyl transferase, lymphocyte 
count decreased, cardiac tamponade, asthenia, autoimmune hepatitis, pneumonia, 
influenza, and hypoxia.
Refer to the Atezolizumab Investigator’s Brochure for details on adverse events 
observed in patients treated with atezolizumab.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
37/Protocol GO29438 , Version 7Immune -Mediated Adverse Events
Given the mechanism of action of atezolizumab, events associated with inflammation 
and/or immune -mediated adverse events have been closely monitored during the 
atezolizumab clinical program.  These include potential dermatologic, hepatic, endocrine, 
gastrointestinal, and respi[INVESTIGATOR_29343].
Refer to the Atezolizumab Investigator’s Brochure for details on immu ne-mediated
adverse events that were observed in patients treated with atezolizumab.  Guidelines for 
the management of immune -mediated adverse events are described in Section [IP_ADDRESS].
[IP_ADDRESS] Single -Agent Clinical Safety  in Patients with NSCLC in the 
POPLAR Study
As of the 8 May 2015 data cutoff date, the Phase II POPLAR study included data from 
142 patients treated with atezolizumab as a fixed dose of 1200 mg IVq3w and 
135patients treated with docetaxel 75 mg/m2IV q3w. The frequency of patients in the 
POPLAR study who reported any adverse event regardless of attribution was 96.3% for 
the atezolizumab arm and 95.8% for the docetaxel arm.  A higher number of Grade 3 
adverse events were observed in the docetaxel arm ( 56.3% vs. 44.4% ), explained 
primarily by [CONTACT_70107] .  Adverse 
events reported in at least 10% of patients in either treatment arm are listed i nTable 3 .

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
38/Protocol GO29438 , Version 7Table 3Adverse Events Reported in at Least 10% of Patients in 
thePOPLA R Study
MedDRA Preferred TermAtezolizumab
n142
(%)Docetaxel
n135
(%)
Fatigue 55 (38.7) 54 (40.0)
Decreased appetite 49 (34.5) 28 (20.7)
Nausea 31 (21.8) 45 (33.3)
Cough 38 (26.8) 33 (24.4)
Dyspnoea 38 (26.8) 27 (20.0)
Diarrh ea 24 (16.9) 38 (28.1)
Constipation 29 (20.4) 32 (23.7)
Alopecia 3 (2.1) 52 (38.5)
Anem ia 23 (16.2) 26 (19.3)
Pyrexia 24 (16.9) 16 (11.9)
Asthenia 14 (9.9) 22 (16.3)
Vomiting 18 (12.7) 18 (13.3)
Arthralgia 22 (15.5) 12 (8.9)
Rash 15 (10.6) 16 (11.9)
Insomnia 19 (13.4) 11 (8.1)
Back pain 16 (11.3) 11 (8.1)
Musculoskeletal pain 19 (13.4) 7 (5.2)
Myalgia 8 (5.6) 18 (13.3)
Neutropenia 2 (1.4) 17 (12.6)
Pneumonia 15 (10.6) 4 (3.0)
Neuropathy ,peripheral 2 (1.4) 16 (11.9)
For additional information, refer to t he Atezolizumab Investigator’s Brochure.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
39/Protocol GO29438 , Version [IP_ADDRESS] Clinical Safety  in Combination Platinum -Based 
Doublet Chemotherapy
Study GP28328 is a Phase Ib study of atezolizumab in combination with bevacizumab or 
cytotoxic chemotherapy in patients with multiple tumor types including NSCLC, 
triple -negative breast can cer, and colorectal cancer (CRC).  As of 10 Fe bruary 2015, 
144patients had been enrolled in this study:  39 in Arm A (atezolizumab bevacizumab), 
36 in Arm B (atezolizumab bevacizumab and FOLFOX [oxaliplatin, leucovorin, and 
5-fluorouracil] ), 14 in Arm C (atezolizumab carboplatin and paclitaxel), 24 in Arm D 
(atezolizumab carboplatin and pemetrexed), 20 in Arm E (atezolizumab carboplatin 
and nab- paclitaxel), and 11 in Arm F (atezolizumab nab paclitaxel).  The treatment 
combinations have been generally well tolerated.  No DLTs have been reported during 
the dose -escalation stage in any study arm.  Patients are being enrolled in safety and 
biopsy expansion cohorts in Arms A and B as well as in additional arms testing 
atezolizumab in combination w ith commonly used NSCLC chemotherapy doublets.
A total of 141 of 144 patients (97.9%) reported at least one adverse event while 
receiving study drug.  The majority of these events were Grade [ADDRESS_76309] commonly reported adverse eve nts across the study arms ( 10% in patients) 
included fatigue, nausea, diarrhea, decreased appetite, and pyrexia.   The adverse 
events were consistent with the known safety profile of each agent (atezolizumab 
monotherapy and chemotherapy).  No additive eff ects were observed when 
atezolizumab was administered with chemotherapy.  See Table 4 for all adverse events 
reported in each treatment arm of Study GP28 328.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
40/Protocol GO29438 , Version 7Table 4Study GP28328:  A ll Reported A dverse Events
ParameterArm A
(n39)
No. (%)Arm B
(n36)
No. (%)Arm C
(n14)
No. (%)Arm D
(n24)
No. (%)Arm E
(n20)
No. (%)Arm F
(n12)
No. (%)All Patients
(n145)
No. (%)
Any AEs 39 (100) 36 (100) 14 (100) 24 (100) 19 (95.0) 10 (83.3) 142 (97.9)
Related AEs 29 (74.4) 28 (77.8) 12 (85.7) 19 (79.2) 19 (95.0) 6 (50.0) 113 (77.9)
Grade 3 5 AEs 20 (51.3) 29 (80.6) 12 (85.7) 17 (70.8) 18 (90.0) 6 (50.0) 102 (70.3)
Related Grade 3 5 AEs 1 (2.6) 7 (19.4) 4 (28.6) 4 (16.7) 11 (55.0) 4 (33.3) 31 (21.4)
Serious AEs 14 (35.9) 15 (41.7) 5 (35.7) 10 (41.7) 8 (40.0) 3 (25.0) 55 (37.9)
Related serious AEs 0 (0) 1 (2.8) 1 (7.1) 2 (8.3) 2 (10.0) 2 (16.7) 8 (5.5)
AEs leading to discontinuation 1 (2.6) 4 (11.1) 0 (0) 1 (4.2) 1 (5.0) 0 (0) 8 (5.6)
AEs leading to death (Grade 5) 0 (0) 2 (2.8) 1 (7.1) 2 (8.3) 2 (10.0) 1 (8.3) 7 (4.8)
Related AEs leading to death (Grade 5) 0 (0) 0 (0) 0 (0) 1 (4.2) 0 (0) 0 (0) 1 (0.7)
Immune -mediated AEs 12 (30.8) 28 (77.8) 8 (57.1) 11 (45.8) 11 (55.0) 2 (16.7) 72 (49.7)
AEadverse event.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
41/Protocol GO29438 , Version 7All [ADDRESS_76310] frequently reported events were consistent with the overall population 
andincluded fatigue, nausea, diarrhea, decreased appetite, and pyrexia.  There were 
36patients enrolled in Arm B, and 97% of patients reported at least one adverse event.  
The most frequently re ported adverse events ( 20% of patients) included fatigue, 
pyrexia, peripheral neuropathy, neutropenia, anemia, diarrhea, decreased appetite, 
temperature intolerance, constipation, vomiting, and nausea.
All patients who were enrolled in Arms C and D exper ienced an adverse event; 95% of 
patients who were enrolled in Arm E experienced an adverse event, and 83.3% of 
patients enrolled in Arm F experienced an adverse event.  The adverse events 
commonly reported in 2 or more patients in Arms C, D, and E included anemia, 
decreased appetite, hypomagnesemia, nausea, neutropenia, constipation, vomiting, 
fatigue, rash, cough, and diarrhea.  Adverse events commonly reported in 2 or more 
patients in Arm F included dermatitis, upper respi[INVESTIGATOR_4416], alopecia, perip heral 
sensory neuropathy, fever, constipation, neutrophil count decreased, anemia, diarrhea, 
headache, nausea, and fatigue.
1.3.3 Clinical A ctivity
Anti-tumor activity, including Response Evaluation Criteria in Solid Tumors 
(RECIST) based responses (i.e., RECIST v1.1 responses), have been observed in 
patients with different tumor types treated with atezolizumab monotherapy in 
Study PCD4989g.
Refer to the Atezolizumab Investigator’s Brochure for details on clinical activity in all 
patients treated to date, regardl ess of tumor type.
[IP_ADDRESS] Single -Agent Clinical A ctivity in Patients with NSCLC in 
Study PCD4989g
As of the clinical data cutoff of 2 December 2014, the efficacy evaluable population 
included 88 patients with locally advanced or metastatic NSCLC.  The median age was 
60.5 years (range :2484 years), and represented a heavily pre- treated patient 
population:  97% of the patients had received 2 prior systemic therapi[INVESTIGATOR_014], and 77.3% 
had received 4 prior systemic therapi[INVESTIGATOR_014] .
Overall, responses were recorded for 20 of 88 (22.7%) patients with NSCLC, and 
included responses in patients with squamous and non -squamous NSCLC (4 in 
21patients and 16 in 67 patients, respectively).  A total of [ADDRESS_76311] continued to respond at the tim e of the clinical data cutoff.
Table 5 displays the investigator -assessed confirmed ORR, confirmed duration of 
response (D OR), and [ADDRESS_76312] v1.1.  Analyses of 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
42/Protocol GO29438 , Version 7tumor -infiltrating immune cells (IC) and tumor cells (TC) for PD-L1 expression on 
baseline tumor tissue from NSCL C patients have been perf ormed.
Refer to the A tezolizumab Investigator’s Brochure for details on the clinical activity in 
patients with NSCLC treated to date.
Table 5Patients with NSCLC in Study  PCD4989g:  Investigator -Assessed 
Confirmed Objective Response Rate by [CONTACT_70108]-L1 Expression , 
Duration of Response, and 6-M onth Progression -Free Survival 
Rates (per RECIST Version 1.1)
PD-L1 IHC 
Expression 
CategoryORR by [CONTACT_393], 
Version 1.1
n88SD
(n/N)PD
(n/N)DOR (range 
in months)6-month 
PFS 
% (95% CI)
TC3 or IC3 50.0% (11of 22)
(95% CI: 2 8.22%, 
71.78%)13.6%
(3/22)31.8%
(7/22)7.16 25.26 50.0
(29.1, 70.9)
TC3 or IC2/3 37.5% ( 15 of 40)
(95% CI: 22.73%
54.2% )12.5%
(5/40)45.0%
(18/40)7.16 26.74+ 44.9
(29.4, 60.3)
TC2/3 or IC2/3 33.3% ( 16of 48)
(95% CI: 20.40 %, 
48.41 %)22.9%
(11/48 )37.5%
(18/48)7.16 26.74+ 41.6
(27.6, 55.5)
TC0/1/2 and IC0/1/2 15.5% ( 9of 58)
(95% CI: 7.35%, 
27.42 %)37.9%
(22/58 )37.9%
(22/58)7.16 26.74+ 41.1 
(28.4, 53.8)
TC0/1/2 and IC0/1 12.5% ( 5 of 40 )
(95% CI: 4.19%, 
26.8%)37.5%
(15/40)40.0%
(16/40 )9.92 24.74 42.3
(27, 57.7)
TC0/1 and IC0/1 12.5% (4 of 32)
(95% CI: 3.51%, 
28.99%)43.8%
(14/32)34.4%
(11/32)9.92 24.74 46.7
(29.3, 64.0)
DOR duration of response; IC tumor-infiltrating immune cell; IHCimmunohistochemistry ; 
NSCLC non small cell lung cancer; ORR objective response rate; PFSprogression -free 
survival; PR partial response; PD progressive disease; PD -L1programmed death ligand 1; 
RECIST Response Evaluation Criteria in Solid Tumo rs; SDstable disease; TC tumorcell.
Note s: This table is based on a data cutoff of 2 Dec 2014 of NSCLC patients. ORR includes 
confirmed responses. “ ” denotes a censored value.
[IP_ADDRESS] Single -Agent Clinical A ctivity in Patients with NSCLC in the 
POPLA RStudy
The primary OS analysis in the POPLAR study was conducted when 173 deaths had 
occurred (clinical cutoff, 8 May 2015).  Demographic characteristics were comparable 
between treatment arms in the intent -to-treat (ITT) population.  The median age was 
62years (range: 42 82 years for the atezolizumab arm, range: 36 84years for the 
docetaxel arm), and the majority of patients had one prior therapy (64.6% for 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
43/Protocol GO29438 , Version 7atezolizumab and 67.1% for docetaxel), non -squamous histology (66.0% for 
atezolizumab and 66.4% for docetaxel), and Eastern Cooperative Oncology Group
(ECOG) performance status of 1 (67.6% for atezolizumab and 68.3% for docetaxel ).  
More females were enrolled in the docetaxel arm (46.9% vs. 35.4%).
Key efficacy results for the ITT population and the PD-L1selected subgroup categories 
are shown in the section below.  Atezolizumab showed significant improvement in 
overall survival compared with docetaxel in patients with advanced, previously treated 
NSCLC unselected for PD -L1 expression.  OS in the ITT population was 12.6 months 
(95% CI: 9.7, 16.4) for atezolizumab versus 9.7 months (95% CI: 8.6, 12.0) for docetaxel 
(HR0.73; 95% CI: 0.53, 0.99; p 0.04).  PFS was similar between groups (2.7 months 
with atezolizumab vs. 3.0 months with docetaxel ). Objective responses with 
atezolizumab were durable, with a median duration of 14.3 months (95% CI: 11.6, not 
estimable) compared with 7.2 months (95% CI: 5.6, 12.5) for docetaxel 
(Fehrenbacher etal. 2016 ).
Table 6Efficacy  Results in the POPLA R Study :  Intent -to-Treat 
Population
Efficacy  EndpointAtezolizumab
(n144)Docetaxel
(n143)
Overall survival
No. of deaths (%) 78 (54.2) 95 (66.4)
Median (months)
95% CI12.[ADDRESS_76313] ratio
95% CI0.73
0.53, 0.99
Progression -free survival
No. of events (%) 124 (86.1) 121 (84.6)
Median (months)
95% CI2.[ADDRESS_76314] ratio
95% CI0.94
0.72, 1.23
Objective response rate (confirmed) 14.6% 14.7%
Duration of response
Median (months) 14.3 7.2
95% CI 11.6, NE 5.6, 12.5
NEnot estimable.
In summary, the data from the POPLAR study show that atezolizumab provides survival 
benefit in previously treated patients with NSCLC.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
44/Protocol GO29438 , Version [IP_ADDRESS] Clinical Efficacy  in Combination with Platinum -Based Doublet 
Chemotherapy  in Patients with NSCLC
As of the 10February [ADDRESS_76315] 
dose of atezolizumab by 10November 2014 were evaluable for efficacy ( n41).  
Patients who were enrolled into Arms C, D, and E received 15 mg/kgatezolizumab 
administered q3w in combination with carboplatin paclitaxel , carboplatin pemetrexed, 
and carboplatin nab-paclitaxel, respectively.  All patients had histologically or 
cytologically documented Stage IIIB, Stage IV ,or recurrent NSCLC and had not received 
prior chemotherapy for advanced disease.  The median age was 65 years, and 79% of 
patients had non -squamous histology.  The overall response rate in all three arms 
combined was 63% (26 of 41 patients) .
Within each cohort, the ORR was 50% (95% CI: 16%, 84%) in Arm C ( 4 PRs among 
8patients), 77% (95% CI: 50%, 93%) in Arm D ( 13PRs among 17patients), and 56%
(95% CI: 3 0%, 80%) in Arm E (5 PRs and 4complete responses [CRs] among 
16patients).  Patients with high levels of PD -L1 expression appeared to have higher 
response rates, but responses were also seen in patients with lower PD -L1 expression 
levels. Care ful attention was paid to the use of steroid premedication with pemetrexed in 
Arm Aof this study because of the potential for steroids to hinder atezolizumab activity.  
Specifically, efforts to reduce prophylactic steroid use were successful without resulting 
in any significant increase in the incidence of rash, nausea, or other related toxicities 
(Liuet al. 2015).
1.3.4 Clinical Pharmacokinetics and Immunogenicity
On the basis of available preliminary PK data (0.03 20 mg/kg), atezolizumab appeared 
to show linear pharmacokinetics at doses 1 mg/kg.  For the 1 -mg/kg and 20- mg/kg 
dose groups, the mean apparent clearance and the mean volume of distribution under 
steady -state conditions had a range of 3.11 to 4.14 mL/kg and 48.1 to67.0 mL/kg, 
respectively, which is consistent with the expected profile of an IgG1 antibody in humans.
The development of anti -therapeutic antibod ies (ATAs) has been observed in patients in 
all dose cohorts and was associated with changes in ph armacokinetics for some patients 
in the lower dose cohorts (0.3, 1, and 3 mg/kg).  The development of detectable ATAs 
has not had a significant impact on pharmacokinetics for doses from 10 to 20 mg/kg.  
Patients inthe 10- , 15-, and 20- mg/kg dose cohorts have maintained the expected target 
trough levels of drug despi[INVESTIGATOR_33384].  To date, no clear relationship 
between the detection of ATAs and adverse events or infusion reactions or efficacy has 
been observed.
1.3.5 Rationale for A tezolizumab Dosage
The fixed dose of 1200 mg (equivalent to an average body weight based dose of 
15 mg/kg) was selected on the basis of both nonclinical studies and available clinical 
data from Study PCD4989g as described below.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
45/Protocol GO29438 , Version 7The target exposure for atezolizumab was proje cted on the basis of nonclinical tissue 
distribution data in tumor -bearing mice, target -receptor occupancy in the tumor, the 
observed atezolizumab interim pharmacokinetics in humans, and other factors. The 
target trough concentrat ion (C trough) was proje cted to be 6 g/mL on the basis of several 
assumptions, including the following:  1) 95% tumor -receptor saturation is needed for 
efficacy and 2) the tumor -interstitial concentration to plasma ratio is 0.30 based on tissue 
distribution data in tumor -bearing mice.
The atezolizumab dose is also informed by [CONTACT_33444], safety, PK, and 
immunogenicity data. Anti-tumor activity has been observed across doses from 1 mg/kg 
to 20 mg/kg. The MTD of atezolizumab was not reached, and no DLTs have been 
observed at any dose in Study PCD4989g. Currently available PK and ATA data 
suggest that the 15 -mg/kg atezolizumab q3w regimen (or fixed -dose equivalent) for 
Phase II and Phase III studies would be sufficient to both maintain C trough6 g/mL and 
further safeguard against both interpatient variability and the potential effect of ATAs that 
could lead to subtherapeutic levels of atezolizumab relative to the 10 -mg/kg 
atezolizumab q3w regimen (or fixed -dose equivalent).  From inspection of available 
observed Ctroughdata, moving further to the 20 -mg/kg atezolizumab q3w regimen does 
not appear to be warranted to maintain targeted C trough levels relative to the proposed 
15-mg/kg atezolizumab q3w level.
Simulations ( Bai et al. 2012 ) do not suggest any clinically meaningful differences in
exposure following a fixed dose or a dose adjusted for weight.  Therefore, a fixed dose 
of 1200 mg has been selected (equivalent to an average body weight based dose of 
15mg/kg).  Selection of an every -21-day dosing interval is s upported by [CONTACT_33445].
Refer to the Atezolizumab Investigator’s Brochure for details regarding nonclinical and 
clinical pharmacology of atezolizumab.
1.[ADDRESS_76316] cancer can 
result in a significant survival benefit in patients with Stage IV cancer ( Hodi etal.2010 ; 
Kantoff et al. 2010 ; Chen et al. 2012 ).
PD-L1 is an extracellular protein that downregulates immune responses primarily in 
peripheral tissues through binding to its two receptors PD -1 and B7.1. PD-1 is an 
inhibitory receptor expressed on T cells following T -cell activation, which is sustained in 
states of chronic stimulation such as in chronic infection or cancer ( Blank etal.2005 ; 
Keir et al. 2008 ).Ligation of PD -L1 with PD -1 inhibits T -cell proliferation, cytokine 
production, and cytolytic activity, leading to the functional inactivation or exhaustion of 
Tcells.  B7.1 is a molecule expressed on antigen -presenting cells and activated T cells.  
PD-L1 binding to B7.1 on T cells and antigen -presenting cells can mediate 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
46/Protocol GO29438 , Version 7downregulation of immune responses, including inhibition of T- cell activation and 
cytokine production ( Butte et al. 2007 ; Yang etal.2011 ).
Overexpression of PD -L1 on TCs has been reported to impede anti -tumor immunity, 
resulting in immune evasion ( Blank and Mackensen 2007 ).  Therefore, interruption of the 
PD-L1/PD -[ADDRESS_76317] represents an attractive strategy to reinvigorate tumor -specific 
T-cell immunity.
PD-L1 expression is prevalent in many human tumors, and elevated PD -L1 expression 
is associated with a poor prognosis in patients with NSCLC ( Mu et al. 2011).
Targeting the PD -L1 pathway with atezolizumab has demonstrated activity in patients 
with advanced malignancies and who have failed standard of care therapi[INVESTIGATOR_014].  At the time 
of Study GO29438 initiation, Study PCD4989g , aPhase Ia dose -escalation and 
expansion st udy of patients treated with atezolizumab as a single agent had the 
following clinical activity :  345 evaluable patients were dosed by 21 October 2013 
(data cutoff date as of 21 April 2014) with a minimum of 6 months of follow -up; 
[ADDRESS_76318] v1.1 with an ORR of 18.0% 
(95% CI: 14.1% , 22.3%).   Objective responses were observed across a broad range of 
malignancies, including NSCLC, RCC, melanoma, and U BC.
In addition, as explained above, the POPLAR study key efficacy results for the ITT 
population and the PD -L1−selected subgroup categories indicate that an OS benefit in 
the atezolizumab arm was observed, with a stratified HR of 0.78 (95% CI: 0.59, 1.03) 
even though PFS and ORR for the atezolizumab arm were similar to those for the 
docetaxel arm.
1.4.[ADDRESS_76319] -line option for patients with locally 
advanced or metastatic NSCLC that is not har boring EGFR mutations or ALK gene 
rearrangements.  However, the survival benefit conferred by [CONTACT_70109] a plateau, with overall response rates of approximately 20% and 1 -year survival 
ranging from 31% to36% ( Schiller et al. 2002 ),leaving considerable room for 
improvement in outcomes.  TC killing by [CONTACT_70110], and 
invigorating tumor -specific T -cell immunity in this setting by [CONTACT_70111] -L1/PD -[ADDRESS_76320] 
chemotherapy alone ( Merritt et al. 2003 ; Apetoh et al. 2007).  Evaluating the safety and 
efficacy of these treatment combinations in NSCLC patients will enable future tests of 
this hypothesis.
The combination of platinum -based doublet chemotherapy and atezolizumab in NSCLC 
was evaluated in the Phase Ib study GP28328 as detailed in Section [IP_ADDRESS].  On the 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
47/Protocol GO29438 , Version 7basis of results observed in GP28328, Study GO29438 is designed to evaluate whether 
the anti -tumor effect seen in atezolizumab- treated patients would translate into
statistically significant and clinically relevant improvement in PFS and OS when used in 
combination with carboplatin or cisplatin pemetrexed compared with carboplatin or 
cisplatin pemetrexed in patients with non -squamous NSCLC. This study will allow for 
the evaluation of the efficacy of atezolizumab in the ITT population .
This study will enroll patients with Stage IV non -squamous NSCLC who are naive to 
chemotherapy treatment and for whom the experimental arm can represent a valuable 
treatment option and a reasonable benefit -risk balance.  Patients whose tumors are 
known to harbor sensitizing EGFR mutations or ALK rearrangements are excluded given 
that the appropriate and current standard -of-care treatments of these patients is with an 
EGFR tyrosine kinase or ALK inhibitor. 
In order to account for the possibility of pseudopr ogression and tumor -immune infiltration 
(i.e., radiographic increase in tumor volume due to the influx of immune cells) 
(Hales etal.2010 ) and the potential for delayed anti -tumor activity, this study will allow
patients treated with atezolizumab to recei ve treatment beyond the initial apparent 
radiographic progression (see Section 3.3.5 and Section 4.6) and will use modified 
RECIST (in addition to RECIST v1.1) to evaluate clinical benefit.  Because it is not yet 
possible to reliably differentiate pseudoprogression and tumor -immune infiltration from
true tumor progression, the risk exists that some patients who are not responding to 
treatment but yet continuing to receive atezolizumab may experience further progression 
of NSCLC and delay treatment with subsequent therapi[INVESTIGATOR_33386] .  
Investigators should make every effort to fully inform patients of this risk.
Atezolizumab has been generally well tolerated (see Section 1.3.2 ); adverse events with 
potentially immune- mediated causes consistent with an immunotherapeutic agent, 
including rash, hypothyroidism, hepatitis/transaminitis, colitis, and myasthenia gravis, 
have been observed in Study PCD4989g.  To date, these events have been 
manageable with treatment.
In summary, treatment with atezolizumab offers the potential for clinical benefit in 
NSCLC patients, in addition to platinum -based chemotherapy.  Patients will be fully 
informed of the risk of continuing study treatment in spi[INVESTIGATOR_70045], and investigators should make a careful assessment of the potential 
benefit of doing so, considering radiographic data, biopsy results, and the clinical status 
of the patient.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
48/Protocol GO29438 , Version 72. OBJECTIVES
Unless stated otherwise, the following objectives will be assessed in patients who are 
chemotherapy -naive and have stage IV non -squamous NSCLC (the ITT population) 
treated with atezolizumab carboplatin or cisplatin pemetrexed (Arm A) in comparison 
withcarboplatin or cisplatin pemetrexed (Arm B).
2.1 EFFICA CY OBJECTIVES
2.1.1 Co-Primary  Efficacy  Objectives
The co-primary objectives of this study are:
To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed 
PFS according to RECIST v1.1
To evaluate the efficacy of atezolizumab as measured by [CONTACT_70112]
2.1.2 Secondary  Efficacy Objectives
The secondary efficacy objectives for this study are:
To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed 
ORR according to RECIST v1.1
To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed 
DOR according to RECIST v1.1
To evalua te the OS rate at 1 and 2 years
To determine the impact of atezolizumab as measured by [CONTACT_70113] (TTD) 
in patient -reported lung cancer symptoms of cough, dy spnea (single- item and 
multi -item subscales), chest pain, or arm/shoulder pain using the European 
Organization for the Research and Treatment of Cancer (EORTC) Quality -of-Life 
Questionnaire Core 30 (QLQ -C30) and the supplemental lung cancer module 
(QLQ -LC13)
To determine the impact of atezolizumab as measured by [CONTACT_70114] -reported lung cancer symptoms (chest pain, dyspnea, and cough) scores 
using the Symptoms in Lung Cancer (SILC) scale symptom severity scores
2.2 SAFETY OBJECTIVES
The safety objectives for this study are:
To evaluate the safety and tolerability of atezolizumab when given in combination 
with carboplatin or cisplatin pemetrexed or as maintenance therapy with 
pemetrexed alone
To evaluate the incidence and titers of ATAs against atezolizumab and to explore 
the potential relationship of the immunogenicity response with pharmacokinetics, 
safety, and efficacy
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
49/Protocol GO29438 , Version 72.3 PHA RMA COKINETIC OBJE CTIVES
The PK objectives for this study are:
To characterize the pharmacokinetics of atezolizumab when given in combination 
with carboplatin or cisplatin pemetrexed or pemetrexed alone
To characterize the pharmacokinetics of carboplatin when given in combination w ith 
atezolizumab and pemetrexed
To characterize the pharmacokinetics of cis platin when given in combination with 
atezolizumab pemetrexed
To characterize the pharmacokinetics of pemetrexed when given in combination 
with atezolizumab carboplatin or cisplatin
2.4 EXPLORA TORY OBJECTIV ES
The exploratory objectives for this study are:
To evaluate the PFS rate at 6 -month and 1 -year landmark timepoints
To evaluate the OS rate at 3 years in each treatment arm
To evaluate the efficacy of atezolizumab as measured by [CONTACT_70115] -assessed PFS according to RECIST v1.1 in subgroups based on 
demographic and baseline characteristics
To evaluate the efficacy of atezolizumab as measured by [CONTACT_70089]
To evaluate the relationship between biomarkers in tumors and blood (including ,but 
not limited to ,PD-L1, PD -1, somatic mutations and others), as defined by
[CONTACT_70116](IHC), quantitative reverse transcriptase polymerase chain 
reaction (qRT -PCR), next -generation sequencing (NGS), and/or other methods and 
measures of efficacy
To assess predictive, prognostic, and pharmacodynamic exploratory biomarkers in 
archival and/or fresh tumor tissue and blood and their association with disease 
status, mechanisms of resistance, and/or response to study treatment
To evaluate and compare patient’s health status as assessed by [CONTACT_70090] 
5Dimensions 5 -Level (EQ -5D-5L) questionnaire to generate utility scores for use in 
economic models for reimbursement
To determine the impact of atezolizumab in each of the treatment comparisons 
described in Section 2.1.1 as measured by [CONTACT_70091] -reported 
outcomes (PROs) of health- related quality of li fe (HRQoL), lung c ancer related
symptoms, and health status as assessed by [CONTACT_20368] -C30 and QLQ -LC13

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
50/Protocol GO29438 , Version 73. STUDY DESIGN
3.1 DESCRIPTION OF STUDY
This is a randomized, Phase III, multicenter, open -label study (IMpower 132) designed to 
evaluate the safety and efficacy of atezolizumab in combi nation with cisplatin or 
carboplatin pemetrexed compared with treatment with cisplatin or 
carboplatin pemetrexed in patients who are chemotherapy -naive and have Stage IV 
non-squamous NSCLC. Figure 1illustrates the study design.  Schedules of 
assessments are provided in Appendix 1andAppendix 2.
Figure 1 Study Schema
ECOG PS Eastern Cooperative Onc ology  Group performance status ; NSCLC non small cell 
lung cancer ; RECIST v1.1 Response Evaluation Criteria in Solid Tumors ,Version 1.1.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
51/Protocol GO29438 , Version 7Eligible patients will be stratified by [CONTACT_4321] (male vs. female), smoking status (never vs. 
current and/or former), ECOG performance status (0 vs. 1) and chemotherapy regimen 
(carboplatin vs. cisplatin) and randomized bya1:1 ratio to receive one of the following 
treatment regimens as shown in Table 7 .
Table 7Study GO29438 Treatment A rms
Treatment ArmInduction
(Four or Six 21-Day Cycles)Maintenance
(21-Day Cycles)
A Atezolizumab carboplatin or 
cisplatin pemetrexedAtezolizumab pemetrexed
B Carboplatin or cisplatin pemetrexed Pemetrexed
The number of cycles of induction treatment (four or six) will be at the discretion of the 
investigator and will be determined and documented prior to randomization.  Induction 
treatment will be administered on a 21- day cycle until the following occurs (whichever 
occurs first):  1) adminis tration of four or six cycles, 2) unacc eptable toxicity, or 
3)documented disease progression .
Following the induction phase, pat ients who have not experienced disease progression 
or unacceptable toxicity will continue treatment with maintenance therapy as shown in 
Table [ADDRESS_76321] igator as described below:
For Treatment A rm A
During treatment (induction or maintenance), patients who show evidence of clinical 
benefit will be permitted to continue atezolizumab after RECIST v1.1 for progressive 
disease are met if they meet all of the following criteria:
Evidence of clinical benefit as assessed by [CONTACT_093]
Absence of symptoms and signs (including worsening of laboratory values 
[e.g., new or worsening hypercalcemia]) indicating unequivocal progression 
ofdisease
No decline in ECO G performance status that can be attributed to disease 
progression
Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal 
disease) that cannot be managed by [CONTACT_990] -allowed medical interventions
Patients must provide written consent to acknowledge deferring other treatment 
options in favor of continuing study treatment at the time of initial progression.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
52/Protocol GO29438 , Version 7Treatment with chemotherapy (both in Arm A and B) should be discontinued in all 
patients who exhibit evidence of progressive dis ease by [CONTACT_393] v1.1.
Patients will undergo tumor assessments at baseline and every [ADDRESS_76322] v1.1 or loss of clinical benefit (for atezolizumab- treated only patients who 
continue treatment after radiographic disease progression according to RE CIST v1.1), 
withdrawal of consent, study termination by [CONTACT_2728], or death, whichever occurs first.  
Patients who discontinue treatment for reasons other than radiographic disease 
progression (e.g., toxicity) will continue scheduled tumor assessments until radiographic 
disease progression per RECIST v1.1 or loss of clinical benefit (for atezolizumab -treated 
patients who continue treatment after radiographic disease progression according to 
RECIST v1.1), withdrawal of consent, study termination by [CONTACT_2728], or death, whichever 
occurs first, regardless of whether patients start a new anti -cancer therapy.
All primary imaging data used for tumor assessment will be collected by [CONTACT_70117], independent review of response endpoints . The indepe ndent 
reviews of the stored scans will be performed when requested.  
This study will initially enroll approximately [ADDRESS_76323] 1 patient is enrolled in China during the global enrollment 
phase, additional patients will be enrolled in a China extension phase as needed to 
ensure a total enrollment of approximately 164 patients in China treate d with cisplatin 
and pemetrexed atezoli zumab.  The China subpopulation will include patients enrolled 
at sites in China during both the global enrollment phase and the China extension phase.
3.1.1 Independent Data Monitoring Committee
An independent Data Monitoring Committee (iDMC) will be used to evaluate safety data 
when a minimum of 12 patients receiving cisplatin -based chemotherapy havebeen 
enrolled into each treatment arm with a minimum follow -up of approximately 60 days , 
and then approximately every 6 months thereafter until the study isunblinded for primary 
efficacy ana lyses or the study is terminated by [CONTACT_1034] .
The Sponsor will remain blinded to the efficacy results until the final PFS analysis.  
Allsummaries and analyses by [CONTACT_70118] (iDCC).  The safety data will include 
disposition, demographic data, adverse event data ( e.g.,serious adverse events and 
adverse events of special interest), study conduct data, and relevant laboratory data. 
Efficacy data (excluding data on deaths ) will not be included in the iDMC safety data 
reviews.  Following the safetydata review, the iDMC will provide a recommendation as 
to whether the study may continue, whether amendment(s) to the protocol should be 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
53/Protocol GO29438 , Version 7implemented, or whether the study should be stopped.  The final decision will rest with 
the Sponsor.
Members of the iDMC will be external to the Sponsor and will follow a separate iDMC 
Charter that outlines their roles and responsibilities.
Any outcomes of these safety or efficacy reviews that af fect study conduct will be 
communicated in a timely manner to the investigators for notification of the Institutional 
Review Boards (IRBs) and Ethics Committees (ECs).
3.[ADDRESS_76324] been enrolled into an extension study.  T he Sponsor may decide 
to terminate the study at any time.  If the Sponsor decides to end the study, patients who 
are still receiving study treatment or are in survival follow -up may be offered enrollment 
in an extension study or a non -interventional study.
3.3 RATIONA LE FOR STUDY DESIGN
3.3.1 Rationale for Testing Atezolizumab in Patients with 
PD-L1Unselected NSCLC
Despi[INVESTIGATOR_70046], the prog nosis for patients with advanced 
NSCLC remains dismal, with a median OS of approximately 12.3 months 
(Sandler etal.2006 ).  Patients who receive second -line treatment for their disease 
have an even more limited prognosis, with a median survival duration o f 
approximately 89months ( Stinchcombe et al. 2008).  Approved therapi[INVESTIGATOR_70047] (e.g., neuropathy, febrile neutropenia, 
myelosuppression, and alopecia) that negatively affect quality of life.  Therefore, there is 
a cont inuing need for more efficacious, better -tolerated treatments.
Inhibition of PD -L1/PD -1 signaling has been shown to produce durable responses in 
some patients, and expression of PD -L1 by [CONTACT_70119] 
(including NSCLC) correlates with response to therapy ( Topalian et al. 2012).
Atezolizumab monotherapy has demonstrated clinical efficacy and is generally 
well-tolerated in patients with squamous or non -squamous NSCLC ( Besse et al. 2015 ; 
Horn etal.2015 ; Spi[INVESTIGATOR_70048]. 2015 ; Fehrenbacher et al. 2016 ).  In the second- and 
third-line setting, the POPLAR study, the first randomized Phase II study of atezolizumab 
inadvanced NSCLC, showed significant improvement in OS with atezolizumab 
(12.6 vs.9.7 months; HR 0.73, 95% CI: 0.53, 0.99, p 0.04) ve rsus docetaxel 
(Fehrenbacher etal. 2016 ).  In patients with squamous and non- squamous disease, 
OSwas 10.1 versus 8.6 months (HR 0.80, 95% CI: 0.49, 1.30) and 15.5 versus 
10.9 months (HR 0.69, 95% CI: 0.47, 1.01), respectively, in the atezolizumab arm
compared with the docetaxel arm ( Fehrenbacher etal. 2016 ).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
54/Protocol GO29438 , Version 7On the basis of promising efficacy activity of atezolizumab as a single agent ( POPLAR,
Study PCD4989g) and in combination with platinum -doublet therapy (Study GP28328) 
and the safety findings from Study GP28328 indicating no additive toxicity of 
atezolizumab in combination with platinum -based chemotherapy or bevacizumab, this 
study will evaluate atezolizumab in combination with platinum -based chemotherapy.  
TCkilling by [CONTACT_70120], and invigorating tumor -specific T -cell immunity in this setting by 
[CONTACT_70121] -L1/PD -[ADDRESS_76325] chemotherapy alone ( Merritt et al. 2003 ; Apetoh et al. 2007 ),
and this may reasonably occur in tumors regardless of PD -L1 expression.
3.3.[ADDRESS_76326] -line treatment for advanced stage non -squamous 
NSCLC is a platinum doublet with eit her cisplatin orcarboplatin and pemetrexed.  In this 
study, all patients in the experimental arm will receive the platinum doublet of carboplatin 
or cisplatin with pemetrexed with atezolizumab followed by [CONTACT_70122] atezolizumab.  The contro l group will receive the combination of 
carboplatin or cisplatin pemetrexed followed by [CONTACT_70123] .  This control 
group is recognized as a standard ofcare for the first -line treatment of non-squamous
NSCLC based on the results of the two previous Phase III studies as stated above 
andis the most commonly used first -line regimen in the [LOCATION_002] and Europe 
(see Section 1.1).
3.3.3 Rationa le for Open -Label Study
An open -label study design was chosen for this study for the following reasons:  
ablinded study would require prolonged administration of placebo during the 
maintenance phase, which could pose a significant burden to patients. Furthermore, 
because of the potential for pseudoprogression in patients randomized to atezolizumab -
containing arms, a blinded study would require the option that all patients continue 
treatment until loss of clinical benefit regardless of whether they were re ceiving 
atezolizumab. In the absence of pseudoprogression, this could then delay subsequent 
treatment with approved therapi[INVESTIGATOR_70049], 
as well as increase the complexity of treatment decisions.
Adequate steps ha ve been taken to ensure the validity of data in an open -label study 
design. This includes performing a sensitivity analysis to demonstrate the robustness of 
the co-primary endpoint s, defining progression using established response evaluation 
criteria (REC IST v1.1), performing tumor assessments at the same frequency in all arms, 
adhering to protocol -defined schedules, and determining the strategy for the final 
analysis of the co-primary endpoint sprior to study start, including predefined methods 
for handli ng missing data and censoring rules. Final efficacy analyses will only be 
performed at the prespecified analysis timepoints in the protocol.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
55/Protocol GO29438 , Version 73.3.[ADDRESS_76327] that OS may be a more sensitive endpoint for cancer 
immunotherapy than PFS.  For example, in the randomized Phase II POPLAR study in 
patients with advanced NSCLC, an OS benefit in the atezolizumab arm compared with 
the docetaxel arm was observed, with a stratified HR of 0.73 (95% CI: 0.53, 0.99) 
(Fehrenbacher et al. 2016 ).  In addition, OS is the most objective and best measure of 
clinical benefit for patients with advanced, unresectabl e, or metastatic lung cancer.
However, given that the majority of patients in this study will likely receive subsequent 
therapi[INVESTIGATOR_13265]/or palliative care (Temel et al. 2010 ), the OS analysis may be 
confounded (Miller et al. 2012 ). Therefore, investigator -assessed PFS is being retained 
as a co -primary endpoint ,and crossover from the control arm to the experimental arm 
will not be permitted with the aim of preserving the study’s ability to potentially 
demonstrate treatment benefit of atezolizum ab on OS.
PFS as an endpoint can reflect tumor growth and can be assessed before the 
determination of a survival benefit; inaddition, its determination is not generally 
confounded by [CONTACT_70124][INVESTIGATOR_014].  W hether an improvement in PFS represents a 
direct clinical benefit or a surrogate for clinical benefit depends on the magnitude of the 
effect and the benefit -risk of the new treatment compared with available therapi[INVESTIGATOR_014] 
(Guidance for Industry 2007 ; European Medicines Agency 2012 ).  To ensure the validity 
of investigator- assessed PFS as a co- primary endpoint, a number of measures have 
been implemented:  a substantial, clinically meaningful target magnitude of benefit 
(target HR of 0.65 in the ITT population), and study assessments that will allow a robust 
evaluation of risk -benefit (standard RECIST to define progression with fixed assessment 
intervals that are identical in all treatment arms and a robust definition of PFS and 
prospectively defined methods to assess, quantify, and analyze PFS, including 
sensit ivity analyses).
New treatment modalities, such as targeted therapi[INVESTIGATOR_70050], are emerging 
as highly effective regimens that are providing improvements in patient outcomes far 
beyond what was achieved before ( Ellis et al. 2014).  In particular, immunotherapy has 
been correlated or associated with durable responses, significant prolongation of PFS, 
and improvement of quality of life.  In addition, meta -analyses have indicated that PFS 
can be considered a good measure of clinical benefit for patien ts with locally advanced
and/or metastatic NSCLC ( Laporte et al. 2013 ).
3.3.5 Rationale for A llowing Patients to Continue A tezolizumab 
Treatment until Loss of Clinical Benefit
Conventional response criteria may not adequately assess the activity of 
immunotherapeutic agents because progressive disease (by [CONTACT_70125]) does not necessarily reflect therapeutic failure.  Because of the potential for 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
56/Protocol GO29438 , Version 7pseudoprogres sion and tumor -immune infiltration, this study will allow patients 
randomized to the atezolizumab treatment arms to remain on atezolizumab after 
apparent radiographic progression, provided the benefit -risk ratio is judged to be 
favorable.  Patients should be discontinued for unacceptable toxicity or symptomatic 
deterioration attributed to disease progression as determined by [CONTACT_70126] (see Section 3.1). 
3.3.[ADDRESS_76328] negative effects on HRQoL
(Hyde andHyde 1974 ; Hopwood and Stephens 1995 ; Sarna et al. 2004).  This is 
especially true for studies that use PFS as a primary endpoint, where it is important 
tobetter understand in what regard the delay in disease progr ession is meaningful 
topatients.
Chest pain, dyspnea, and cough have been regarded as the most frequent and clinically 
relevant disease- related symptoms experienced by [CONTACT_70127].  The BR.21 
study (erlotinib vs. BSC in second- or third- line NSCLC) demonstrated that longer TTD in 
the pain, dyspnea, and cough scales of the EORTC QLQ -C30 and EORTC QLQ -LC13 
was consistent with superior PFS, OS, and QoL benef its in the erlotinib arm compared 
with the placebo arm ( Aaronson et al. 1993 ; Bergman etal.1994 ; Bezjak etal.2006 ).  
Patients in the afatinib LUX -Lung first -line study also reported significant delay of TTD in 
lung cancer symptoms (chest pain, dyspnea, and cough ) as measured by [CONTACT_70128] -C30 and EORTC QLQ -LC13 ( Yang et al. 2013).  In this st udy, the validated 
EORTC QLQ -C30 and EORTC QLQ -LC13 will be used to assess HRQoL and 
symptom severity.
In addition, the SILC scale wi ll be used to assess the effect and impact of atezolizumab 
as measured by [CONTACT_70129] -reported spec ific lung cancer 
symptoms (chest pain, dyspnea, and cough) in patients with Stage IV, non- squamous 
NSCLC in the first -line setting.
The EQ -5D-5L (see Appendix 9) is included in the study to generate utility scores for use 
in economic models for reimbursement.  Results from the EQ -5D-5L are not planned to 
be used for market authorization.
3.3.7 Rationale fo r Collection of A rchiv al and/or Fresh Tumor 
Specimens
Published results suggest that the expression of PD -L1 in tumors correlate swith 
response to anti PD-1 therapy ( Topalian et al. 2012).  This correlation was als o 
observed with atezolizumab in Study PCD4989g (Herbst et al. 2014 ; Horn et al. 2015 ), 
and the FIR ( Spi[INVESTIGATOR_70051]. 2015 ), BIRCH (Study GO28754) (Besse et al. 2015), and 
POPLAR (Fehrenbacher etal.2016 ) studies. In this study, although tumor tissues are 
not required for enrollment, baseline archival and/or fresh tumor specimens from 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
57/Protocol GO29438 , Version 7patients will be obtained if available and may be tested (retrospectively) for PD -L1 
expression by a central laboratory .
In addition to the assessment of PD -L1 status, other exploratory markers, such as 
potential predictive and prognostic markers related to the clinical benefit of atezolizumab, 
tumor immunobiology, mechanisms of resistance, or tumor type, may also be analyzed.  
DNA and/or RNA extraction and analysis may be performed to enable identification of 
somatic mutations by [CONTACT_70130] (including ,but 
not limited to ,PD-L1, PD -1, T-effector cells,and others) to assess their association with 
efficacy and to increase understanding of disease pathobiology.
3.3.8 Rationale for Blood Sampling for Biomarker s
An exploratory objective of this study is to evaluate surrogate biomarkers (that may 
include circulating tumor DNA [ ctDNA ], gene expression, and others ) in blood samples.  
Evaluation of blood biomarkers may provide evidence for biologic activity of 
atezolizumab in patients with NSCLC and may allow for the development of blood -based 
biomarkers to help predict which patients may benefit from atezolizumab.
In addition, potential correlations of these biomarkers with the safety and activity of 
atezolizumab will be explored.
3.4 OUTCOME MEA SURES
3.4.1 Efficacy  Outcome Measures
[IP_ADDRESS] Co-Primary  Efficacy  Outcome Measures
The primary efficacy outcome measure sfor this study are:
PFS, defined as the time from randomization to the first occurrence of disease 
progression as determined by [CONTACT_26309] v1.[ADDRESS_76329] -baseline tumor assessment will be censored at 
the randomization date plus 1 day.
OS, defined as the time from randomization to death from any cause
[IP_ADDRESS] Seco ndary  Efficacy Outcome Measures
The secondary efficacy outcome measures for this study are:
Objective response, defined as PR or CR as determined by [CONTACT_70131] v1.1
DOR, defined as the time interval from first occurrence of a documented objective 
response to the time of disease progression as determined by [CONTACT_26218] v1.[ADDRESS_76330]
OS at 1 -and 2-year landmark timepoints
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
58/Protocol GO29438 , Version 7TTD in patient -reported lung cancer symptoms, defined as time from randomization 
to deterioration (10 -point change) on each of the EORTC QLQ -C30 and 
EORTC QLQ -LC13 symptom subscales 
Change from baseline in patient -reported lung cancer symptoms (cough, dyspnea, 
or chest pain )with use of the SILC scale symptom score
3.4.2 Safety  Outcome Measures
The safety outcome measures for this study are:
Incidence, nature, and severity of adverse events graded according to the 
NCICTCAE v4.0
Changes in vital signs, physical findings, and clinical laboratory results during an d 
following study treatment administration
Incidence of ATA response to atezolizumab and potential correlation with PK, 
pharmacodynamic, safety, and efficacy parameters
3.4.3 Pharmacokinetic Outcome Measures
The PK outcome measures for this study are the following:
Maximum observed serum atezolizumab concentratio n (C max) after infusion (Arm A)
Minimum observed serum atezolizumab concentrati on (C min) prior to infusion at 
selected cycles, at treatment discontinuation, and at 120 days ( 30days) after the 
last dose of atezolizumab (Arm A)
Plasma concentrations for carboplatin or cisplatin (Arm A)
Plasma concentrations for pemetrexed (Arm A) 
SeeAppendix 2for specific sample collection times.
3.4.4 Exploratory  Outcome Measures
The exploratory outcome measures for this study are:
PFS at 6-month and 1 -year landmark timepoints
OS rate at 3 -year landmark timepoint
Milestone survival
OS and investigator -assessed PFS according to RECIST v1.1 in subgroups based 
on demographic and baseline characteristics
Status of PD -L1, immune -and NSCLC- related and other exploratory biomarkers in 
archival and/or fresh tumor tissues, and blood (or blood derivatives) collected before, 
during, or after treatment with atezolizumab or at progression and association with 
disease status and/o r response to atezolizumab in combination with chemotherapy
Utility scores of the EQ -5D-5L
Change from baseline in PROs of HRQoL , lung cancer related symptoms, and 
health status as assessed by [CONTACT_20368] -C30 and QLQ -LC13

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
59/Protocol GO29438 , Version 74. MATERI ALS AND METHOD S
4.[ADDRESS_76331] meet all of the following criteria to be eligible for study entry:
Signed Informed Consent Form
Male or female, 18 years of age or older
ECOG performance status of 0 or 1 (see Appendix 10)
Histologically or cytologically confirmed, Stage IV non -squamous NSCLC ( per the 
Union Internationale contre le Cancer/American Joint Committee on Cancer staging 
system, 7th edition; Detterbeck et al. 2009 ; see Appendix 3)
Patients with tumors of mixed non -small cell histology (i.e., squamous and 
non-squamous) are eligible if the major histological component appears to be 
non-squamous.
No prior treatment for Stage IV non -squamous NSCLC
Patients with a sensitizing mutation in the EGFR gene are excluded given that 
erlotinib, gefitinib, or another EGFR TKI is the appropriate initial treatment of 
EGFR -mutant NSCLC.
Patients with an ALK fusion oncogene are excluded given that crizotinib or 
other ALK inhibitors is the appropriate initial treatment of NSCLC in patients 
having an ALK fusion oncogene.
Patients with unknown EGFR and ALK status require test results at screening. 
ALK and/or EGFR may be assessed at a local or central laboratory.
Patients who have received prior neo- adjuvant, adjuvant chemotherapy, 
radiotherapy, or chemoradiotherapy with curative intent for non -metastatic disease 
must have experienced a treatment -free interval of at least [ADDRESS_76332] dose ofchemotherapy and/or radiotherapy
Patients with a history of treated asymptomatic CNS metastases are eligible, 
provided they meet all of the following criteria:
Only supratentorial and cerebellar metastases allowed (i.e., no metastases to 
midbrain, pons, medulla ,or spi[INVESTIGATOR_1831])
No ongoing requirement for corticosteroids as therapy for CNS disease
No stereotactic radiation within 7 days or whole -brain radiation within 14 days 
prior to randomization

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
60/Protocol GO29438 , Version 7No evidence of interim progression between the completion of CNS -directed 
therapy and t he screening radiographic study
Patients with new asymptomatic CNS metastases detected at the screening scan 
must receive radiation therapy and/or surgery for CNS metastases.  Following 
treatment, these patients may then be el igible without the need for an additional 
brain scan prior to randomization, if all other criteria are met.
Patients should submit a pre -treatment tumor tissue sample (if available).  If tumor 
tissue is not available (e.g., depleted for prior diagnostic te sting), patients are still 
eligible. 
If tumor tissue is available, a representative formalin -fixed paraffin -embedded 
(FFPE) tu mor specimen in paraffin block or unstained, freshly cut, serial sections 
(preferably at least 10) from an FFPE tumor spe cimen are preferred.  If 10 sections 
are not available, fewer can be submitted. 
If FFPE specimens described above are not available, any type of specimens 
(including fine -needle aspi[INVESTIGATOR_1516], cell pellet specimens [e.g., from pleural effusion], 
and lavage samples) are also acceptable.
This specimen should be accompanied by [CONTACT_40869].  
See Section [IP_ADDRESS] for further details.
Any available tumor tissue sample should be submitted before or within 
4weeks after enrollment.
Measurable disease, as defined by [CONTACT_393] v1.1
Previously irradiated lesions can only be considered as measurable disease if 
disease progr ession has been unequivocally documented at that site since 
radiation and the previously irradiated lesion i s not the only site of disease.
Adequate hematologic and end organ function, defined by [CONTACT_40855] 14 days pri or to randomization:
ANC 1500 cells/ L without granulocyte colony -stimulating factor support
Lymphocyte count 500/ L
Platelet count 100,000/ L without transfusion
Hemoglobin 9.0 g/dL
Patients may be transfused to meet this criterion.
INR or aPTT 1.5upper limit of normal (ULN)
This applies only to patients who are not receiving therapeutic anticoagulation; 
patients receiving therapeutic anticoagulation should be receiving a stable 
dose.
AST, ALT, and alkaline phosphatase 2.5ULN, with the following exceptions:
Patients with documented liver metastases:  AST and/or ALT 5ULN
Patients with documented liver or bone metastases:  alkaline phosphatase 
5ULN

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
61/Protocol GO29438 , Version 7Serum bilirubin 1.25ULN
Patients with known Gilbert disease who have serum bilirubin level 3ULN 
may be enrolled.
Calculated creatinine clearance (CRCL) 45 m L/min or, if using cisplatin, 
calculated CRCL must be 60 mL/min
For patients enrolled in the extended China enrollment phase: current resident of 
mainland China, Hong Kong, or Taiwan and of Chinese ancestry
For women of childbearing potential:  agreement to remain abstinent (refrain 
from heterosexual intercourse) or use contraceptive methods that result in 
afailure rate of 1% per year during the tr eatment period and for at least
5months after the last dose of atezolizumab and6 months after the last dose of 
cisplatin , carboplatin, or pemetrexed .  Women must refrain from donating eggs 
during this same period.
A woman is considered to be of childbearing potential if she is postmenarcheal , 
has not reached a postmenopausal state ( 12continuous months of 
amenorrhea with no identified cause other than menopause), and has not 
undergone surgical sterilization (removal of ovaries and/or uterus).
Examples of non -hormonal contraceptive methods with a failure rate of 
1%per year include bilateral tubal ligation, male sterilization, established, 
proper use of hormonal contraceptives that inhibit ovulation, hormone -releasing 
intrauterine devices, and copper intrauterine devices.
The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., c alendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contraception.
For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or 
use contraceptive measures and agreement to refrain from donating sperm, as 
defined below:
With partners of childbearing potential, men must remain abstinent or use a 
condom plus an additional contraceptive method that together result in a failure 
rate of 1% per year during the chemotherapy treatment peri od and for at least 
6months after the last dose of chemotherapy .
With pregnant partners, men must remain abstinent or use a condom during the 
chemotherapy treatment period and for at least [ADDRESS_76333] dose of 
chemotherapy .
The reliability of s exual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not ac ceptable methods of contraception.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
62/Protocol GO29438 , Version 74.1.2 Exclusion Criteria
Patients who meet any of the criteria below will be excluded from study entry.
[IP_ADDRESS] Cancer- Specific Exclusions
Patients with a sensitizing mutation in the EGFR gene or an ALK fusion oncogene
Active or untreated CNS metastases as determined by [CONTACT_70132] ( MRI) evaluation during screening and prior radiographic assessments
Spi[INVESTIGATOR_33373]/or radiation or 
previously diagnosed and treat ed spi[INVESTIGATOR_33395]2weeks prior to randomization
Leptomeningeal disease
Uncontrolled tumor -related pain
Patients requiring pain medication must be receiving a stable regimen at s tudy 
entry.
Symptomatic lesions amenable to palliative radiotherapy (e.g., bone 
metastases or metastases causing nerve impi[INVESTIGATOR_20804]) should be treated prior 
to randomization.  Patients should be recovered from the effects of radiation.  
There is no required minimum recovery period.
Asymptomatic metastatic lesions whose further growth would likely cause 
functional deficits or intractable pain (e.g., epi[INVESTIGATOR_70052]) should be considered 
forloco-regional therapy, if appropriate, prior to randomization.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent 
drainage procedures (once monthly or more frequently)
Patients with indwelling catheters (e.g., PleurX®) are allowed.
Uncontrolled or symptomatic hypercalcemia ( 1.5 mmol/L ionized calcium or 
calcium 12 mg/dL or corrected serum calcium ULN)
Patients who are receiving denosumab prior to randomization must be willing 
and eligible to discontinue its use and replace it with a bisphosphonate instead 
while in the study.
Malignancies other than NSCLC within 5 years prior to randomization, with the 
exception of those with a negligible risk of metastasis or death (e.g., expected 
5-year OS90%) treated with expected cura tive outcome (such as adequately 
treated carcinoma in situ of the cervix, basal or squamous -cell skin cancer, localized 
prostate cancer treated surgically with curative intent, ductal carcinoma in situ 
treated surgically with curative intent)
Known tumor P D-L1 expression status as determined by [CONTACT_70133] (e.g., patients whose PD -L1 expression status was determined 
during screening for entry into a study with anti -PD-1 or anti PD-L1 antibodies 
butwere not eligible are excluded )
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
63/Protocol GO29438 , Version [IP_ADDRESS] General Medical Exclusions
Women who are pregnant, lactating, or intending to become pregnant during the 
study
History of severe allergic, anaphylactic, or other hypersensitivity reactions 
tochimeric or humanized antibodies or fusion proteins
Known hyp ersensitivity or allergy to biopharmaceuticals produced in Chinese 
hamster ovary cells or any component of the atezolizumab formulation
History of autoimmune disease, including but not limited to myasthenia gravis, 
myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, 
inflammatory bowel disease, vascular thrombosis associated with antiphospholipid 
syndrome, W e gener granulomatosis, Sjögren’s syndrome, Guillain -Barré syndrome, 
multiple sclerosis, vasculitis, or glomerulonephritis (see Appendix 12fora 
comprehensive list of autoimmune diseases)
Patients with a history of autoimmune -related hypothyroidism who are receiving
a stable dose of thyroid- replacement hormone are eligible for this study.
Patients with controlled Type 1 diabetes mellitus who are receiving a stable 
dose of insulin regimen are eligible for this study.
Patients with eczema, psoriasis, lichen simplex chr onicus of vitiligo with 
dermatologic manifestations only (e.g., patients with psoriatic arthritis would be 
excluded) are permitted provided that they meet the following conditions:
Rash must cover less than 10% of body surface area .
Disease is well controlled at baseline and only requiring low -potency topi[INVESTIGATOR_28709] .
No acute exacerbations of underlying condition within the last 12 months 
(not requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, 
retinoids, biologic agents, or al calcineurin inhibitors, or high-potency or oral 
steroids)
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis 
obliterans), drug -induced pneumonitis, idiopathic pneumonitis, or evidence of active 
pneumonitis on screening chest CT scan
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
Positive test for HIV
All patients will be tested for HIV prior to the inclusion into the study and 
HIV-positive patients will be excluded from the clinical study.
Patients with active hepatiti s B (chronic or acute; defined as having a positive 
hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C
Patients with past hepatitis B virus (HBV) infection or resolved HBV infection 
(defined as the presence of hepatit is B core antibody [HBcAb] and absence of 
HBsAg) are eligible only if they are negative for HBV DNA.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
64/Protocol GO29438 , Version 7Patients positive for hepatitis C virus (HCV) antib ody are eligible only if P CR is 
negative for HCV RNA.
Active tuberculosis
Severe infections within 4 wee ks prior to randomization, including but not limited to 
hospi[INVESTIGATOR_33377], bacteremia, or severe pneumonia
Received therapeutic oral or IV antibiotics within 2 weeks prior to randomization
Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract 
infection or to prevent chronic obstructive pulmonary disease exacerbation) are 
eligible.
Significant cardiovascular disease, such as [LOCATION_001] Heart Association cardiac 
disease (Class II or greater), myocardial infarction, or cerebrovascular accident
within [ADDRESS_76334] ion fraction 50% must be 
receiv inga stable medical regimen that is optimized in the opi[INVESTIGATOR_70053], in consultation with a cardiologist if appropriate.
Major surgical procedure other than for diagnosis within 28 days prior to 
randomiz ation or anticipation of need for a major surgical procedure during the 
course of the study
Prior allogeneic bone marrow transplantation or solid organ transplant
Administration of a live attenuated vaccine within 4 weeks before randomization or 
anticipati on that such a live attenuated vaccine will be required during the study
Any other diseases, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding giving reasonable suspi[INVESTIGATOR_1884] a disease or condition that 
contraindicates the use of an investigational drug or that may affect the 
interpretation of the results or render sthe patient at high risk from treatment 
complications
Illness or condition that may interfere with a patient’s capacity to understand, follow, 
and/or comply with study procedures
[IP_ADDRESS] Exclusion Criteria Related to Medications
Prior treatment with EGFR inhibitors or ALK inhibitors
Any approved anti -cancer therapy, including hormonal therapy within 21days prior 
to initiation of study treatment .
Treatment with any other investigational agent with therapeutic intent within 28 days 
prior to randomization
Prior treatment with CD137 agonists or immune checkpoint blockade therapi[INVESTIGATOR_014], 
antiPD-1, and anti PD-L1 therapeutic antibodies
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
65/Protocol GO29438 , Version 7Patients who have had prior anti cytotoxic T -lymphocyte associated antigen 4 
(CTLA -4) treatment may be enrolled, provided the following requirements 
aremet:
Last dose of anti -CTLA-[ADDRESS_76335] 6 weeks prior to randomization
No history of severe immune- related adverse effects from anti -CTLA-4 
(NCI CTCAE Grade 3 and 4)
Treatment with systemic immunostimulatory agents (including ,but not limited to ,
interferons, interleukin 2) within 4 weeks or 5 half -lives of the drug, whichever is 
longer, prior to randomization
Prior treatment with cancer vacci nes is allowed.
Treatment with systemic immunosuppressive medications (including ,but not limited 
to,corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and 
antitumor necrosis factor [anti -TNF] agents) within [ADDRESS_76336] received acute, low -dose (10mg oral prednisone or 
equivalent) , systemic immunosuppressant medications may be enrolled in 
thestudy.
The use of corticosteroids (10mg oral prednisone or equivalen t) for chronic 
obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone ) 
forpatients with orthostatic hypotension, and low -dose supplemental 
corticosteroids for adrenocortical insufficiency are allowed.
[IP_ADDRESS] Exclusion Criteria Related to Chemo therapy
History of allergic reactions to cisplatin, carboplatin, or other platinum -containing 
compounds
Patients with hearing impairment (cisplatin)
Grade 2peripheral neuropathy as defined by [CONTACT_4652] v4.0 (cisplatin)
CRCL 60 mL/min for cisplatin or 45 mL/min for carboplatin
4.2 METHOD OF TREA TMENT ASSIGNMENT A ND BLIND ING
This is an open -label study.
After written informed consent has been obtained and eligibility has been established, 
the study site will enter demographic and baseline characteristics in the interactive 
voice/W eb response syste m (IxRS).  For patients who are eligible for enrollment, the 
study site will obtain the patient’s randomization number and treatment assignment from 
the IxRS.  The number of cycles of induction treatment (four or six) will be determined by 
[CONTACT_70134].
Randomization to one of the two treatment arms 
(carboplatin/cisplatin pemetrexed atezolizumab or carboplatin/cisplatin pemetrexed) 
will occur in a 1:1 ratio.  Permuted -block randomization will be applied to ensure a 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
66/Protocol GO29438 , Version 7balanced assignment to each treatment arm.  Randomization will be stratified by [CONTACT_70135]:
Sex (male vs. female)
Smoking status (never vs. current or former)
ECOG performance status (0 vs. 1)
Chemotherapy (cisplatin vs. carboplatin)
Patients should receive their first dose of study drug on the day of randomization if 
possible.  If this is not possible, the first dose should occur within 5 business days after 
randomization.
4.3 STUDY TRE ATMENT
4.3.1 Formulation, Packaging, and Handling
[IP_ADDRESS] Atezolizumab
The atezolizumab drug product is provided as a sterile liquid in 20- mL glass vial s.  
Thevial is designed to deliver 20 mL (1200 mg ) of atezolizumab solution but may 
contain more than the stated volume to e nable delivery of the entire 20 -mL volume.
For further details on the formulation and handling of atezolizumab , see the Pharmacy 
Manual and Investigator’s Brochure.
[IP_ADDRESS] Carboplatin or Cisplatin Pemetrexed
The comparator arm includes a platinum -based regimen (carboplatin or cisplatin 
based on investigator’s choice) pemetrexed.  This stu dy will randomize approximately
568patients in the global enrollment phase.
After the global enrollment phase, additional patients may be enrolled in China to ensure 
a total of approximately 164 patients in the China cisplatin subpopulation, including 
those enrolled in China in the global enrollment phase.  P atients enrolled in the China 
extension phase will receive cisplatin.
Each study drug will be used in the commercially a vailable formulation (with the 
exception of atezolizumab) and will be provided by [CONTACT_70136] (IMP) by [CONTACT_19566] l regulations (see Section 4.3.3 ).
For information on the formulation, packaging, and handling of cisplatin, carboplatin, and 
pemetrexed, see the local prescribing information for each drug .

 
Atezolizumab—F. Hoffmann-La [COMPANY_002] Ltd 
67/Protocol GO29438, Version [ADDRESS_76337] of four or six cycles of chemotherapy, each 
cycle being 21 days in duration.  On Day 1 of each cycle, all eligible patients will receive drug infusions in the following order: 
Arm A:  Atezolizumab  [carboplatin or cisplatin
  pemetrexed] 
Arm B:  [carboplatin or cisplatin   pemetrexed] 
 
During the induction phase, a chemotherapy cycle counts toward the prespecified 
number of induction chemotherapy cycles (4 or 6) as long as at least one chemotherapy component has been administered at least once during a 21-day cycle.  Cycles in which no chemotherapy component is given do not count toward the total number of induction chemotherapy cycles.  Additional gu idance is provided in Appendix 14. 
Patients who experience no further clinical benefit (for patients enrolled into Arm A, see Section 3.1 for definition) or disease progression (for patients enrolled into Arm B) at any time during the induction phase will discontinue all study treatment.  In the absence of the above criteria, after the 4 or 6-cycle induction phase, patients will begin maintenance therapy (atezolizumab
  pemetrexed in Arm A or pemetrexed in Arm B). 
During treatment (induction or maintenance), Arm A patients who show evidence of clinical benefit will be permitted to continue atezolizumab after RECIST v1.[ADDRESS_76338] of care and manufacturer’s instruction.  
However, due to their immunomodulatory effects, premedication with steroids should be limited when clinically feasible.  In addition, in the event of pemetrexed-related skin rash, 
topi[INVESTIGATOR_70054]-line treatment whenever is clinically feasible.  Table 8 lists the premedication for pemetrex ed.  Table 9 lists the suggested infusion 
times for treatment administration for pemetrexed
  platinum during the induction and 
maintenance phases. 
Table 8 Premedication for Pemetrexed 
Premedication  Dose and Route  Timing  
Folic acid  350–1000 g PO Once daily beginning at least 5–7 days before 
Cycle 1, Day 1 and continuing until 3 weeks after 
discontinuation of pemetrexed  
Vitamin B 12 1000 g IM q9w beginning Cycle 1, Day 1 and continuing until 
3 weeks after discontinuation of pemetrexed  
Dexamethasone 
(suggested) 4 mg PO Twice daily the day before, the day of, and the day 
after pemetrexed administration 
IM   intramuscular; PO   oral; q9w   every 9 weeks. 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
68/Protocol GO29438 , Version 7Table 9Treatment Regimen for Pemetrexed Platinum -Based 
Chemotherapy
StudyDrugDose and 
RouteInduction Period 
(Four or Six Cycles)Maintenance Period 
(Until PD)
Pemetrexed 500 mg/m2IVOver approximately10 minutes 
on Day 1 q3wOver approximately 
10minutes on Day 1 q3w
Carboplatin AUC 6 IVOver approximately 
3060minutes on Day 1 q3WNot applicable
OR
Cisplatin 75mg/m² Over 1 –2hours on Day 1 q3w Not applicable
AUC area under the concentration time curve; IV intravenous; PDprogressive disease; 
q3wevery 3 weeks.
Guidelines for dose modification and treatment interruption or discontinuation for 
carboplatin or cisplatin and pemetrexed are provided in Section [IP_ADDRESS] , Section 5.1.8 , 
and Section 5.1.9 .
[IP_ADDRESS] Atezolizumab
Patients randomized to atezolizumab will receive 1200 mg of atezolizumab administered 
by [CONTACT_33433] 21 days in a monitored setting where there is immediate access to 
trained personnel and adequate equipment and medicine to manage potentially serious 
reactions .
Atezolizumab infusions will be administered per the instructions outlined in Table 10.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
69/Protocol GO29438 , Version 7Table 10Administration of First and Subsequent Infusions 
ofAtezolizumab
First Infusion Subsequent Infusions
No premedication administered for 
atezolizumab specifically is permitted
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_13521] y rate, blood pressure, and 
temperature) within 60 minutes before 
starting infusion.
Infuse atezolizumab (1200 mg in a 250 mL 
0.9% NaCl IV bag) over 60(15) minutes.
If clinically indicated, record patient’s vital 
signs ( pulse rate, respi[INVESTIGATOR_697], blood 
pressure, and temperature) during the 
infusion at 15, 30, 45, and 60 minutes 
(5-minute windows are allowed for all 
timepoints).
If clinically indicated, record patient’s vital 
signs ( pulse rate, respi[INVESTIGATOR_697], blood
pressure, and temperature) at 
30(10)minutes after the infusion.
Patients will be informed about the 
possibility of delayed post -infusion 
symptoms and instructed to contact [CONTACT_33459].If patient experienced infusion -related 
reaction during any previous infusion, 
premedication with antihistamines may  be 
administered for C ycles  2 at the 
discretion of the treating physician.
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_13521] y rate, blood pressure, and 
temperatur e) within 60 minutes before 
starting infusion.
If the patient tolerated the first infusion 
well without infusion- associated adverse 
events, the second infusion may  be 
delivered over 30 (10) minutes.
If no reaction occurs, subsequent 
infusions may be deli vered over 
30(10)minutes.
Continue to record vital signs within 
60minutes before starting infusion.  
Record vital signs during and after the 
infusion, if clinically indicated.
If the patient had an infusion -related 
reaction during the previous infusion , the 
subsequent infusion must be delivered 
over 60 ( 15) minutes.
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_13521] y rate, blood pressure, and 
temperature) every 15 ( 5) minutes 
during the infusion if clinically indicated or 
patient experienced symptoms d uring the 
previous infusion.
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_13521] y rate, blood pressure, and 
temperature) 30 ( 10)minutes after the 
infusion if clinically indicated or patient 
experienced s ymptoms during the
previous infusion.
IVintravenous ; NaCl sodium chloride .
Dose modifications to atezolizumab are not permitted.  Guidelines for treatment 
interruption or discontinuation and the management of specific adverse events are 
provided in Section [IP_ADDRESS] and Appendix 15.
Refer to the Pharmacy Manual for detailed instructions on drug preparation, storage, and 
administration.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
70/Protocol GO29438 , Version [IP_ADDRESS] Pemetrexed Carboplatin or Cisplatin
[IP_ADDRESS].[ADDRESS_76339] 2 days following pemetrexed administration.
[IP_ADDRESS].2 Cisplatin
IV infusion should be administered approximately 30 minutes after completion of the 
pemetrexed infusion at a dose of 75 mg/m² over 1 –2hours or per standard ofcare at the 
institution.  Patients must receive adequate anti -emetic treatment and app ropriate 
hydration prior to and after receiving cisplatin.
Refer to local clinical practice guidelines for further details.
[IP_ADDRESS].3 Carboplatin
Carboplatin should be administered 30 minutes a fter completion of pemetrexed 
administration by [CONTACT_12781] 30 60minutes to achieve an initial target area under 
the concentration time curv e (AUC) of 6 mg/mL/min (Calvert formula dosing) with 
standard anti -emetics per local practice guidelines.
The carboplatin dose of AUC 6 will be calculated using the Calvert formula 
(Calvert etal.1989 ):
Calvert Formula
Total dose (mg) (target AUC) (glomerular filtration rate [ GFR] 25)
NOTE:  The GFR used in the Calvert formula to calculate AUC -based dosing should 
not exceed 125 mL/min.
For the purposes of this protocol, the GFR is considered to be equivalent to the CRCL.  
The CRCL is calculated by [CONTACT_70137] ( 1976 ) using the following formula:
CRCL (140 –age) (wt)(0.85 if female)72Scr
Where: CRCL creatinine clearance in mL/min
agepatient ’s age in years 
wtpatient’s weight in kg
Scrserum creatinine in mg/dL
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
71/Protocol GO29438 , Version 7NOTE:  For patients with an abnormally low serum creatinine level, estimate the GFR 
through use of a minimum creatinine level of 0.8 mg/dL or cap the estimated GFR at 
125mL/min.
If a patient’s GFR is estimated based on serum creatinine measurements by [CONTACT_70138], the U.S. Food and Drug Administration (FDA)
recommends that physicians consider cappi[INVESTIGATOR_70055] (AUC) to avoid potential toxicity due to overdosing. Based on the Calvert 
formula described in the carboplatin label, the maximum doses can be calculated 
as follows:
Maximum carboplatin dose (mg) target AUC ( mgmin/mL)(GFR25mL/min)
The maximum dose is based on a GFR estimate that is capped at 150 mL/min for 
patients with normal renal function.  No higher estimated GFR values should be used.
For a target AUC6, the maximum dose is 6 150900 mg.
For a target AUC 5, the maximum dose is 5 150750 mg.
For a target AUC 4, the maximum dose is 4 150600 mg.
Refer to the FDA’s communication regarding carboplatin dosing at the following W eb site
for more details:
http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/
ucm228974.htm
4.3.[ADDRESS_76340] A ccountability
The investigational medicinal products for this study are atezolizumab an d pemetrexed.   
Depending on local classification, in this study, cisplatin and carboplatin may either be 
considered a non−in vestigational medicinal product or an IMP.
The study site will acknowledge receipt of the IMPs using IxRS to confirm shipment 
condition and content.  Any damaged shipments will be replaced.
IMPs will either be disposed of at the study site according to the study site’s institutional 
standard operating procedure or returned to the Sponsor with the appropriate 
documentation.  The site’ s method of IMP destruction must be agreed to by [CONTACT_1034].  
The site must obtain written authorization from the Sponsor before any IMP is destroyed, 
and IMP destruction must be documented on the appropriate form.
Accurate records of all IMPs receive d at, dispensed from, returned to, and disposed of by 
[CONTACT_25729].
4.3.[ADDRESS_76341] -Study Access to A tezolizumab
The Sponsor will evaluate the appropriateness of continuing to provide atezolizumab to 
patients assigned to this treatment after evaluating the primary and secondary efficacy 
outcome measures and safety data gathered in the study and in accordance with the 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
72/Protocol GO29438 , Version 7[COMPANY_002] Global Policy on Continued Access to Investigational Medicinal Product, available 
at the following W eb site:
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
These analyses may be conducted prior to completion of the study.
4.4 CONCOMITA NT THERA PY
Concomitant therapy includes any medication (e.g., prescription drugs, over-the-counter 
drugs or homeopathic remedies, nutritional supplements) used by a patient from 7 days 
prior to screening until the treatment discontinuation visit.  All such medications should be 
reported to the investigator.
4.4.1 Permitted Therapy
Premedicati on with antihistamines may be administered for any atezolizumab infusions 
after Cycle 1.
The following therapi[INVESTIGATOR_70056]:
Oral contraceptives
Hormone -replacement therapy
Prophylactic or therapeutic anticoagulation therapy (such as low molecular weight 
heparin or warfarin at a stable dose level)
Palliative radiotherapy (e.g., treatment of known bony metastases) provided it does 
not interfere with the assessment of tumor target lesions (e.g., the lesion being 
irradiated is not the only site of disease, as that would render the patient not 
evaluable for response by [CONTACT_70139] v1.1)
It is not a requirement to withhold atezolizumab during palliative radiotherapy .
Inactive influenza vaccinations
Megestrol admini stered as an appetite stimulant
Inhaled corticosteroids for chronic obstructive pulmonary disease
Mineralocor ticoids (e.g., fludrocortisone)
Low-dose corticosteroids for patients with orthostatic hypotension or adrenocortical 
insufficiency
In general, investigators should manage a patient’s care with supportive therapi[INVESTIGATOR_33399].  Patients who experience infusion -associated 
symptoms may be treated symptomatically with acetaminophen, ibuprofen, 
diphenhydramine, and/or famotidine or another H 2-receptor antagonist per standard 
practice (for sites outside the [LOCATION_002], equivalent medications may be substituted 
perlocal practice).  Serious infusion -associated events manifested by [CONTACT_27926], 
hypot ension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation, or 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
73/Protocol GO29438 , Version 7respi[INVESTIGATOR_40802] 
(e.g., supplemental oxygen and 2-adrenergic agonists; see Appendix 11). 
All medications must be recorded on the appropriate Concomitant Medications electronic 
Case Report Form (eCRF).
4.4.2 Cautionary  Therapy for A tezolizumab -Treated Patients
Systemic corticosteroids and TNF -inhibitors may attenuate potential beneficial 
immunologic effects of treatment with atezolizumab.  Therefore, in situations where 
systemic corticosteroids or TNF -inhibitors would be routinely administered, alternatives, 
including antihistamines, should be considered first by [CONTACT_1963].  If the 
alternatives are not feasible, systemic corticosteroids and TNF -inhibitors may be 
administered at the discretion of the treating physician except in the case of patients for 
whom CT scans with contrast are contraindicated (i.e., patients with contrast allergy or 
impaired renal clearance) (see also Section 4.4.3 ).
Systemic corticosteroids are recommended, with caution at the discretion of the treating 
physician, for the treatment of specific adverse events when associated with 
atezolizumab therapy.  Guidelines for the management of immune -mediated adverse 
events are described in Section [IP_ADDRESS] and Appendix 15.
4.4.3 Prohibited Therapy
Any concomitant therapy intended for the treatment of cancer, whether health 
authority approved or experimental, is prohibited for various time periods prior to 
starting study treatment, depending on the anti -cancer agent (see Section 4.1.2 ), and 
during study treatment until disease progression is documented and patient has 
discontinued study treatment.  This includ es,but is not limited to,chemotherapy, 
hormonal therapy, immunotherapy, radiotherapy, investigational agents, or herbal 
therapy (unless otherwise noted).
The following medications are prohibited while the patient is in the study, unless 
otherwise noted:
Denosumab; patients who are receiving denosumab prior to enrollment must be 
willing and eligible to receive a bisphosphon ate instead.
Any live attenuated vaccine (e.g., FluMist®) within [ADDRESS_76342] atezolizumab dose (for 
patients randomized to atezolizumab).
Use of steroids to premedicate patients for whom CT scans with contrast are 
contraindicated (i.e., patients with contrast allergy or impaired renal clearance); in 
such patients , non -contrast CT scans of the chest and non -contrast CT scans or 
MRIs of the abdomen and pelvis should be performed.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
74/Protocol GO29438 , Version 7The concomitant use of herbal therapi[INVESTIGATOR_33401], safety profiles, and potential drug- drug inter actions are generally 
unknown.  However, their use for patients in the study is allowed at the discretion of the 
investigator provided that there are no known interactions with any study treatment .  
Asnoted above, herbal therapi[INVESTIGATOR_70057].
4.[ADDRESS_76343] be performed and documented for each patient.
Patients should be assessed for toxicity prior to each dose; dosing will occur only if the 
clinical assessment and local laboratory test values are acceptable.
4.5.[ADDRESS_76344] sign consent to acknowledge deferring 
other treatment options before continuing treatment with atezolizumab beyond apparent 
radiogr aphic progression.
4.5.2 Medical History  and Demographic Data
Medical history includes clinically significant diseases, surgeries, cancer history 
(including prior cancer therapi[INVESTIGATOR_26649]), reproductive status, smoking history, 
and all medications (e.g., prescription drugs, over -the-counter drugs, herbal or 
homeopathic remedies, nutritional supplements) used by [CONTACT_25701] 7 days prior 
to the screening visit.
NSCLC cancer history will include prior cancer therapi[INVESTIGATOR_014], procedures, and an 
assessment of tumor mutational status (e.g., sensitizing EGFR mutation, ALK fusion 
status).  For patients not previously tested for tumor mutational status, testing will be 
required at screening.  For these patients, testing can either be performed locally or 
submitted for central evaluation during the screening period.  If EGFR mutations or ALK
status testing is not performed locally, additional tumor sections may be required for 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
75/Protocol GO29438 , Version 7central evaluation of the mutational status of these genes.  Review tissue requirements 
forcentral evaluation in the central laboratory instruction manual.
Demographic data will include age, sex, and self -reported race/ethnicity.
4.5.3 Physical Examinations
A complete physical examination should include an evaluation of the head, eyes, ears, 
nose, an d throat andthe cardiovascular, dermatological, musculoskeletal, respi[INVESTIGATOR_696], 
gastrointestinal, genitourinary, and neurological systems.  Any abnormality identified at 
baseline should be recorded on the General Medical History and Baseline Conditions 
eCRF .
At subsequent visits (or as clinically indicated), limited, symptom -directed physical 
examinations should be performed.  Changes from baseline abnormalities should be 
recorded in patient notes.  New orworsened clinically significant abnormalities should be 
recorded as adverse events on the Adverse Event eCRF.
4.5.4 Vital Signs
Vital signs will include measurements of temperature, pulse rate, respi[INVESTIGATOR_697], and 
systolic and diastolic blood pressures while the patient is in a seated position.
Vital signs will be measured and recorded at screening and as described in Table 11.
Table 11Vital Sign Measurements at Cy cle 1 and A ll Subsequent Cy cles
Treatment ArmCycle 1
Timepoints
Arm A  Within 60 minutes prior to atezolizumab infusion
 During the atezolizumab infusion (every 15 [5]minutes) if clinically 
indicated
 Within 30 (10) minutes after atezolizumab infusion if clinically indicated
Arms A and B Within 30 ( 10)minutes after carboplatin or cisplatin infusion
Treatment ArmSubsequent Cycles
Timepoints
Arm A  Within 60 minutes prior to atezolizumab infusion
 During the atezolizumab infusion (every 15 [5]minutes) if clinically 
indicated or sy mptoms occurred during prior infusion
 Within 30 (10) minutes after atezolizumab infusion if clinically indicated 
or sy mptoms occurred during prior infusion
For patients in the atezolizumab arm, also refer to Section [IP_ADDRESS].

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
76/Protocol GO29438 , Version 74.5.[ADDRESS_76345] scans (with oral/IV contrast unless 
contraindicated) or MRIs of the chest and abdomen.  A CT or MRI scan of the pelvis is
required at screening and as clinically ind icated or as per local standard of care at 
subsequent response evaluations.  A spi[INVESTIGATOR_70058] a requirement.
A CT (with contrast if not contraindicated) or MRI scan of the head must be done at 
screening to exclude CNS metastasis.  An MRI scan of the brain is required to confirm or 
refute the diagnosis of CNS metastases at baseline in the event of an equivocal scan.  
Patients with active or untreated CNS metastases are not el igible for the study 
(see Section [IP_ADDRESS]).
If a CT scan for tumor assessment is performed in a positron emission tomograph y 
(PET )or CT scanner, the CT acquisition must be consistent with the standards for a 
full-contrast diagnostic CT scan.
Bone scans and CT scans of the neck should also be performed if clinically indicated.  
Atthe investigator’s discretion, other methods of assessment of measurable disease as 
per RECIST v1.[ADDRESS_76346] be documented at sc reening and re assessed at each 
subsequent tumor evaluation.  Patients with history of irradiated brain metastases at 
screening are not required to undergo imaging brain scans at subsequent tumor 
evaluations, unless scans are clinically indicated.  The same radiographic procedure 
used to assess disease sites at screening should be used throughout the study (e.g., the 
same contrast protocol for CT scans).  Response will be assessed by [CONTACT_70140] v1.1 (see Appendix 4) and modified RECIST (see Appendix 5)for 
patients in Arm A and RECIST v1.[ADDRESS_76347] 
be reviewed by [CONTACT_33464]. 
Tumor assessments should occur every 6 weeks (7 days) for 48 weeks following Cycle 
1, Day 1 and then every 9 weeks ( 7 days) thereafter, after the completion of the 
Week48 tumor assessment, regardless of treatment delays, until radiographic disease 
progression per RECIST v1.1 (loss of clinical benefit for atezolizumab -treated patients 
who continue treatment beyond disease progression according to RECIST v1.1 only), 
withdrawal of consent, death, or study termination by [CONTACT_1034], whichever occurs first.
Patients who discontinue treatment for reasons other than radiographic disease 
progression per RECISTv1.1 (e.g., toxicity, symptomatic deterioration) will continue 
scheduled tumor assessment suntil radiographic disease progression per RECIST v1.1 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
77/Protocol GO29438 , Version 7(or loss of clinical benefit for atezolizumab -treated patients who had continued treatment 
with atezolizumab after radiographic disease progression according to RECIST v1.1), 
withdrawal of consent, death, or study termination by [CONTACT_2728], whichever occurs first.
Patients who start a new anti -cancer therapy in the absence of radiographic disease 
progression per RECIST v1.[ADDRESS_76348] v1.1 (or loss of clinical benefit for 
atezolizumab -treated patients who had continued treatment with atezolizumab after 
radiographic disease progression according to RECIST v1.1), withdrawal of consent, 
death, or study termination by [CONTACT_1034], whichever occurs first.
Patients who are treated w ith atezolizumab who continue to experience clinical benefit, 
despi[INVESTIGATOR_70059], will continue tumor assessments as per 
the schedule listed above.
Scans will be submitted to an IRF.
4.5.6 Laboratory  Assessments and Biomarker Samples
Samples for the following laboratory tests will be sent to the study site’ s local laboratory 
for analysis:
Hematology (CBC, including RBC count, hemoglobin, hematocrit, W BC count with 
differential [neutrophils, eosinophils, lymphocytes, monocytes, basophils, and other 
cells], and platelet count)
Serum chemistries (glucose, BUN or urea, creatinine, sodium, potassium, 
magnesium, chloride, bicarbonate or total CO 2, calcium, phosphorus, total bilirubin, 
ALT, AST, alkaline phosphatase, LDH, total protein, and albumin)
Coagulation (aPTT or INR)
Serum pregnancy test for women of childbearing potential, including women who 
have had a tubal ligation; urine pregnancy tests will be performed at Day [ADDRESS_76349].
Childbearing potential is defined as not having undergone surgical sterilization, 
hysterectomy, or bilateral oophorectomy or not being postmenopausal 
(12months of amenorrhea).
Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood); dipstick 
permitted
Thyroid function testing (thyroid- stimulating hormone, free T3, free T4)
Total T3 (instead of free T3) will be tested only at sites where free T3 testing 
cannot be performed .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
78/Protocol GO29438 , Version 7HBV serology:  HBsAg , antibodies against H BsAg (HBsAb or anti -HBs), and 
hepatitis B core antibody (HBcAb)
If the patient has a negative serology for H BsAg and a positive serology for 
HBcAb, an HBV DNA test must be obtained prior to randomization and must be 
negative.
HCV serology:  HCV antibody (anti -HCV)
If the patient tests positive for anti -HCV, an HCV RNA must be obtained prior to 
randomization and be negative.
HIV testing
All patients wi ll be tested for HIV prior to the inclusion into the study and 
HIV-positive patients will be excluded from the clinical study.
A central laboratory will coordinate the sample collection of tissue and blood samples for 
research -related testing at central l aboratories or at the Sponsor. Instruction manuals 
and supply kits will be provided for all central laboratory assessments.  Samples for the 
following laboratory tests will be sent to one or several central laboratories or to the 
Sponsor for analysis:
ATA assays (all atezolizumab -treated patients)
Serum samples will be assayed for the presence of ATAs to atezolizumab with 
use of validated immunoassays.  Accompanying PK samples will be collected 
at the same timepoints.
PK assays
Blood samples for PK assessments will be obtained according to the schedule 
inAppendix 2.
Serum samples will be assayed for atezolizumab concentration with use of a 
validat edimmunoassay.
At selected sites, a subset of 20 patients in Arm A willundergo additional PK 
assessments for carboplat in, cisplatin, and pemetrexed.
Plasma carboplatin, cisplatin, and pemetrexed concentrations will be 
assayed using validated methods.
Biomarker assays in blood samples
Blood samples will be obtained for biomarker evaluation (including ,but not 
limited to, biomarkers that are related to NSCLC or tumor immune biology) from 
all eligible patients according to the schedule in Appendix 2.  Samples will be 
processed to obtain EDTA plasma and serum for the determination of changes 
in blood -based biomarkers (e.g., ctDNA , cytokines ).  Whole blood samples may 
be processed to obtain their derivatives (e.g., RNA and DNA) and evaluated for 
immune -related, tumor typerelated , and other exploratory biomarkers 
(e.g., alterations in gene expression or single nucleotide polymorphisms).

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
79/Protocol GO29438 , Version 7Residual PK and ATA samples will be retained for further method development, 
validation, and characterization.  Samples will be stored for up to 5years after 
the date of final completion of the Clinical Study Report .
For patients who consent to the optional collection of samples for the [COMPANY_002] Clinical 
Repository (RCR) any leftover material from the above sample collection will be 
stored and used for exploratory analyses as indicated in Section 4.5.11 .  For 
patients who consent to RCR optional future research on their whole blood samples 
collected at screening but are determined to be ineligible for study participat ion, 
these samples and their derivatives (e.g., DNA, RNA, protein) may be used for 
future development of biomarker and/or diagnostic tests as indicated in 
Section 4.5.11.
4.5.7 Tumor Tissue Samples
[IP_ADDRESS] Archival orFreshly  Collected Tumor Tissue Samples at 
Screening
A pre -treatment tumor tissue (archival or freshly obtained) sample (if available) should 
be submitted before or within [ADDRESS_76350] be 
accompanied by [CONTACT_40869].  Although any available tumor tissue 
sample can be submitted, it is strongly encouraged that the sites submit representative 
tumor specimens in paraffin blocks (preferred) or 10 (or more) serial, freshly cut,
unstained slides exploratory biomarker analysis (including ,but not limited to, markers 
related to immune or NSCLC biology, such as T- cell markers or non- inherited 
biomarkers identified through NGS on extracted DNA and/or RNA) .
The preferred sample types include resections, core needle, excisional, incisional, punch, 
or forceps biopsies. If specimens described above are not available, any type of 
specimens (including fine -needle aspi[INVESTIGATOR_1516], cell pellet specimens e.g., from pleural 
effusion, and lavage samples) are also acceptable.
Tumor tissue should be of good quality based on total and viable tumor content .  Tumor 
tissue from bone metastases that is subject to decalcification is not advisable.   If tumor 
tissue is not available, the patient isstilleligible .
For archival samples, theremaining tumor tissue block for all patients enrolled will be 
returned to the site upon request or 18 months after final closure of the study database, 
whichever is sooner.  Tissue sam ples from patients who are deemed ineligible to enroll 
in the study will be returned no later than 6 weeks after eligibility determination.
[IP_ADDRESS] Optional Tumor Samples at the Time of Radiographic 
Progression
Patients in all treatment arms can undergo an optional tumor biopsy to obtain a tumor 
sample at the time of radiographic disease progression (preferably within 40 days of 
radiographic progression or prior to start of the next anti -cancer treatment, whichever is 
sooner) if they have provided consent for Optional Biopsy.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
80/Protocol GO29438 , Version 7The preferred sample types include resections, core needle, excisional, incisional, punch, 
or forceps biopsies.  If such specimens are not available, any type of specimens 
including fine- needle aspi[INVESTIGATOR_1516], cell pellet specimens (e.g., from pleural effusion and 
lavage s amples) can also be submitted.
The status of immune -related, tumor type related and other exploratory biomarkers 
(including but not limited to T -cell markers and non -inherited biomarkers identified 
through NGS on extracte d DNA and RNA) in tumor tissue samples may be evaluated.
NGS may be performed by [CONTACT_33430]. If it is performed by [CONTACT_33429], the investigator can obtain results from the samples collected at the time of 
disease progression in the form of an NGS report, which is available upon request 
directly from Foundation Medicine. The investigator may share and discuss the results 
with the patient, unless the patient chooses otherwise. The Foundation Medicine NGS 
assay has not been cleared or appr oved by [CONTACT_1622]; results from these investigational 
tests should not be used to guide future treatment decisions.
[IP_ADDRESS] Tumor Samples at Other Timepoints
If a patient undergoes a medically indicated procedure (e.g., bronchoscopy, 
esophagogastroduodenoscopy, colo noscopy) any time during the course of the study 
that has the likelihood of yielding tumor tissue, any remaining samples or a portion of the 
sample not necessary for medical diagnosis (leftover tumor tissue) may be obtained 
forexploratory analysis.
Patients with additional tissue samples from procedures performed at different times 
during the course of their study participation (during treatment and during survival 
follow -up) who have signed the RCR optional consent will be requested (but not required) 
to also submit these optional fresh biopsy samples for central testing.  Tumor tissue 
samples collected at the time of clinical events (e.g. ,clinical response, etc.) are 
preferred.  Tissue samples obtained at multiple times for individual patients will greatly 
contribute to an improved understanding of the dynamics of PD -L1 expression and 
relationship with intervening anti -cancer therapy.
[IP_ADDRESS] Use and Storage of Remaining Samples from 
Study -Related Procedures
The remainder of samples obtained for study -relate d procedures will be destroyed no 
later than 5 years after the end of the study or earlier depending on local regulations.  
Ifthe patient provides optional consent for storing samples in the RCR for future 
research (see Section 4.5.11), the samples will be destroyed no later than 15 years after 
the date of final closure of the clinical database.
4.5.8 Anti-Therapeutic A ntibody Testing
Treatment with atezoli zumab may elicit an immune response.  Patients with signs of any 
potential immune response to atezolizumab will be closely monitored.  Validated 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
81/Protocol GO29438 , Version 7screening and confirmatory assays will be employed to detect ATAs at multiple 
timepoints before, during, and af ter treatment with atezolizumab (see Appendix 1and 
Appendix 2for the schedule).  The immunogenicity evaluation will usea risk -based 
immunogenicity strategy ( Rosenberg and Worobec 2004 ; Koren etal.2008 ) to
characterize ATA responses to atezolizumab in support of the clinical development 
program.  This tiered strategy will include an assessment of whether ATA respon ses 
detected correlate with relevant clinical endpoints.  Implementation of ATA 
characterizati on assays will depend on the safety profile and clinical 
immunogenicity data.
4.5.[ADDRESS_76351] review, sign, and date all ECG 
tracings.  Paper copi[INVESTIGATOR_1309] E CG tracings will be kept as part of the patient's permanent 
study file at the site.  Any morphologic waveform changes or other ECG abnormalities 
must be documented on the eCRF.
4.5.10 Patient -Reported Outcomes
PRO data will be collected via the EORTC QLQ -C30, EOR TC QLQ -LC13, SILC, and 
EQ-5D-5L to fully characterize the clinical profile of atezolizumab.
The questionnaires will be translated as required in the local language.  To ensure 
instrument validity and that data standards meet health authority requirements, 
questionnaires scheduled for administration during a clinic visit will be completed in their 
entirety by [CONTACT_40873] -PRO assessments and the 
administration of study treatment.
Patients will use an electronic PRO (ePRO ) device to capture PRO data.  The ePRO 
device and instructions for completing the PRO questionnaires electronically will be 
provided by [CONTACT_6649].  The data will be transmitted via a prespecified 
transmission method (e.g., W eb or wireless) autom atically after entry to a centralized 
database at the ePRO vendor.  The data can be accessed by [CONTACT_70141] .
The EORTC QLQ -C30 (see Appendix 7) is a validated and reliable self -report measure 
(Aaronson et al. 1993 ; Fitzsimmons etal.1999 ) that consists of 30 questions that assess
five aspects of patient functioning (physical, emotional, role, cognitive, and social), 
three symptom scales (fatigue, nausea and vomiting, pain), global health and quality of 
life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and 
financial difficulties).  Scale scores can be obtained for the multi -item scales.  

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
82/Protocol GO29438 , Version 7TheEORTC QLQ -C30 module takes approximately 15 minutes to complete.  
This questionnaire will be completed on the ePRO tablet at each scheduled study visit 
during study treatment and during survival follow -up at 3 months and 6 months following 
disease progression or loss of clinical benefit (for atezolizumab -treated patients who 
continue treatment after radiographic disease progress ion according to RECIST v1.1).
The EORTC QLQ -LC13 (see Appendix 8)module incorporates one multiple -item scale 
to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, 
dysphagia, peripheral neuropathy, alopecia, and hemoptysis.  The EORTC QLQ -LC13 
module takes approximately 15 minutes to complete.  This questionnaire will be 
completed on the ePRO tablet at each scheduled study visit during the study treatment 
period a ndduring survival follow -up at 3 months and 6 months following disease or los s 
of clinical benefit (for atezolizumab -treated patients who continued treatment after 
disease progression according to RECIST v1.1) .
The SILC scale (see Appendix 13) will be used to assess patient -reported severity of 
lung cancer symptoms (chest pain, dyspnea, and cough). The SILC scale is a 9-item 
content valid self -report measure of lung cancer symptoms. It measures severity of 
cough, dyspnea, and chest pain with a symptom severity score. This questionnaire will 
be completed using an ePRO device at the patient’s home on a weekly basis, then 
during survival follow -up every month for 6 months following disease progression or loss 
of clinical benefit (for atezolizumab -treated patients who continue treatment after disease 
progression according to RECIST v1.1 ).
The EQ -5D-5L is a generic, preference -based health utility measure with questions 
about mobility, self -care, usual activities, pain and discomfort, and anxiety and 
depression that is used to build a composite of the patient’s health status 
(see Appendix 9).  The EQ -5D-5L will be used in this study for economic modeling.  
This questionnaire will be completed on the ePRO tablet at each scheduled study 
visitduring the study treatment period and during survival follow -up at 3 months 
and6months following disease progression or loss of clinical benefit (for 
atezolizumab- treated patients who continued treatment after disease progression 
according to RECIST v1.1 ).
Patients who discontinue study treatment for any reason other than radiographic
progressive disease or loss of clinical benefit will complete the EORTC QLQ -C30, 
EORTC QLQ -LC13, and EQ -5D-5L at each tumor assessment visit and will complete the
SILC at home on a weekly basis until radiographic disease progression per RECIST v1.1 
(or loss of clinical benefit as determined by [CONTACT_70142] -treated 
patients who continue treatment after radiographic disease progression) (unless the 
patient withdraws consent or the Sponsor terminates the study ).

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
83/Protocol GO29438 , Version 7Patients whose native language is not available in the ePRO device or who are deemed 
incapable of inputting their ePRO assessment after undergoing appropriate training are 
exempt from all ePRO assessments.
4.5.11 Samples for Ro che Clinical Repository
[IP_ADDRESS] Overview  of the [COMPANY_002] Clinical Repository
The RCR is a centrally administered group of facilities used for the long -term storage of 
human biologic specimens, including body fluids, solid tissues, and derivatives thereof 
(e.g., DNA, RNA, proteins, peptides).  The collection and analysis of RCR specimens will 
facilitate the rational design of new pharmaceutical agents and the development of 
diagnostic tests, which may allow for individualized drug therapy for patients in the future.
Specimens for the RCR will be collected from patients who give specific consent to 
participate in this optional research.  RCR specimens will be used to achieve the 
following objectives:
To study the association of biomarkers with efficacy, adverse events, o r disease 
progression
To increase knowledge and understanding of disease biology
To study drug response, including drug effects and the processes of drug absorption 
and disposition
To develop biomarker or diagnostic assays and establish the performance 
characteristics of these assays
[IP_ADDRESS] Approval by [CONTACT_70143]’ s IRB or EC and, if applicable, an appropriate regulatory 
body.  If a site has not been granted approval for RCR sampling, this section of the 
protocol (Section 4.5.11) will not be applicable at that site.
[IP_ADDRESS] Sample Collection
The following samples may be collected for patients who have signed the RCR optional 
consent:
Optional fresh biopsy samples
Leftover tumor tissue samples
Remaining fluids (serum, plasma, blood cell derivatives) after study -related tests 
have been performed 
Remaining FFPE tissue (with the exception of archival FFPE blocks, which will be 
returned to sites) after study -related tests have been performed
Whole blood samples collected at screening (for screen -fail patients only)

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
84/Protocol GO29438 , Version 7The following sample will be used for identification of genetic (inherited) biomarkers:
Whole blood sample for DNA extraction (6 mL) (see Appe ndix 1and Appendix 2)
For all samples, dates of consent should be recorded on the associated RCR page of 
the eCRF.  For sampling procedures, storage conditions, and shipment instructions, see 
the laboratory manual.
RCR specimens will be destroyed no later than 15 years after the date of final closure of 
the associated clinical database. The RCR storage period will be in accordance with the 
IRB/EC -approved Informed Consent Form and applicable laws (e.g., health authority 
requirements).
The dynamic biomarker specimens will be subject to the confidentiality standards 
described in Section 8.4.  The genetic biomarker specimens collected for the RCR will 
undergo additional processes to ensure confidentiality as described below.
[IP_ADDRESS] Confidentia lity
Given the sensitive nature of genetic data, [COMPANY_002] has implemented additional processes 
to ensure patient confidentiality for RCR specimens and associated data.  Upon receipt 
by [CONTACT_25736], each specimen is “double -coded ”by [CONTACT_70144] a new independent number.  Data generated from the use of these 
specimens and all clinical data transferred from the clinical database and considered 
relevant are also labeled with this same independent number.  A “linking key ”between 
the patient identification number and this new independent number is stored in a secure 
database system.  Access to the linking key is restricted to authorized individuals and is 
monitored by [CONTACT_25738].  Legitimate operat ional reasons for accessing the linking key are 
documented in a standard operating procedure.  Access to the linking key for any other 
reason requires written approval from the Pharma Repository Governance Committee 
and [COMPANY_002]’ s Legal Department, as applica ble.
Data generated from RCR specimens must be available for inspection upon request 
by[CONTACT_70145], 
representatives, and collaborators, as appropriate.
Patient medical information associated with RCR specimens is confidential and may be 
disclosed to third parties only as permitted by [CONTACT_25734] (or separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].
Data derived from RCR specimen analysis on individual patients will generally not 
beprovided to study investigators unless a request for research use is granted.  
Theaggregate results of any research conducted using RCR specimens will be available 
in accordance with the effective [COMPANY_002] policy on study data publication.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
85/Protocol GO29438 , Version 7Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of the RCR data will become and remain the exclusive and unburdened property 
of [COMPANY_002], exc ept where agreed otherwise.
[IP_ADDRESS] Consent to Participate in the [COMPANY_002] Clinical Repository
The Informed Consent Form will contain a separate section that addresses participation 
in the RCR.  The investigator or authorized designee will explain to each patient the
objectives, methods, and potential hazards of participation in the RCR.  Patients will be 
told that they are free to refuse to participate and may withdraw their specimens at any 
time and for any reason during the storage period.  A separate, specific sig nature will be 
required to document a patient ’s agreement to provide optional RCR specimens.  
Patients who decline to participate will not provide a separate signature.
The investigator should document whether or not the patient has given consent to 
partic ipate by [CONTACT_26806].
In the event of an RCR participant ’s death or loss of competence, the participant ’s 
specimens and data will continue to be used as part of the RCR research.
[IP_ADDRESS] Withdrawal from the [COMPANY_002] Clinic al Repository
Patients who give consent to provide RCR specimens have the right to withdraw their 
specimens from the RCR at any time for any reason.  After withdrawal of consent, any 
remaining samples will be destroyed or will no longer be linked to the pa tient.  If a 
patient wishes to withdraw consent to the testing of his or her specimens, the 
investigator must inform the Medical Monitor in writing of the patient ’s wishes through 
use of the RCR Subject W ithdrawal Form and, if the study is ongoing, must enter the 
date of withdrawal on the RCR Research Sample W ithdrawal of Informed Consent eCRF. 
If a patient wishes to withdraw consent to the testing of his or her R CR samples after 
closure of the site, the investigator must inform the Sponsor by [CONTACT_70146]:
global_rcr -[EMAIL_1377]
A patient ’s withdrawal from Study GO29438 does not, by [CONTACT_5071], constitute withdrawal of 
specimens from the RCR.  Likewise, a patient ’s withdrawal from the RCR does not 
constitute withdrawal from Study GO29438.
[IP_ADDRESS] Monitoring and Oversight
RCR specimens will be tracked in a manner consistent with Good Clinical Practice by 
[CONTACT_70147] -controlled, auditable, and appropriately validated laboratory information 
management s ystem to ensure compliance with data confidentiality, as well as 
adherence to authorized use of specimens as specified in this protocol and in the 
Informed Consent Form.  Monitors and auditors will have direct access to appropriate 
parts of records relatin g to patient participation in the RCR for the purposes of verifying 
the data provided to [COMPANY_002].  The site will permit monitoring, audits, IRB/EC review, and 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
86/Protocol GO29438 , Version 7health authority inspections by [CONTACT_70148].
4.5.12 Timing of A ssessments
[IP_ADDRESS] Screening and Baseline A ssessments
Screening tests and evaluations will be performed within [ADDRESS_76352] -of-care tests or examinations performed prior toobtaining informed 
consent and within 28 days prior to Cycle 1, Day 1 may be used; such tests do not need 
to be repeated for screening.
See Appendix 1forthe schedule of screening assessments and Appendix 2for the 
schedule of PK, ATA, and biomarker sampling.
[IP_ADDRESS] Assessments during Treatment
All visits must occur 3 days from the scheduled date unless otherwise noted 
(see Appendix 1).All assessments will be performed on the day of the specified visit 
unless a time window is specified.  Assessments scheduled on the day of study 
treatment administration (Day 1) of each cycle should be performed prior to study 
treatment infusion unless otherwise noted.
If scheduled dosing and study assessments are precluded because of a holiday, 
weekend, or other event, then dosing may be postponed to the soonest following date, 
with subsequent dosing continuing on a 21-day schedule.  If treatment was postponed 
for fewer than 3 days, the patient can resume the original sched ule.
After completion of the induction phase ,one of three cycles may be delayed by 1 week 
(28 days instead of 21 days for one cycle) to allow for vacations or holidays.  Following 
the delay, the next cycle must be delivered 21 days from the previous dose 
administration:  two consecutive 28 cycles are not permitted.  If a dose modification is 
required due to toxicity, refer to Section 5.1.
Tumor assessments should occur every 6 weeks ( 7 days) for 48 weeks following 
Cycle 1, Day 1 and every 9 weeks ( 7 days) after completion of the Week48 tumor 
assessment, regardless of treatment delays until radiogra phic disease progression per 
RECIST v1.[ADDRESS_76353] v1.1 (e.g., toxicity, 
symptomatic deterioration) and patients who start non -protocol anti -cancer therapy in the 
absence of radiographic disease progressin per RECIST v1.[ADDRESS_76354] v1.1 (or loss of 
clinical benefit for atezolizumab -treated patients who had continued treatment with 
atezolizumab aft er radiographic disease progression according to RECIST v1.1), 
withdrawal of consent, death, or study termination by [CONTACT_2728], whichever occurs first.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
87/Protocol GO29438 , Version 7The following assessments may be performed 96hours before Day 1 of each cycle :
ECOG performance status
Limited physical examination
Local laboratory tests
Screening assessments performed 96hours before Cycle 1, Day 1 are not required to 
be repeated for Cycle 1, Day 1 .
See Appendix 1for the Schedule of Assessments performed during the treatment period 
and Appendix 2forthe schedule of PK, pharmacodynamic, ATA, and biomarker 
sampling.
[IP_ADDRESS] Assessments at Study Drug Discontinuation Visit
When a patient discontinues all study treatment, regardless of the reason for 
discontinuation, the patient will be asked to return to the cli nic within 30 days after the 
treatment for a study drug discontinuation visit.  The visit at which the decision is made 
to discontinue treatment (e.g., loss of clinical benefit is confirmed [atezolizumab -treated 
patients who continued treatment after disease progression according to RECIST v1.1] 
or disease progression occurs) may be used as the study drug discontinuation visit.
See Appendix 1and Appendix 2for the schedule of follow -up assessments.
[IP_ADDRESS] Follow -Up A ssessments
After the study drug discontinuation visit, adve rse events should be followed as outlined 
in Section 5.3.[ADDRESS_76355] v1.1 (or loss of clinical benefit for 
patients treated with atezolizumab who continued treatment after disease progression 
according to RECIST v1.1), withdrawal of consent, death, or study termination by [CONTACT_429] , whichever occurs first .
Patients who start a new anti -cancer therapy in the absence of radiographic disease 
progression per RECIST v1.[ADDRESS_76356] v1.1 (or loss of clinical benefit for atezolizuma b-treated patients who continue
treatment after radiographic disease progression according to RECIST v1.1), withdrawal 
of consent, death, or study termination by [CONTACT_1034] , whichever occurs first.
Follow -up da ta collection will also include ePROs (theSILC will be completed monthly 
only for the first 6 months after disease progression or loss of clinical benef it 
(foratezolizumab -treated patients )using an ePRO device at the patient’s home .

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
88/Protocol GO29438 , Version 7EORTC QLQ -C30, EORTC QLQ -LC13, and the EQ -5D-5L will be completed 3 and 
6months after disease progression or loss of clinical benefit (foratezolizumab- treated 
patient s)at the site using the ePRO tablet to record study treatment related adverse 
events (including serious adv erse events), subsequent anti -cancer therapi[INVESTIGATOR_014], and date 
and cause of death.
Patients who discontinue study treatment for any reason other than radiographic
progressive disease or loss of clinical benefit will complete the EORTC QLQ -C30, 
EORTC QLQ -LC13, and EQ -5D-5L at each tumor assessment visit and will complete the 
SILC at home on a weekly basis, until radiographic disease progression per RECIST
v1.1 (or loss of clinical benefit as determined by [CONTACT_70142] -treated 
patients who co ntinue treatment after radiographic disease progression) , withdraw al of
consent ,death, loss to follow -up, termination of the study by [CONTACT_1034] , whichever 
occurs first .
Survival follow -upi[INVESTIGATOR_70060], patient medica l 
records, and/or clinic visits approximately every [ADDRESS_76357].  All patients will be 
periodically contact[CONTACT_70149] -cancer therapy information unle ss the 
patient requests to be withdrawn from the study (this request must be documented in the 
source documents and signed by [CONTACT_093] ).  If the patient withdraws from study, 
the study staff may use a public information source (e.g., county records ) when 
permissible, to obtain information about survival status only.
See Appendix 1and Appendix 2for the schedule of follow -up assessments.
[IP_ADDRESS] Assessments at Unplanned Visits
Assessments for unscheduled visits related to a patient’s underlying NSCLC, study drug, 
or adverse event should be p erformed as clinically indicated and entered on the 
Unscheduled Visit eCRFs.
4.[ADDRESS_76358] the right to voluntarily withdraw from the study at any time for any reason.  
In addition , the investigator has the right to withdraw a patient from the study at any time.  
Reasons for withdrawal from the study may include but are not limited to the following:
Patient withdrawal of consent at any time
Any medical condition that the investigato r or Sponsor determines may jeopardize 
the patient’s safety if he or she continues in the study
Investigator or Sponsor determines it is in the best interest of the patient
Patient non -compliance

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
89/Protocol GO29438 , Version 7Every effort should be made to obtain information on patients who withdraw from the 
study.  The primary reason for withdrawal from the study should be documented on the 
appropriate eCRF.  However, patients will not be followed up for any reason after 
consent has been withdrawn.  Patients who withdraw from the study will not be replaced.
4.6.[ADDRESS_76359] discontinue study treatment if they experience any of the following:
Symptomatic deterioration attributed to disease progression as determined by [CONTACT_40876], biopsy results, and 
clinical status
Intolerable toxicity related to atezolizumab, including development of an 
immune -mediated adverse event determined by [CONTACT_70150]’s potential response to therapy and severity of the event
Intolerable toxicity related to other components of study treatment
If one component of study treatment is discontinued permanently due to tolerabili ty 
concerns, the patient may continue with other components of study treatment until 
disease progression or loss of clinical benefit (for atezolizumab -treated patients who 
continue treatment after disease progression according to RECIST v1.1) if agreed 
upon by [CONTACT_70151]
Any medical condition that may jeopardize the patient’s safety if he or she continues 
on study treatment
Use of another nonprotocol -specified anti-cancer therapy (see Section 4.4.3 )
Pregnancy
Radiographic disease progression per RECIST v1.1
Exception for atezolizumab treatment:   patients randomized to atezolizumab 
treatment will be permitted to continue study treatmen t after RECIST v1.1 for 
progressive disease are met if they meet all of the following criteria ( see Figure 2for 
schematic representation):
Evidence of clinical benefit as assessed by [CONTACT_33470] (including worsening of laboratory values 
[e.g., new or worsening hypercalcemia]) indicating unequivocal progression of 
disease
No decline in ECOG performance status
Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal 
disease) that cannot be readily managed and stabilized by [CONTACT_990] -allowed 
medical interventions prior to repeat dosing
Patients must provide written consent to acknowledge deferring any standard 
treatment options that may exist in favor of continuing atezolizumab treatment 
at the time of initial progression

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
90/Protocol GO29438 , Version 7A mandatory biopsy sample collection, unless not clinically feasible as 
assessed by [CONTACT_473], at the site of local or metast atic progression
The primary reason for study treatment discontinuation should be docu mented on the 
appropriate eCRF.
Figure 2 Criteria for Continuing A tezolizumab in Presence of Increased 
Radiographic Tumor Size (A tezolizumab Arm s)
ECOG PSEastern Cooperative Oncology Group performance status; ICF Informed Consent 
Form ; RECIST v1.1 Response Evaluation Criteria in Solid Tumors Version 1.1.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
91/Protocol GO29438 , Version 74.6.3 Study and Site Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include but are not limited to the following:
The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to patients.
Patient enrollment is unsatisfactory.
TheSponsor will notify the investigator if the Sponsor decides to discontinue the study.
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include but are not limited to the following:
Excessively slow recruitment
Poor pr otocol adherence
Inaccurate or incomplete data recording
Non-compliance with the International Conference for Harmonisation (ICH) guideline 
for Good Clinical Practice
No study activity (i.e., all patients have completed and all obligations have 
been fulfilled)
5. ASSESSMENT OF SA FETY
Atezolizumab is approved in the [LOCATION_002] for the treatment of locally advanced or 
metastatic urothelial carcinoma.  Human experience is currently limited and the entire 
safety profile is not known at this time.  The followin g information is based on results 
from nonclinical and clinical studies and published data on similar molecules.
5.1 SAFETY PLA N
Measures will be taken to ensure the safety of patients participating in this study, 
including the use of stringent inclusion and e xclusion criteria (see Sections 4.1.1
and4.1.2 ) and close monitoring (as indicated below and in Section 4.5).  
SeeSection 5.3(Methods and Timing for Capturing and Assessing Safety Parameters ) 
for complete details regarding safety reporting for this study.
Administration of atezolizumab will be performed in a setting with emergency medical 
facilities and staff who are trained to monitor for and respond to medical emergencies.  
All serious adve rse events and adverse events of special interest will be recorded during 
the study and for up to [ADDRESS_76360].  After the adverse event 
reporting period, all deaths should continue to be reported.  In addition, the Sponsor 
should be notified if the investigator becomes aware of any serious adverse event or 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
92/Protocol GO29438 , Version 7adverse event of special interest that is believed to be related to prior exposure to study 
treatment (see Section 5.6for reporting instructions ). These events should be reported 
through use of the Adverse Event eCRF. Howev er, if the EDC system is not available, 
the investigator should report these events directly to the Sponsor or its designee, either 
by [CONTACT_33477] e- mailing the paper Clinical Trial Serious Adverse 
Event/Adverse Event of Special Interest Repo rting Form using the fax number or e -mail 
address provided to investigators. 
Thepotential safety issues anticipated in this study, as well as measures intended to 
avoid or minimize such toxicities, are outlined in the following sections and in
Appendix 15.
5.1.1 Risks A ssociated with A tezolizumab
Atezolizumab has been associated with risks such as the following:  IRRs and 
immune -mediated hepatitis, pneumonitis, colitis, pancreatitis, diabetes mellitus, 
hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, Guillain -Barré
syndrome, myasthenic syndrome or myasthenia gravis, meningoencephalitis, 
myocarditis, nephritis ,and myositis.  Immune -mediated reactions may involve any 
organ system and may lead to hemophagocytic lymphohistiocytosis and macrophage 
activation syndrome (considered to be potential risks for atezolizumab) .  Refer to 
Section [IP_ADDRESS] and Appendix 15of the protocol and Section 6 of the Atezolizumab 
Investigator's Brochure for a detailed description of anticipated safety risks for 
atezolizumab.  
5.1.[ADDRESS_76361] common side effects of pemetrexed include gastrointestinal symptoms 
(nausea, vomiting, diarrhea, or constipation), myelosuppression, infection, fatigue, 
stomatitis, loss of appetite, and rash.
For more details regarding the safety profile of pemetrexed, see the prescribing 
information for pemetrexed .
5.1.3 Risks A ssociated with Carboplatin
Carboplatin is known to cause bone marrow suppression including myelosuppression, 
anemia, and thrombocytopenia.  Carboplatin -based chemotherapy is considered to be 
moderately emetogenic.  Patients will be monitored for carboplatin -related adverse 
events.
For more details regarding the safety profile of carboplatin, refer to the prescribing 
information for carboplatin.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
93/Protocol GO29438 , Version 75.1.4 Risks A ssociated with Cisplatin Chemotherapy
Cisplatin is known to cause myelosuppression, ototoxicity, and nephrotoxicity.  
Cisplatin -based chemotherapy is considered to be moderately emetogenic.  Patients will 
be monitored for cisplatin -related adverse events.
For more details regarding the safety profile of cisplatin, see the prescribing information 
for cisplatin .
5.1.5 General Plan to Manage Safety Concerns
[IP_ADDRESS] Monitoring
Safety will be evaluated in this study through the mo nitoring of all adverse events
defined and graded a ccording to NCI CTCAE v4.0.  Patients will be assessed for safety 
(including laboratory values) according to the schedule in Appendix 1.  Laboratory 
values must be reviewed prior to each infusion.
General safety assessments will include serial interval histories, physical examinations, 
and specific laboratory studies, including serum chemistries and blood counts 
(see Appendix 1for the list and timing of study assessments).
During the study, patients will be closely monitored for the development of any signs or 
symptoms of autoimmune conditions and infecti on.
Allserious adverse events and protocol -defined events of special interest (see 
Sections 5.2.2 and 5.2.3 ) will be reported in an expedited fashion (see Section 5.4.2 ).  
Inaddition, the iDMC and Medical Monitor will review and evaluate observed adverse 
events on a regular basis.
Patients will be followed for adverse events (including deaths, serious adver se events, 
and adverse events of special interest) during and after the adverse event reporting 
period as described in Sections 5.3.1 , [IP_ADDRESS], 5.5,and5.6.
5.1.6 Dose Modification
[IP_ADDRESS] General Notes Regarding Dose Modification
Reasons for dose modifications or delays, the supportive measures taken, and the 
outcomes will be documented in the patient ’s chart and recorded on the eCRF.  
Theseverity of adverse events will be graded according to the NCI CTCAE v4.0 grading 
system.
For any concomitant conditions already apparent at baseline, the dose modifications 
will apply according to the corresponding shift in toxicity grade, if the investigator 
feels it is appropriate.  For example, if a patient has Grade 1 asthenia at baseline 
that increases to Grade 2 during treatment, this will be considered a shift of one 
grade and treated as Grade 1 toxicity for dose -modification purposes.
When several toxicities with different grades of severity occur at the same time, 
thedose modification s should be according to the highest grade observed.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
94/Protocol GO29438 , Version 7If, in the opi[INVESTIGATOR_871], a toxicity is considered to be due solely to one 
component of the study treatment (i.e., atezolizumab, carboplatin, or cisplatin and/or 
pemetrexed if applicable) and the dose of that component is delayed or modified in 
accordance with the guidelines below, other components may be administered 
ifthere is no contraindication.
When treatment is temporarily interrupted because of toxicity caused by 
[CONTACT_70152], carboplatin or cisplatin and/or pemetrexed (if applicable), 
thetreatment cycles will be restarted such that the atezolizumab (if applicable) 
infusions remain synchronized and aligned with the chemotherapy schedule.
If, in the opi[INVESTIGATOR_871], a toxicity is considered to be due solely to 
onechemotherapy drug, the dose of the other chemotherapy drug does not 
require modification.
The investigator may use discretion in modifying or accelerating the 
dose modification guidelines described below depending on the severity of toxicity 
and an assessment of the risk versus benefit for the patient, with the goal of 
maximizing patient compliance and access to supportive care.
[IP_ADDRESS] Atezolizumab Dose Modification and Management of 
Specific Adverse Events
There will be no dose reduction for atezolizumab in this study.  Patients may temporarily 
suspend study treatment for up to [ADDRESS_76362] dose until steroids are 
discontinued or reduced to prednisone dose (or dose equivalent) 10mg/day .  The 
acceptable length of interruption will depend on agreement between the investigator and 
the Medical Monitor.
Dose interruptions for reason(s) other than adverse events, such as surgical procedures, 
may be allowed with Medical Monitor approval.  The acceptable length of interruption will 
depend on agreement between the investigator and the Medical Monitor.
Refer to Appendix 15for details on management of infusion -related reactions, 
gastrointestinal, dermatologic, endocrine, pulmonary toxicity, hepatotoxicity, pancreatic
toxicity, neurologic toxicity, orpotent ialeye toxicity, and other immune -mediated
adverse events.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
95/Protocol GO29438 , Version 7Refer to Appendix 11for precautions for anaphylaxis.
5.1.7 Pemetrexed Dose Modification and Management of 
Specific Adverse Events
The dose modification guidelines are applicable for pemetrexed used as a single agent 
or in combination with cisplatin or carboplatin.
Treatment with pemetrexed should be discontinued if a patient experiences any 
hematologic or non -hematologic Grade 3 or 4 toxicity after two dose reductions or if 
treatment is delayed for more than 63 days du e to toxicities (see Table 13).
Hematologic Toxicity
At the start of each cycle, the ANC must be 1500/ Land the platelet count must 
be100,000/ L.  Treatment should be delayed for up to 63 days to allow sufficient time 
for recovery.  Growth factors may be used in accordance with American Society of 
Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) 
guidelines (Smith et al. 2006 ; NCCN 2012 ).  Upon recovery, dose adjustments at the 
start of a subsequent cycle will be made on the basis of the lowest (nadir) platelet and 
neutrophil values from the previous cycle (see Table 12).
In the event that dose adjustments are needed for both ANC and platelets, patients are 
to receive the lower dose.
Table 12Pemetrexed Dose Modification for Hematologic Toxicities
ToxicityaPemetrexed Dose 
ANC  500cells/L and platelets 50,000/ L 75% of previous dose
Platelets 50,000/ L, regardless of ANC 75% of previous dose
Platelets 50,000/ Lwith Grade 2bleeding, regardless of 
ANC50% of previous dose
aNadir of prior cycle.
Investigators should be vigilant and alert to early and overt signs of myelosuppression, 
infection, or febrile neutropenia so that these complications can be promptly and 
appropriately managed.  Patients should be made aware of these signs and encouraged 
to seek medical attention at the earliest opportunity.
If chemotherapy must be withheld because of hematologic toxicity, full blood counts 
(including differential W BC) should be obtained weekly until the counts r each the lower 
limits for treatment as outlined.  The treatment then can be resumed.
No dose reductions are recommended for anemia.  Patients should be supported per the 
treating physician’s institution’s guidelines .

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
96/Protocol GO29438 , Version 7Non- Hematologic Toxicity
At the start o f each cycle, the CRCL must be 45mL/min. For enrollment and dosing 
decisions, CRCL will be estimated using the original, weight -based Cockcroft and 
Gault formula or measured using the appropriate radiolabeled method (51 -CrEDTA or 
Tc99m -DTPA) to determine the GFR.  The method of CRCL assessment used at 
baseline should be used throughout the study
If a patient develops a non -hematologic toxicity ( Table 13), pemetrexed should be 
withheld for up to 63days until resolution to equal or less than the patient’s baseline 
(orGrade [ADDRESS_76363] that toxicity at baseline).  Treatment should be 
resumed according to the guideli nes in Table 13.  For a Grade 3 or 4 neurotoxicity, 
pemetrexed should be resumed at 50% of the previous dose upon improvement, or 
discont inued immediately (based on investigator’s clinical judg ment).
Table 13Pemetrexed Dose Modification for Non -Hematologic Toxicities
Toxicity Pemetrexed Dose
Any diarrhea requiring hospi[INVESTIGATOR_059] (irrespective of 
grade) or Grade 3 or 4 diarrhea that occurs on 
adequate anti -diarrhea medication75% of previous dose
Neurotoxicity
Grade 2 75% of previous dose
Grade 3 or 4 50% of previous dose or 
permanent discontinuation
Any other Grade 3 or 4 toxicities 75% of previous dose
Treatment Delay s Caused by  [CONTACT_70153] A cid or Vitamin B12 
Supplementation
Cycle 1 should not be started until both of the following requirements are met:
The patient has taken folic acid for at least [ADDRESS_76364] 
dose of p emetrexed, and
The patient has received a vitamin B 12injection (which can be given on Cycle 1, 
Day1)
Delay subsequent cycles until the patient has taken folic acid for at least 14 of the 
21 days before Day 1 of the subsequent cycle.
For more details regarding pemetrexed dose modification, see the prescribing 
information for pemetrexed .

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
97/Protocol GO29438 , Version 75.1.8 Platinum Chemotherapy  Dose Modification and Management of 
Specific A dverse Events
[IP_ADDRESS] Cisplatin
Treatment with cisplatin should be discontinued if a patient experiences any hematologic 
or non -hematologic Grade [ADDRESS_76365] be 1500/ L and the platelet count must 
be100,000/ L.  Treatment should be delayed for up to 63 days to allow sufficient time 
for recovery.  Growth factors may be used in accordance with ASCO and NCCN 
guidelines (Smith et al. 2006; NCCN 2012 ).  Upon recovery, dose adjustments at the 
start of a su bsequent cycle will be made on the basis of the lowest platelet and 
neutrophil values from the previous cycle (see Table 14).
In the event that dose adjustments are needed for both ANC and platelets, patients are 
to receive the lower dose.
Table 14Cisplatin Dose Modification for Hematologi c Toxicities
ToxicityaCisplatin Dose
ANC  500cells/Land platelets 50,000/ L 75% of previous dose
Platelets 50,000/ L, regardless of ANC 75% of previous dose
Platelets 50,000/ Lwith Grade  2 bleeding, regardless of ANC 50% of previous dose
ANC  1000/ Lplus fever of 38.5°C 75% of previous dose
aNadir ofprior cycle.
Investigators should be vigilant and alert to early and overt signs of myelosuppression, 
infection, or febrile neutropenia so that these complications can be promptly and
appropriately managed.  Patients should be made aware of these signs and encouraged 
to seek medical attention at the earliest opportunity.
If chemotherapy must be withheld because of hematologic toxicity, full blood counts 
(including differential W BC) should be obtained weekly until the counts reach the lower 
limits for treatment as outlined.  The treatment then can be resumed.
No dose reductions are recommended for anemia.  Patients should be supported per the 
treating physician’s institution’s guideli nes.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
98/Protocol GO29438 , Version 7Non- Hematologic Toxicity
If a patient develops a non -hematologic toxicity ( see Table 15) cisplatin should be 
withheld for up to 63 days until resolution to equal or less than the patient’s baseline
(orGrade ≤[ADDRESS_76366] that toxicity at baseline).   Treatment shoul d be 
resumed according to the guidelines in Table 15.
Diarrhea should be controlled with adequate anti -diarrhea medication. Nausea and/ or 
vomiting should be controll ed with adequate anti -emetics.
Table 15Cisplatin Dose Modification for Non -Hematologic Toxicities 
(Excluding Neurotoxicity)
Toxicity Cisplatin Dose
Any diarrhea requiring hospi[INVESTIGATOR_059] (irrespective of 
grade) or Grade 3 or 4 diarrhea that occurs on adequate 
anti-diarrhea medication75% of previous dose
Grade 3 or 4 nausea/vomiting a75% of previous dose
Any other Grade 3 or 4 toxicity 75% of previous dose
aDespi[INVESTIGATOR_70061] -emetics.
Nephrotoxicity
CRCL must be 60 mL/min prior to the start of any cycle.  If there is a decrease in CRCL 
between cycles, but the CRCL is still above 60 mL/min at time of next cycle, the treating 
physician should use his or her clinical judgment regarding con tinuing cisplatin, dose 
reduction, or delaying the cycle.  If a patient’s CRCL value has not returned to 
60mL/min within 63days following last cisplatin administration, the patient must be 
discontinued from cisplatin.
Neurotoxicity
In the event of neurotoxicity, the recommended dose adjustment for cisplatin 
isdocumented in Table 16.  For a Grade 3 or 4 neurotoxicity, cisplatin should be 
resumed at 50% of the previous dose upon improvement or discontinued immediately 
(based on investigator’s clinical judgment).
Table 16Cisplatin Dose Modification for A ssociated Neurotoxicity
Toxicity Cisplatin Dose
Grade 0 –1 neurotoxicity 100% of previous dose
Grade 2 neurotoxicity 75% of previous dose
Grade 3 or 4 neurotoxicity 50% of previous dose or 
permanent discontinuation

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
99/Protocol GO29438 , Version 7If the patient develops ototoxicity, subsequent doses of cisplatin should not be given until 
an audiometric analysis indicates that auditory acuity is within normal limits 
(http://www.drugs.com/pro/platinol.html). Refer to Table 16for dose modification.
[IP_ADDRESS] Carboplatin
Treatment with carboplatin should be discontinued if a patient experiences any 
hematologic or non -hematologic Grade 3 or Grade 4 toxicity after two dose reductions or 
treatment is delayed for more than 63 days due to toxicities.
Additional guidance has been provided regarding recommended dose reductions, holds, 
and discontinuations of study treatment for toxicities and/or to comply with the 
prescribing information (see Section 4.3.2 ).
Hematologic Toxicity
At the start of each cycle, the ANC must be 1500 /Land the platelet count must 
be100,000 /L.  Treatment should be delayed for up to63days to allow sufficient time 
for recovery.  G rowth factors may be used in accordance with ASCO and NCCN
guidelines (Smith et al. 2006; NCCN 2012 ). Upon recovery, dose adjustments at the
start of a subsequent cycle will be made on the basis of the lowest platelet and 
neutrophil values from the previous cycle (see Table 17).
Table 17Carboplatin Dose Modification for Hematologic Toxicities
ToxicityaCarboplatin Dose 
ANC  500cells/Land platelets 50,000/ L 75% of previous dose
Platelets 50,000/ L, regardless of ANC 75% of previous dose
Platelets 50,000/ Lwith Grade 2bleeding, regardless of ANC 50% of previous dose
ANC  1000/ Lplus fever of 38.5°C 75% of previous dose
aNadir prior c ycle.
In the event that dose adjustments are needed for both ANC and platelets, patients are 
to receive the lower dose.
Investigators should be vigilant and alert to early and overt signs of myelosuppression, 
infection, or febrile neutropenia so that these complications can be promptly and 
appropriately managed.  Patients should be made aware of these signs and encouraged 
to seek medical attention at the earliest opportunity.
If chemotherapy must be withheld because of hematologic toxicity, full blood counts 
(including differential WBC) should be obtained weekly until the counts reach the lower 
limits for treatment as outlined.  The treatment will then be resumed.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
100/Protocol GO29438 , Version 7No dose reductions are recommended foranemia.  Patients should be supported per the 
treating physician’s institution’s guidelines.
Non-Hematologic Toxicity
For a non-hematologic toxicity (seeTable 18), treatment should be delayed for up to 
63days until resolution to less than or equal to the patient’s bas eline value (or Grade [ADDRESS_76367] that toxicity at baseline).  Dose reductions at the start of the 
subsequent cycle will be made on the basis of non -hematologic toxicities from the dose 
administered in the preceding cycle.   Table 18provides the relevant dose adjustments 
for non -hematologic toxicities.
Table 18Carboplatin Dose Modifi cation on the Basis of Non- Hematologic 
Toxicities in the Preceding Cy cle
ToxicityAdjusted Carboplatin Dose as % of 
Previous Dosea
Diarrhea Grade 3 or 4 b75%
Nausea/vomiting Grade 3 or 4c75%
Neurotoxicity Grade 2 75%
Grade 3 or 4 50% or permanent discontinuation
Transaminase elevation Grade 3 75%
Grade 4 Discontinue
Other Grade 3 or 4 75%
AUC area under the concentration time curve.
aIf deemed appropriate by [CONTACT_1963], adjust carboplatin dose to the 
specified percentage of the previous AUC.
bGrade 3 or 4 diarrhea that occurs on adequate anti -diarrhea medication or 
any grade of diarrhea requiring hospi[INVESTIGATOR_059].
cDespi[INVESTIGATOR_70061] -emetics.
Diarrhea should be controlled with adequate anti -diarrhea medication.  Nausea and/or 
vomiting should be controlled with adequate anti- emetics.  For a Grade 3 or 4 
neurotoxicity, carboplatin should be resumed at 50% of the previous dose upon 
improvement, or discontinued immediately (based on investigator’s clinical judgment).
5.1.[ADDRESS_76368] been associated with each agent separately (e.g., hepatotoxicity, skin, and 
gastrointestinal toxicity) may not be unambiguous when the agents are administered 
together.  It is theoretically possible that allergic or inflamm atory adverse events 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
101/Protocol GO29438 , Version 7associated with these chemotherapeutic agents (e.g., hepatotoxicity) could be 
exacerbated by [CONTACT_70154].
Toxicities should initially be managed according to the recommendations in 
Section [IP_ADDRESS] , Section 5.1.8 , and Section 5.1.9 with dose holds and modifications 
(ifapplicable) applied to the component of the study drug judged to be the primary cause.  
For severe ( Grade 3) or persistent Grade 1or2 diarrhea, an endoscopic evaluation 
should be considered.  Additional tests, such as autoimmune serology or biopsies, may 
be used to determine a possible immunogenic etiology for adverse events listed above.  
If, in the opi[INVESTIGATOR_70062], atezolizumab is a potential inciting factor, the dose of 
atezolizumab may be withheld for a maximum of [ADDRESS_76369] been given (see Section [IP_ADDRESS]).  Prompt symptomatic management is 
appropriate for mild immune -mediated adverse events.  In severe cases, 
immune -mediated toxicities may be acutely managed with systemic corticosteroids 
orTNF-inhibitors.  These cases should be discussed with the Medical Monitor.
5.[ADDRESS_76370]; measu rement of 
protocol -specified safety laboratory assessments; measurement of protocol -specified 
vital signs; and other protocol -specified tests that are deemed critical to the safety 
evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4.
5.2.[ADDRESS_76371], regardless of causal attribution.  An adverse event can 
therefore be any of the following:
Any unfavorable and unintended sign (including an abnormal laborator y finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product
Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition), except as described in 
Section [IP_ADDRESS]
Recurrence of an intermittent medical condition (e.g., headache) not present at
baseline
Any deterioration in a laboratory value or other clinical test result (e.g., ECG, X -ray) 
that is associated with symptoms or leads to a change in study treatment or 
concomitant treatment or discontinuation from study drug

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
102/Protocol GO29438 , Version 7Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assignment of study treatment (e.g., screening invasive 
procedures such as biopsies)
5.2.2 Serious A dverse Events (Immediately  Reportable to the 
Sponsor)
A serious adverse event is any adverse event that meets any of the following criteria:
Is fatal (i.e., the adverse event actually causes or leads to death)
Is life threatening (i.e., the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)
This does not include any adverse event that had it occurred in a more severe 
form or was allowed to continue might have caused death.
Requires or prolongs inpatient hospi[INVESTIGATOR_059] (see Section [IP_ADDRESS])
Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient’s ability to conduct normal life 
functions)
Results in a congenital anomaly and/or birth defect in a neonate or infant born to a 
mother exposed to study drug
Is a significant medical event in the investigator ’s judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the ou tcomes 
listed above)
The terms “severe ”and “serious ”are notsynonymous.  Severity refers to the intensity 
ofan adverse event (e.g., rated as mild, moderate, or se vere, or according to 
NCICTCAE ; see Section 5.3.3 ); the event itself may be of relatively minor medical 
significance (such as severe headache without any further findings).
Severity and seriousness need to be independently assessed for eac h adverse event 
recorded on the eCRF.
Serious adverse events are required to be reported by [CONTACT_25741] (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for 
reporting instructions).

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
103/Protocol GO29438 , Version 75.2.[ADDRESS_76372] (Immediately  Reportable to 
the Sponsor)
Adverse events of special interest are required to be reported by [CONTACT_43073] t he 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 for reporting instructions).  Adverse events of special interest for this study 
include the following:
Confirmed treatment -emergent autoimmune conditions:
Pneumonitis
Colitis
Endocrinopathies: diabetes mellitus, pancreatitis, adrenal insufficiency ,and 
hyperthyroidism
Hepatitis
Transaminitis: Grade 2(AST or ALT3ULN and bilirubin 2ULN) or 
AST/ALT 10ULN
Systemic lupus erythematosus
Neurologic disorders : Guillain -Barré syndrome , myasthenia g ravis, and 
meningoencephalitis
Nephritis
Events suggestive of hypersensitivity, cytokine release syndrome , influenza -like 
illness, systemic inflammatory response syndrome, andinfusion -reaction syndromes
Cases of potential drug- induced liver injury that include an elevated ALT or AST
level in combination with either an elevated bilirubin level or cli nical jaundice, as 
defined by [CONTACT_25742]’s law (see Section [IP_ADDRESS] )
Suspected transmission of an infectious agent by [CONTACT_5257], as defined below:
Any o rganism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical sympto ms or laboratory findings that indicate an 
infection in a patient exposed to a medicinal product.  This term applies only
when a contamination of the study drug is suspected.
5.3 METHODS A ND TIMING F OR CA PTURING A ND ASSESSING 
SAFETY PARAMETERS
The investigato r is responsible for ensuring that all adverse events (see Section 5.2.1 for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Sections 5.45.6.
For each adverse event recorded on the Adverse Event eCRF, the i nvestigator will make 
an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity 
(see Section 5.3.3 ), and causality (see Section 5.3.4 ).

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
104/Protocol GO29438 , Version 75.3.[ADDRESS_76373].  
Alladverse events, whether reported by [CONTACT_70155] l,will be 
recorded in the patient’s medical record and on the Adverse Event eCRF.
After informed consent has been obtained, but prior to initiation of s tudy drug,only 
serious adverse events caused by a protocol -mandated intervention (e.g., invasive 
proce dures such as biopsies, discontinuation of medications) should be reported 
(see Section 5.4.2 for instructions for reporting serious adverse events).
After initiation of study drug,allserious adverse events and adverse events of special 
interest, regardless of relationship to study drug,will be reported until [ADDRESS_76374] dose of study drug or initiation of non protocol -specified systemic anti-cancer 
therapy after the last dose of study treatment ,whichever occurs first.  All other adverse 
events, regardless of relationship to study drug, will be reported until [ADDRESS_76375].  Instructions for reporting adverse events that occur 
after the safety reporting period are provided in Section 5.6.
5.3.2 Eliciting A dverse Ev ent Information
A consistent methodology of non -directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non -directive 
questions include the following:
“How have you felt since your last clinic visit? ”
“Have you had any new or changed health problems since you were last here? ”
5.3.3 Assessment of Severity  of A dverse Events
The adverse event severity g rading scale for the NCI CTCAE v4.0 will be used for 
assessing adverse event severity.  Table 19will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
105/Protocol GO29438 , Version 7Table 19Adverse Event Severity Grading Scale for Events Not Specifically  
Listed in NCI CTCA E
Grade Severity
1 Mild; as ymptomatic or mild sy mptoms; clinical or diagnostic observations only; or 
intervention not indicated
2 Moderate; minimal, local, or non -invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily livinga
3 Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; or 
limiting self-care activities of daily livingb, c
4 Life-threatening consequences or urgent intervention indicatedd
5 Death related to adverse eventd
NCICTCAE National Cancer Institute Common Terminology Criteria for Adverse Events .
Note:  Based on the most recent version of NCI CTCA E v4.0, which can be found at
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
aInstrumental activitie s of daily living refer to preparing meals, shoppi[INVESTIGATOR_19640], using the telephone, managing money, etc.
bExamples of self -care activities of daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and tak ing m edications, as performed by [CONTACT_25744].
cIf an event is assessed as a “significant medical event, ”it must be reported as a serious 
adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious 
adverse event in Section 5.2.[ADDRESS_76376] be reported as serious adverse events (see Section 5.4.2 for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2 .
5.3.4 Assessment of Causality  of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surro unding 
theevent and an evaluation of any potential alternative causes to determine whether or 
not an adverse event is considered to be related to the study drug, indicating “yes”or “no”
accordingly.  The following guidance should be taken into consideration:
Tempo ral relationship of event onset to the initiation of study drug
Course of the event, considering especially the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable)
Known association of the event with th e study drug or with similar treatments
Known association of the event with the disease under study
Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event
Presence of non treatment -related fa ctors that are known to be associated with the 
occurrence of the event

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
106/Protocol GO29438 , Version 7For patients receiving combination therapy, causality will be assessed individually for 
each protocol -mandated therapy.
5.3.[ADDRESS_76377] medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations.
Only one adverse event term should be recorded in the event field on the Adverse 
Event eCRF.
[IP_ADDRESS] Diagnosis versus Signs and Symptoms
For alladverse events, a diagnosis (if known) rather than individual signs and symptoms 
should be recorded on the Adverse Event eCRF (e.g., record only liver failure or 
hepatitis rather than jaundice, asterixis, and elevated transaminase levels).  However, if 
a constellation of signs and/or symptoms cannot be medically characterized as a single 
diagnosis or syndrome at the time of reporting, each individual event should be recorded 
on the Adverse Event eCRF.  If a diagnosis is subsequently establi shed, all previously 
reported adverse events based on signs and symptoms should be nullified and replaced 
by [CONTACT_25746], with a starting date that 
corresponds to the starting date of the first symptom of the even tual diagnosis.
[IP_ADDRESS] Adverse Events That A re Secondary  to Other Events
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by [CONTACT_5252], with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:
If vomiting results in mild dehydration with no addi tional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.
If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.
If a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF.
If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF.
If neutropenia is accompanied by [CONTACT_25747], both events should be reported 
separately on the eC RF.
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
107/Protocol GO29438 , Version [IP_ADDRESS] Persistent or Recurrent A dverse Events
A persistent adverse event is one that extends continuously, without resolution , between 
patient evaluation timepoints.  Such events should only be recorded once on the 
Adverse Event eCRF.  The initial severity (intensity) of the event will be recorded at the 
time the event is first reported.  If a persistent adverse event becomes mo re severe, the 
most extreme intensity should also be recorded on the Adverse Event eCRF.  If the 
event becomes serious, it should be reported to the Sponsor immediately (i.e., no more 
than 24 hours after learning that the event became serious; see Section 5.4.2 for 
reporting instructions).  The Adverse Event eCRF should be updated by [CONTACT_70156] “non-serious ”to “serious, ”providing the dat e that the event became serious, 
and completing all data fields related to serious adverse events.
A recurrent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF.
[IP_ADDRESS] Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it is a change from baseline and meets any of 
the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention (e.g., potassium supplementation for h ypokalemia) 
or a change in concomitant therapy
Is clinically significant in the investigator’s judgment
It is the investigator’s responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5 ULN associated with cholestasis), only the 
diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descrip tor indicating if the test result is above or below the normal range (e.g., “elevated 
potassium, ”as opposed to “abnormal potassium ”).  If the laboratory abnormality can be 
characterized by a precise clinical term per standard definitions, the clinical ter m should 
be recorded as the adverse event.  For example, an elevated serum potassium level of 
7.0 mEq/L should be recorded as “hyperkalemia. ”

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
108/Protocol GO29438 , Version 7Observations of the same clinically significant laboratory abnormality from visit to visit 
should not be repeatedl y recorded on the Adverse Event eCRF, unless the etiology 
changes.  The initial severity of the event should be recorded, and the severity or 
seriousness should be updated any time the event worsens.
[IP_ADDRESS] Abnormal Vital Sign Values
Not every vital sign abnormal ity qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it is a change from baseline and meets any of the 
following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage m odification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention or a change in concomitant therapy
Is clinically significant in the investigator’s judgment
It is the investigator’s responsibility to review all vital si gn findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on 
the Adverse Event eCRF.
Observations of the same clinically significant vital sign abnormality from visit to visit 
should not be repeatedly recorded on the Adverse Event eC RF, unless the etiology 
changes.  The initial severity of the event should be recorded, and the severity or 
seriousness should be updated any time the event worsens.
[IP_ADDRESS] Abnormal Liver Function Tests
The finding of an elevated ALT or AST ( 3baseline value) in combination with either 
an elevated total bilirubin ( 2ULN) or clinical jaundice in the absence of cholestasis or 
other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury.  
Therefore, investigators must report as an adverse event the occurrence of either of the 
following:
Treatment -emergent ALT or AST 3baseline value in combination with total 
bilirubin 2ULN (of which 35% is direct bilirubin)
Treatment -emergent ALT or AST 3baseline value in combination with clinical 
jaundice
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
109/Protocol GO29438 , Version 7The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section [IP_ADDRESS]) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or a nadverse event of special interest 
(see Section 5.4.2 ).
[IP_ADDRESS] Deaths
For this protocol, mortality is an efficacy endpoint.  Deaths that occur during the 
protocol -specified adverse event reporting period (see Section 5.3.1 ) that are attributed 
by [CONTACT_70157].  All other deaths occurring du ring the 
adverse event reporting period , regardless of relationship to study drug, must be 
recorded on the Adverse Event eCRF and immediately reported to the Sponsor 
(see Section 5.4.2 ).  The iDMC will monitor the frequency of deaths from all causes.
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported .  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, “Death due to Unknown Cause” should be recorded on the Adver se Event 
eCRF.  If the cause of death later becomes available (e.g., after autopsy), the event 
should be replaced by [CONTACT_25749].   The term "sudden death" should 
not be used unless combined with the presumed cause of death (e.g., "sudden cardiac 
death").
Deaths that occur after the adverse event reporting period should be reported as 
described in Section 5.6.
[IP_ADDRESS] Preexist ing Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  W hen 
recording such events on the Adverse Event eCRF, it is important to convey the concept 
that the preexisting condition has changed by [CONTACT_9672] 
(e.g., “more frequent headaches ”or “worsened headache” ).

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
110/Protocol GO29438 , Version [IP_ADDRESS] Worsening of NSCLC
Events that are clearly consistent with the expected pattern of progression of the NSCLC 
should not be recorded as adverse events.  These data will be captured as efficacy 
assessment data only.  In most cases, the expected pattern of progression will be based 
on RECIST.   In rare cases, the determination of clinical progression will be based on 
symptomat ic deterioration.  However, every effort should be made to document 
progression through use of objective criteria.  If there is any uncertainty as to whether an 
event is due to disease progression, it should be reported as an adverse event.
[IP_ADDRESS] Hospi[INVESTIGATOR_26663] (i.e., in -patient admission to a hospi[INVESTIGATOR_307]) 
or prolonged hospi[INVESTIGATOR_25676] a serious adverse 
event (per the definition of serious adverse even t in Section 5.2.2 ), except as 
outlined below.
An event that leads to hospi[INVESTIGATOR_70063] a dverse event or a serious adverse event:
Hospi[INVESTIGATOR_25678]
Planned hospi[INVESTIGATOR_33402] (e.g., for study drug administration or 
to perform an efficacy measurement for the study)
Hospi[INVESTIGATOR_272] a preexisting condition, provided that all of the following criteria 
aremet:
The hospi[INVESTIGATOR_70064]
Hospi[INVESTIGATOR_26667] a serious adverse event, but should be reported as an adverse
event instead:
Hospi[INVESTIGATOR_25682]
[IP_ADDRESS] Adverse Events A ssociated with an Overdose or Error in Drug 
Administration
Study overdose is the accidental or intentional use of a drug in an amount higher than 
the dose being studied.  An overdose or incorrect administration of study treatment is not 
itself an adverse event, but it may result in an adverse event.  All adverse events 
associated with an overdose or incorrect administration of study drug should be 
recorded on the Study Drug Administration eCRF.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
111/Protocol GO29438 , Version 7All adverse events associated with an overdose or incorrect administration of study drug 
should be recorded on the Adverse Event eCRF.  If the a ssociated adverse event fulfills 
seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2 ).
[IP_ADDRESS] Patient -Reported Outcome Data
Adverse events will not be derived from PRO data by [CONTACT_1034], and safety analyses 
will not be performed using PRO data. Sites are not expected to review the PRO data 
for adverse events. 
5.[ADDRESS_76378] report
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than [ADDRESS_76379] report to the Sponsor within 24 hours a fter learning 
of the event, regardless of relationship to study drug:
Serious adverse events
Adverse events of special interest
Pregnancies
The investigator must report new significant follow -up information for these events to the 
Sponsor immediately (i.e ., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following:
New signs or symptoms or a change in the diagnosis
Significant new diagnostic test results
Change in causality based on new information
Change in the event’s outcome, including recovery
Additional narrative information on the clinical course of the event
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.
5.4.[ADDRESS_76380] Information
Medical Monitor: , M.D.
E-Mail:
Mobile Telephone No.:

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
112/Protocol GO29438 , Version 7To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will 
access the [COMPANY_002] Medical Emergency List , escalate emergency medical calls, provide 
medical translation service (if necessary), connect the investigator with a [COMPANY_002] Medical 
Monitor, and track all calls.  The Emergency Medical Call Center Help Desk will be 
available [ADDRESS_76381]
[IP_ADDRESS] Events That Occur prior to Study  Drug Initiation
After informed consent has been obtained, but prior to initiation of study drug, only 
serious adverse events caused by a protocol -mandated intervention should be reported.  
The Serious Adverse Event/Ad verse Event of Special Interest Reporting Form provided 
to investigators should be completed and submitted to [COMPANY_002] or its designee 
immediately (i.e., no more than 24 hours after learning of the event), either by [CONTACT_40879].
[IP_ADDRESS] Events That Occur after Study  Drug Initiation
After initiation of study drug, serious adverse events and adverse events of special 
interest will be reported until [ADDRESS_76382] all case details that can be gathered immediately (i.e., within 
24 hours after learning of the event) on t he Adverse Event eCRF and submit the report 
via the electronic data capture ( EDC) system.  A report will be generated and sent to 
[COMPANY_002] Safety Risk Management by [CONTACT_27950].
In the event that the EDC system is unavailable, the Serious Adverse Event/Adv erse 
Event of Special Interest Reporting Form provided to investigators should be completed 
and submitted to [COMPANY_002] or its designee immediately (i.e., no more than 24 hours after 
learning of the event), either by [CONTACT_70158].  Once the EDC system is 
available, all information will need to be entered and submitted via the EDC system.
Instructions for reporting adverse events that occur after the adverse event reporting 
period are provided in Section 5.6.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
113/Protocol GO29438 , Version 75.4.3 Reporting Requirements for Pregnancies
[IP_ADDRESS] Pregnancies i n Female Patients
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregnant during the study ,within [ADDRESS_76383] dose of c isplatin.  A Clinical Trial 
Pregnancy Reporting Form should be completed and submitted to the Sponsor or its 
designee immediately (i.e., no more than 24 hours after learning of the pregnancy), 
either by [CONTACT_70159].   Pregnancy should not be recorded on the 
Adverse Event eCRF.  The investigator should discontinue study drug and counsel the 
patient, discussing the risks of the pregnancy and the possible effec ts on the fetus.  
Monitoring of the patient should continue until conclusion of the pregnancy.  Any serious 
adverse events associated with the pregnancy (e.g., an event in the fetus, an event in 
the mother during or after the pregnancy, or a congenital ano maly or birth defect in the 
child) should be reported on the Adverse Event eCRF. In addition, the investigator will 
submit a Clinical Trial Pregnancy Reporting Form when updated information on the 
course and outcome of the pregnancy becomes available.
[IP_ADDRESS] Preg nancies in Female Partners of Male Patients
Atezolizumab is not expected to be genotoxic. In addition, the anticipated 
concentrations of atezolizumab in seminal fluid as well as the potential risk to the 
developi[INVESTIGATOR_70065] a female partner .
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant during the chemotherapy 
treatment period or within 6months after the last dose of chemotherapy (i.e., carboplatin, 
cisplatin, or pemetrexed) .  A Clinical Trial Pregnancy Reporting Form should be 
completed and submitted to the Sponsor or its designee immediately (i.e., no more than 
24 hours after learning of the pre gnancy), either by [CONTACT_70160].   Attempts 
should be made to collect and report details of the course and outcome of any 
pregnancy in the partner of a male patient exposed to study drug.  When permitted by 
[CONTACT_779], t he pregnant partner w ould need to sign an Authorization for Use and 
Disclosure of Pregnancy Health Information to allow for follow -up on her pregnancy.  
Ifthe authorization has been signed, the investigator should submit a Clinical Trial 
Pregnancy Reporting Form when updated information on the course and outcome of the 
pregnancy becomes available.   An investigator who is contact[CONTACT_70161]/or obstetrician.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
114/Protocol GO29438 , Version [IP_ADDRESS] Abortions
A spontaneous abortion should be classified as a serious adverse event (as the Sponsor 
considers abortions to be medically significant), recorded on the Adverse Event eCRF, 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event; see Section 5.4.2 ).
If a therapeutic or elective abortion was performed because of an underlying maternal 
or embryofetal toxicity, the toxicity should be classified as a serious adverse event, 
recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2).   A therapeu tic or 
elective abortion performed for reasons other than an underlying maternal or 
embryofetal toxicity is not considered an adverse event.
All abortions should be reported as pregnancy outcomes on the paper Clinical Trial 
Pregnancy Reporting Form.
[IP_ADDRESS] Congen ital A nomalies and Birth Defects
Any congenital anomaly or birth defect in a child born to a female patient exposed to 
study drug or the female partner of a male patient exposed to study drug should be 
classified as a serious adverse event, recorded on the Adverse Event eCRF, and 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section 5.4.2 ).
5.[ADDRESS_76384] to follow -up, or the patient withdraws consent.  Every effort should be made to follow 
up all serious adverse events considered to be related to study drug or study -related 
procedures until a final outcome can be reported.
During the study period, resolution of adverse events (with dates) should be documented 
on the Adverse Event eCRF and in the patient’s medical record to facilitate source data 
verification.  If, after follow -up, return to baseline status or stabilization cannot be 
established, an explanation should be recorded on the Adverse Event eCRF.
All pregnancies reported during the study should be followed up until pregnancy 
outcome.  If the EDC system is not available at the time of pregnancy outcome, follow 
reporting instructions provided in Section [IP_ADDRESS] .

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
115/Protocol GO29438 , Version 75.5.[ADDRESS_76385], and pregnancies, the 
Sponsor or a designee may follow up by [CONTACT_756], fax, electronic mail, and/or a 
monitoring visit to obtain additional case details and outcome information (e.g., from 
hospi[INVESTIGATOR_8838], consultant reports, autopsy reports) in order to perform 
an independent medical assessment of the repor ted case.
5.6 ADVERSE EVENTS THA T OCCUR AFTER THE A DVERSE 
EVENT REPORTING PERI OD
After the end of the adverse event reporting period (as defined in Section 5.3.1 ), all 
deaths, regardless of cause, should be reported through use of the Long -Term Survival 
Follow -up eCRF.
In addition, if the investigator becomes aware of a serious adverse event or adverse 
event of special interest that is beli eved to be related to prior exposure to study 
treatment, the event should be reported through use of the Adverse Event eCRF.  
However, if the EDC system is not available, the investigator should report these events 
directly to the Sponsor or its designee, either by [CONTACT_70162]/Adverse Event of Special Interest Reporting 
Form using the fax number or email address provided to investigators.
5.[ADDRESS_76386] experience to identify and expeditiously 
communicate possible new saf ety findings to investigators, IRBs, ECs, and applicable 
health authorities based on applicable legislation.
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events using the following reference documents:
Atezolizumab Investigator’s Brochure
Prescribing information for each chemotherapy agent (cisplatin, carboplatin ,
andpemetrexed)
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by [CONTACT_25753].

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
116/Protocol GO29438 , Version 7An iDMC wi ll monitor safety data during the study.  An aggregate report of any clinically 
relevant imbalances that do not favor the test product will be submitted to health 
authorities.
6. STATISTICA L CONSIDER ATIONS AND ANAL YSIS PLAN
This is a randomized, Phase III, gl obal, multicenter, open- label study designed to 
evaluate the safety and efficacy of atezolizumab in combination with carboplatin or 
cisplatin pemetrexed compared with treatment with carboplatin or 
cisplatin pemetrexed in patients who are chemotherapy -naive and have Stage IV 
non-squamous NSCLC.
Approximately [ADDRESS_76387] 1 patient is enrolled in China during the global enrollment phase, 
additional patients will be enrolled in a China extension phase to ensure a total 
enrollment of approximately 164 patients in the China subpopulation. 
The primary analyses of Study GO29438 will include patients enrolled during the global 
enrollment phase.  The China subpopulation will include pa tients enrolled at sites in 
China receiving cisplatin and pemetrexed, with or without atezolizumab, during both the 
global enrollment phase and the China extension phase, which will be analyzed
separately from the analyses of patients enrolled during the global enrollment phase.
The efficacy analyses will be performed on all randomized patients ( ITT) with patients 
grouped according to the treatment assigned at randomization, regardless of whethe r 
they received any assigned study drug.  
Safety analyses will be performed on data for all randomized patients who received any 
amount of study drug , with patients grouped according to whether any amount of 
atezolizumab was received , including cases when atezolizumab was received in error .
6.[ADDRESS_76388] one patient is enrolled in China during the global enrollment phase.
To control the overall type I error rate using the group sequential Holm procedure 
(Yeetal. 2012 ) for the one-sided test at 0.025 in the analyses of patients enrolled during 
the global enrollment phase, PFS in the ITTpopulation will be tested at a one -sided 
-level of 0.002 and OS in the ITT population will be tested at a one -sided -level of 
0.023 . If only PFS isstatistically significant, OS in the ITT population will be tested at a 
one-sided -level of 0.025. Otherwise , OS in the ITT population will be tested at a 
one-sided -level of 0.023. If only OS is statistically significant, PFS in the ITT 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
117/Protocol GO29438 , Version 7populat ion will be tested at a one- sided -level of 0.025 at the time of the final analysis 
of PFS.  Otherwise, PFS in the ITT population will be tested at a one -sided -level of 
0.002 at the time of PFS final analysis. Theoverview of the control strategy is shown 
in Figure 3.
Figure 3 Overview  of the A lpha Control Strategy
ITTintent to treat; PFS progressio n-free survival; OS overall survival.
The sample size of this study is determined on the basis of the number of events 
required to demonstrate efficacy with regard to both PFS and OS (as defined in 
Section 6.4).
The estimates of the number of events required to demonstrate efficacy in the ITT 
population with regard to PFS and OS are based on the following assumptions:
1:1 randomization ratio
One-sided significance level of 0.002 for PFS and 0.023 for OS
96.0 % power to detect an HR of 0.65, corresponding to an improvement in median 
PFS from 6 months to 9.2 months
No interim analysis for PFS
81% power to detect an HR of 0.75, corresponding to an improvement in median 
OS from 14 months to 18.7 months
One interim OS analyses will be performed at the time of the PFS final analysis with 
an information fraction of approximately 78% (i.e., 78% of the required OS events 
have occurred) . Toadjust for the multiplicity due to the interim analyses, the 
Lan-DeMets approximation to the O’Brien -Fleming boundary will be used.
Dropout rate of 10% per 24 months assumed for all treatment arms 
Event times exponen tially distributed

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
118/Protocol GO29438 , Version 7With these assumptions, the PFS final analysis will be conducted after 
approximately 458PFS events have occurred in the ITTpopulation, and at least 
10months after the last patient is enrolled during the global enrollment phase , whichever 
occurs later.  This is expected to occur approximately [ADDRESS_76389] patient is 
randomized.  This number of events corresponds to a minimum detectable difference in 
HR of approximately 0.764 for a one- sided -level of 0.002.  Based on the group 
sequential Holm procedure ( Yeetal. 2012 ), if only OS is statistically significant, then 
PFS in the ITT population will be tested at a one -sided -level of 0.025 at the time of 
PFS final analysis.  In this case, the number of events correspon ds to a minimum 
detectable difference of approximately 0.833 in HR.
The interim OS analysis is planned to be performed at the time of the PFS final analysis. 
However, if there are significantly fewer than the expected 312 OS events at the time of 
the fina l PFS analysis, a nominal of 0.01% (negligible impact on overall type I error 
rate) will be spent on the OS analysis at the time of the final PFS analysis and a second 
interim OS analysis will then be conducted after approximately [ADDRESS_76390] 
occu rred(see Section 6.8.1 ).
Given the sample size of 568, this will result in approximately [ADDRESS_76391] OF STUDY
Study enrollment, study drug administration, reasons for discontinuation from the study 
drug,and reasons for study termination will be summarized by [CONTACT_2939]. Major 
protocol deviations, including major deviations of inclusion /exclusion criteria, will be 
reported and summarized by [CONTACT_2939] .
6.3 SUMMA RIES OF TREA TME NT GROUP COMPA RABILITY
Demographic characteristics, such as age, sex, race/ethnicity, and baseline disease 
characteristics (e.g., ECOG performance status), will be summarized by [CONTACT_5268].  
Descriptive statistics (mean, median, SD, and range) will be presented for continuous 
data, and frequencies and percentages will be presented for categorical data.
Baseline measurements are the l ast available data obtained prior to the patient receiving 
the first dose of any component of study drug.
6.[ADDRESS_76392] v1.1 ,and OS .  The primary efficacy analyses for PFS and OS will be analyzed
in the ITT population.   

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
119/Protocol GO29438 , Version 7PFS is defined as the time between the date of randomization and the date of first 
documented disease progression or death, whichever occurs first.  Patients who have 
not experienced disease progression or death at the time of analysis will be censored 
atthe time of the last tumor assessment.  Patients with no post -baseline tumor 
assessment will be censored at the date of randomization plus [ADDRESS_76393] patient is 
enrolled in the study.  Details about the timing of the OS interim analysis and stoppi[INVESTIGATOR_70066] 6.8.1 .  Details about the hypothesis testing will be 
provided in the SAP.  On t he basis of emerging external data, the testing strategy may 
be modified to improve the efficiency of the design.  Should this occur, modifications to 
the testing strategy will be documented in the SAP prior to theunblinding of the study .
The null and alt ernative hypotheses regarding PFS and OS can be phrased in terms of 
the survival functions SPFS_A (t), SOS_A (t)inthe atezolizumab -containing treatment arm
(Arm A )and S PFS_B (t), SOS_B (t)in the control arm ( Arm B) , respectively:
H0: SPFS_A (t)SPFS_B (t) versus H 1: SPFS_A(t) SPFS_B (t)
H0: SOS_A(t)SOS_B(t) versus H 1: SOS_A(t) SOS_B(t)
Comparisons with respect to PFS and OS between the treatment and control arms will 
be tested based on a stratified log -rank test.  The stratification factors will be sex (male 
vs. female), ECOG performance status (0 vs.1), type of chemotherary (carboplatin vs. 
cisplatin), and smoking status (never vs. current and/or former).  The stratification factors 
will be those used during randomization, as recorded in IxRS.  Results from an 
unstratified analysis will also be presented.  The HR will be estimated using a stratified 
Cox regression model.  Kaplan- Meier methodology will be used to estimate medi an PFS 
and OS for each treatment arm and to construct survival curves forvisual descriptions of 
the difference between the treatment and control arms.
The Brookmeyer -Crowley methodology will be used to construct the 95% CI for the 
median PFS and OS for each treatment arm ( Brookmeyer and Crowley 1982 ).

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
120/Protocol GO29438 , Version 76.4.2 Secondary  Efficacy Endpoints
[IP_ADDRESS] Objective Response Rate
An objective response is defined as either an unconfirmed CR or a PR, as determined 
by [CONTACT_26309] v1.1.  Patients not meeting these crit eria, including
patients without any post -baseline tumor assessment, will be considered 
non-responders.
ORR is defined as the proportion of patients who had an objective response.  
Theanalysis population for ORR will be all randomized patients .  The confirmation of 
response in accordance with RECIST v.1.1 is not required, but ORR with confirmation 
may be evaluated as an exploratory endpoint .  An estimate of ORR and its 95% CI will 
be calculated using the Clopper Pearson method for each treatment arm. CIs for the 
difference in ORRs between the two treatment arms will be determined using the normal 
approximation to the binomial distribution.   The ORR will be compared between the two 
arms using the stratified Cochran- Mantel -Haenszel test, stratified by t he same factors 
used in the primary PFS and OS analysis ( see Section 6.4.1 ).
[IP_ADDRESS] Duration of Response
DOR will be assessed in patients who had an objective response as determined by [CONTACT_70163] v1.1.  DOR is defined as the time interval from the date of the 
first occurrence of a CR or PR (whichever status is recorded first) until the first date that 
progressive disease or d eath is documented, whichever occurs first.  Patients who have 
not progressed and who have not died at the time of analysis will be censored at the 
time of last tumor assessment date.  If no tumor assessments were performed after the 
date of the first occu rrence of a CR or PR, DOR will be censored at the date of the 
firstoccurrence of a CR or PR plus 1 day.  DOR is based on a non -randomized subset 
of patients (specifically, patients who achieved an objective response); therefore, formal 
hypothesis testing will not be performed for this endpoint.  Comparisons between 
treatment arms will be made for descriptive purposes.  The methodologies detailed for 
the PFS analysis will be used for the DOR analysis.
[IP_ADDRESS] Overall Survival Rate at Landmark Timepoints
The OS rate s at 1 and 2 years will be estimated using Kaplan- Meier methodology for 
each treatment arm, along with 95% CIs calculated using the standard error derived 
from Greenwood’s formula.  The 95% CI for the difference in OS rates between the 
twotreatment arms w ill be estimated using the normal approximation method.
[IP_ADDRESS] Patient -Reported Outcomes
The change from baseline per SILC scale will be analyzed for each of the lung cancer 
symptom scores (chest pain, cough, dyspnea) .  The analysis will be performed for 
patients in the ITT population with a non-missing baseline and at least a post -baseline 
PRO assessment (i.e., PRO evaluable population) .  
Further details regarding all SILC analyses will be described in the SAP.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
121/Protocol GO29438 , Version 7TTD in lung -related symptoms is defined as the time from baseline to the time the 
patient’s score on the EORTC QLQ C30 or LC13 shows a 10-point increase above 
baseline in each of the following EORTC -transformed scores for cough, dyspnea 
(single item), dyspnea (multi -item subscale) andchest pain.  A 10-point change in 
score is perceived by [CONTACT_70164] ( Osoba et al. 1998 ).  If no 
baseline or post -baseline assessment is performed, data for patients will be censored at 
the date of random ization plus 1 day.  TTD in symptoms will be analyzed in the ITT 
population through use of the same methods described for the PFS and OS analyses 
(see Section 6.4.1 ).  Additional details regarding the analysis for the EORTC measures 
will be described in the SAP.
6.4.[ADDRESS_76394] -baseline 
tumor assessment is available, PFS will be censored at the date of randomization plus 
1day.  Data for patients with a P FS event who missed two or more scheduled 
assessments immediately prior to the PFS event will be handled as described in the 
sensitivity analysis in Section [IP_ADDRESS].
For OS, data for patients who are not reported as having died will be analyzed as 
censored observations on the date they were last known to be alive.  If no post -baseline 
data are available, OS will be censored at the date o f randomization plus [ADDRESS_76395]-baseline assessment is performed, patients will be censored at the randomization 
date plus 1 day.
6.5 SAFETY ANAL YSES
Safety analyses will be performed on the safety -evaluable population, which is defined 
as all randomized patients who receive any amount of an y component of protocol 
treatment.  Patients will be allocated according to whether any full or partial dose of 
atezolizumab was received , including when atezolizumab was received in error .
Study drug exposure , including treatment duration, number of doses , and dose intensity,
will be summarized for each treatment arm using descriptive statistics .

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
122/Protocol GO29438 , Version 7Verbatim description of adverse events will be mapped to MedDRA thesaurus terms and 
graded according to NCI CTCAE v4.0.  All adverse events occurring during or af ter the 
first study drug dose will be summarized by [CONTACT_26736].  In 
addition, serious adverse events, severe adverse events (Grade 3), adverse events of 
special interest, and adverse events leading to study drug discontinuation or interruption 
will be summarized accordingly.  Multiple occurrences of the same event will be counted 
once at the maximum severity.   The proportion of patient s experiencing at least one 
adverse event will be reported by [CONTACT_40890].
Laboratory data with values outside the normal ranges will be identified.  In addition, 
selected laboratory data will be summarized by [CONTACT_70165].
Changes in vital signs will be summarized by [CONTACT_2939].
Deaths reported during the study treatment period and those reported during the 
follow -up period after treatment completion/discontinuation will be summarized by 
[CONTACT_2939].
6.6 PHA RMA COKINETIC A NALYSES
PK samples will be collected in this study as outlined in Appendix 2.  Atezolizumab 
serum concentration data (C minand C max) will be tabulated and s ummarized.  Descriptive 
statistics will include means, medians, ranges, and SDs, as appropriate.
Plasma concentrations of carboplatin, cisplatin, and pemetrexed will be collected in this 
study as outlined in Appendix 2.  The concentrations of carboplatin, cisplatin, and 
pemetrexed will be summarized using descriptive statistics as described above.
Additional PK analyses will be conducted, as appropriate, based on the availability of 
data.
6.7 EXPLORA TORY ANALYSES
6.7.1 Exploratory  Analyses of Progression -Free Survival
[IP_ADDRESS] Progression -Free Survival Rate at Landmark Timepoints
The PFS rate , defined as the probability that a patient will be alive without disease 
progression after randomization (e.g., at 6 months and at 1 year),will be estimated using 
Kaplan -Meier methodology for each treatment arm, along with 95% CIs calculated using 
Greenwood’s formula.  The 95% CIs for the difference in PFS rates between the 
treatment ar ms will be estimated using the normal approximation method , and standard 
errors will be computed through use of the Greenwood method .
[IP_ADDRESS] Non Protocol -Specified Anti-Cancer Therapy
The impact of non protocol -specified anti -cancer therapy on PFS will be assesse d 
depending on the number of patients who receive non protocol -specified anti -cancer
therapy before a PFS event.  If 5% of patients received non protocol -specified 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
123/Protocol GO29438 , Version 7anti-cancer therapy before a PFS event in any treatment arm, a sensitivity analysis will 
be performed for the comparisons between treatment arms in which patients who 
receive non protocol -specified anti -cancer therapy before a PFS event will be censored 
at the last tumor assessment date before receipt of non protocol -specified anti -cancer 
therapy.
[IP_ADDRESS] Subgroup A nalysis
To assess the consistency of the study results in subgroups define d by [CONTACT_70166] 
(e.g., age, sex, and race/ethnicity), baseline prognostic characteristics (e.g., ECOG 
performance status, smoking status ,and type of chemotherapy), the duration of PFS in 
these subgroups will be examined.  Summaries of PFS, including unstratified HRs 
estimated from Cox proportional hazards models and Kaplan -Meier estimates of median 
PFS, will be produced separately for each level of the categorical va riables for the 
comparisons between treatment arms.
[IP_ADDRESS] Sensitivity Analyses
Sensitivity analyses will be performed to evaluate the potential impact of missing 
scheduled tumor assessments on the primary analysis of PFS, as determined by [CONTACT_70167] a PFS event imputation rule. The following two imputation rules will 
be considered:
If a patient missed two or more scheduled tumor assessments immediately prior to 
the date of the PFS event according to RECIST v1.1, the patient will be censored at 
the la st tumor assessment prior to the first of these missed visits.
If a patient missed two or more tumor assessments scheduled immediately prior to 
the date of the PFS event according to RECIST v1.[ADDRESS_76396] of these missing assessments.
The imputation rule will be applied to patients in both treatment arms.  Statistical 
methodologies that are analogous to those used in the primary analysis of PFS as 
specified in Section 6.4.1 will be used for this sensitivity analysis.
6.7.2 Exploratory  Analyses of Overall Survival
[IP_ADDRESS] Loss to Follow -Up
The impact of loss to fo llow-up on OS will be assessed depending on the number of 
patients who are lost to follow -up.  If 5% of patients are lost to follow -up for OS in either 
treatment arm, a sensitivity analysis will be performed for the comparisons between 
treatment arms in which patients who are lost to follow -up will be considered as having 
died at the last date they were known to be alive.
[IP_ADDRESS] Subgroup A nalysis
To assess the consistency of the study results in subgroups defined by [CONTACT_70166] 
(e.g., age, sex, and race/ethnici ty), baseline prognostic characteristics (e.g., ECOG 
performance status, smoking status ,type of chemotherapy, presence of liver metastases 
at baseline) , the duration of OS in these subgroups will be examined.  Summaries of 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
124/Protocol GO29438 , Version 7survival, including unstratified HRs estimated from Cox proportional hazards models and 
Kaplan -Meier estimates of median survival time, will be produced separately for each 
level of the categorical variables for the comparisons between treatment arms.
[IP_ADDRESS] Overall Survival Rate at 3-Year Land mark
The OS rates at 3 years will be estimated using Kaplan- Meier methodology for each 
treatment arm, along with 95% CIs calculated using the standard error derived from 
Greenwood’s formula.  The 95% CI for the difference in OS rates between the 
twotreatm ent arms will be estimated using the normal approximation method.
[IP_ADDRESS] Milestone Overall Survival A nalysis
To assess the effect of long -term survival and delayed clinical effects, a milestone OS 
analysis will be conducted ( Chen 2015 ).  The milestone OS is an OS endpoint with 
cross- sectional assessment at a pre -specified timepoint.  The milestone OS analysis will 
be performed using the same methods as those specified for the primary OS analysis, 
and the specific definition of milestone will be documented in the S tatistical Analysis 
Plan (SAP).
[IP_ADDRESS] Non Protocol -Specified A nti-Cancer Therapy
The impact of non protocol -specified anti -cancer therapy on OS may be assessed, 
depending on the number of patients who receive such therapy.  For example, the 
duration from initiation of non protocol -specified anti -cancer therapy to death or 
censoring date could be discounted in accordance with a range of possible effects on 
OS of subsequent non protocol -specified anti -cancer therapy (e.g., 10%, 20%, 30%).  
Further details r egarding these sensitivity analyses will be described in the SAP.
6.7.3 Exploratory  Biomarker A nalysis
Exploratory biomarker analyses will be performed in an effort to understand the 
association of these markers with study drug response, including efficacy and/or adverse 
events.  The tumor biomarkers include but are not limited to PD -L1 and CD8, as defined 
by [CONTACT_4658], qRT -PCR, or other methods.  Additional pharmacodynamic analyses will be 
conducted as appropriate.  Results from these exploratory analyses will not be included 
in the Clinical Study Report. 
6.7.4 EQ-5D-5L Health Status Data
EQ-5D-5L health status data will be used for obtaining utility measures for economic 
modeling.  These analyses will not be included in the Clinical Study Report.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
125/Protocol GO29438 , Version 76.7.5 Exploratory  Patient -Report ed Outcome A nalyses
Compliance rates for each questionnaire will be summarized in the ITT population as 
detailed in the SAP.
Summary statistics (mean, SD, median, 25th and 75th percentiles, and range) and the 
mean change from baseline at each timepoint will be reported for each score of the PRO 
questionnaires.  
Change from baseline with use of the EORTC will be analyzed for pa tients in the 
exploratory efficacy analysis populations with a baseline and a post -baseline PRO 
assessment. 
6.8 INTERIM A NALYSES
6.8.1 Planned Interim A nalyses
There are no interim analyses planned for PFS in this study.  An external iDMC will be 
set up to evaluate safety data on an ongoing basis .  All summaries and analyses by 
[CONTACT_70097]’s review will be prepared by [CONTACT_70168].  Members of the 
iDMC will be external to the Sponsor and will follow a charter that outlines their roles and 
responsibilities.   Any outcomes of these safety reviews that affect study conduct will be 
communicated in a timely manner to the investigators for notification of the IRBs/ECs.  
Adetailed plan will be included in the iDMC Charter.
The interim efficacy analysis of OS will be conducted by [CONTACT_70169].  
The interim OS analysis will be conducted when approximately 312OS events in the ITT 
population have been observed.  This is expected to occur approximately 30months 
after th e first patient is randomized, but the exact timing of this analysis will depend on 
the actual number and timing of OS events.   If there are significantly fewer than the 
expected 312 OS events at the time of the final PFS analysis, a nominal two-sided of
0.01% (negligible impact on overall type I error rate) will be spent on the OS analysis at 
the time of the final PFS analysis and a second interim OS analysis will then be 
conducted after approximately [ADDRESS_76397] timing of this analysis will depend on 
the actual number and timing of OS events.
To control type I error for OS, the stoppi[INVESTIGATOR_70067] -DeMets approximation to the 
O’Brien- Fleming boundary as shown in Table 20.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
126/Protocol GO29438 , Version 7Table 20Analysis Timing and Stoppi[INVESTIGATOR_70068] y for Rejection of H 0
ITT Population
One-sided alpha 0.023 One-sided alpha 0.025
Interim analysis 78% HR0.769
(p0.0102)HR.773
(p0.0114)
Final analysis 100% HR0.814
(p0.0200)HR0.817
(p0.0217)
HRhazard ratio; ITT intent -to-treat; p one-sided p -value .
6.8.[ADDRESS_76398] one interim efficacy analysis for the primary endpoint of PFS 
and/or OS beyond what is specified in Section 6.8.[ADDRESS_76399] of the 
interim analysis.  The iDM C Charter will document potential recommendations the iDMC 
can make to the Sponsor as a result of the analysis (e.g., stop the study for positive 
efficacy, stop the study for futility), and the iDMC Charter will also be made available to 
relevant health au thorities.
6.[ADDRESS_76400] 1 patient is enrolled in China during the global enrollment phase, 
additional patients in China will be enrolle din a subsequent China extension phase as 
needed to ensure a total enrollment of approximately 164 patients in the China 
subpopulation . The China subpopulation will include patients enrolled at sites in China 
receiving cisplatin and pemetrexed with or wi thout atezolizumab, during both the global 
enrollment phase and the China extension phase, whose data will be analyzed 
separately from data of patients enrolled during the global enrollment phase. 
The objective of the China extension phase and the China subpopulation analyses is to 
assess the treatment effects of atezolizumab in the population of patients in China and 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
127/Protocol GO29438 , Version 7to investigate the consistency in treatment effects between the China subpopulation and 
the global population for the purpose of registrati on in China.
The final analysis of PFS in the China subpopulation will be conducted after 
approximately 115PFS events in the China subpopulation have occurred.  The 
proposed 115PFS events will provide 89% probability of observing at least 50% of the 
riskreduction in PFS expected to be observed in the global population.
The final analysis of OS in the China subpopulation will be conducted after 
approximately [ADDRESS_76401] occurred.  The proposed 
120 OS events will provide 7 9% probability of observing at least 50% of the risk 
reduction in OS expected to be observed in the global population. The timing for OS 
anlaysis in the China subpopulation will be revised according to the observed HR and 
data maturity from the global analysis. Methods for analyzing data from the China 
subpopulation will be provided in the SAP.   Results from these analyses will be 
summarized in a separate report.
7. DATA COLLECTION A ND MANAGEMENT
7.[ADDRESS_76402] data clarification from the sites, which the 
sites will resolve electronically in the EDC system.
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  Central laboratory data will be sent 
directly to the Sponsor, using the Sponsor’s standard procedures to handle and process 
the electronic transfer of these data.
eCRFs and correction documentation will be maintained in the EDC system’s audit trail.  
System backups for data stored by [CONTACT_40892]’s standard procedures.
7.[ADDRESS_76403] access to a manual for appropriate eCRF completion.  
eCRFs will be submitted electronically to the Sponsor and should be handled in 
accordance with instructions from the Sponsor.
All eCRFs should be completed by [CONTACT_25755], trained site staff.  eCRFs should be 
reviewed and electronically signed and dated by [CONTACT_1720] a designee.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
128/Protocol GO29438 , Version 7At the end of the study, the investigator will receive pa tient data for his or her site in a 
readable format on a compact disc that must be kept with the study records.  
Acknowledgement of receipt of the compact disc is required.
7.[ADDRESS_76404] that is attributable, secure, and accurate, in compliance with the FDA regulations for 
electronic records (21 Code of Federal Regulations, Part 11).  The data will be 
transmitted to a centralized database at the ePRO vendor.  The data from the ePRO 
devices are available for view access only via secure access to a W eb portal provided 
by [CONTACT_70170].  Only identified and trained users may view the data, and their 
actions become part of the audit trail.  The Sponsor will have view access only.  Regular 
data transfers will occur from the centralized database at the vendor to the database at 
the Sponsor.
Once the study is co mplete, the ePRO data, audit trail, and study and system 
documentation will be archived.  The Sponsor will receive all data entered by [CONTACT_70171] e -diary and tablet device and all study documentation.
Details regarding patient -reported data and the electronic device is available in the 
Study Reference Manual.  System backups for data stored by [CONTACT_70172]’s standard procedures.
7.4 SOURCE DA TA DOCUMENT ATION
Study monitors will per form ongoing source data verification to confirm that critical 
protocol data (i.e., source data) entered into the eCRFs by [CONTACT_26831], complete, and verifiable from source documents.
Source documents (paper or electronic) are th ose in which patient data are recorded 
and documented for the first time.  They include but are not limited to hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, PROs, evaluation checklists, 
pharmacy dispensing records, recorded dat a from automated instruments, copi[INVESTIGATOR_70069], 
microfiche, photographic negatives, microfilm or magnetic media, X -rays, patient files, 
and records kept at pharmacies, laboratorie s, and medico- technical departments 
involved in a clinical study.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
129/Protocol GO29438 , Version 7Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section 7.6.
To facilitate source data verification, the investigators and institutions must provide the 
Sponsor direct access to applicable source documents and reports for study -related 
monitoring, Sponsor audits, and IRB/EC review.  The study site must also allow 
inspection by [CONTACT_25756].
7.5 USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site’s computerized medical 
record system (i.e., in lieu o f original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computerized systems used in clinical research.  
Anacceptable computerized data collection system allows preservation of the original 
entry of data.  If original data are modified, the system should maintain a viewable audit 
trail that shows the original data as well as the reason for the change, the name [CONTACT_40916], and the date of the change.
7.[ADDRESS_76405] been reported 
or for the length of time required by [CONTACT_70173] , 
whichever is longer.
8. ETHICA L CONSIDERA TIONS
8.1 COMPLIA NCE WITH LA WS AND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the applicable laws 
and regulations of the country in which the research is conduc ted, whichever affords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for 
Expedited Reporting).  Studies conducted in the United S tates or under a 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
130/Protocol GO29438 , Version 7U.S. Investigational New Drug (IND) Application will comply with the FDA regulations 
and applicable local, state, and federal laws.  Studies conducted in the European Union 
(E.U.) or European Economic Area will comply with the E.U. Clinical Trial Directive 
(2001/20/EC) and applicable local, regional, and national laws .
8.2 INFORMED CONSENT
The Sponsor’s sample Informed Consent Form will be provided to each site.  
Ifapplicable, it will be provided in a certified translation of the local languag e.  
TheSponsor or its designee must review and approve any proposed deviations from the 
Sponsor's sample Informed Consent Forms or any alternate consent forms proposed by 
[CONTACT_779] (collectively, the “Consent Forms ”) before IRB/EC submission.  The final 
IRB/EC approved Consent Forms must be provided to the Sponsor for health authority 
submission purposes according to local requirements.
The Informed Consent Form will contain a separate section that addresses the use of 
remaining samples for optional exploratory research.  The investigator or authorized 
designee will explain to each patient the objectives of the exploratory research.  Patients 
will be told that they are free to refuse to participate and may withdraw their specimens 
at any time and for any reason during the storage period.  A separate, specific signature 
[CONTACT_22862] a patient ’s agreement to allow any remaining specimens to 
be used for exploratory research.  Patients who decline to participate will not provide a 
separate signature.
The Informed Consent Form will also contain the following additional signature [CONTACT_1787]:
A signature [CONTACT_70197], if approved by [CONTACT_47806], to continue treatment beyond initial radiographic disease
progression and meet criteria specified in Section 4.6.[ADDRESS_76406] discussed other available treatment options and the potential risks of 
continuing treatment.
A signature [CONTACT_70198] (see Section [IP_ADDRESS] )
The Consent Forms must be signed and dated by [CONTACT_12718]’s legally 
authorized representative before his or her participation in the s tudy.  The case history or 
clinical records for each patient shall document the inf ormed consent process and that 
written informed consent was obtained prior to participation in the study.
The Consent Forms should be revised whenever there are changes to s tudy procedures 
or when new information becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/EC -approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
131/Protocol GO29438 , Version 7Patients mus t be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent For ms, the case history or clinical records for each patient shall document the 
informed consent process and that written informed consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.
A copy of each signed Con sent Form must be provided to the patient or the patient’s 
legally authorized representative.  All signed and dated Consent For ms must remain in 
each patient’s study file or in the site file and must be available for verification by [CONTACT_70174] t ime.
For sites in the [LOCATION_002], each Consent Form may also include patient authorization 
to allow use and disclosure of personal health information in compliance with the 
U.S. Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If the site 
utilizes a separate Authorization Form for patient authorization for use and disclosure of 
personal health information under the HIPAA regulations, the review, approval, 
andother processes outlined above apply except that IRB review and approval may not 
be required per study site policies.
8.[ADDRESS_76407] be submitted to the IRB/EC by [CONTACT_70175]/EC before the study is initiated.  
Inaddition, any patient recruitment materials must be approved by [CONTACT_1201]/EC.
The Principal Investigator [INVESTIGATOR_70070]/EC annually or more frequently in accordance with the requirements, 
policies, and procedures established by [CONTACT_1201]/EC.  Investigators are also responsible 
for promptly informing the IRB/EC of any protocol amendments (see Section 9.6).
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting se rious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety reports 
or other safety -related communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and pro cessed in accordance with health 
authority requirements and the policies and procedures established by [CONTACT_11577]/EC, and 
archived in the site’s study file.
8.4 CONFIDENTIA LITY
The Sponsor maintains confidentiality standards by [CONTACT_70176] t he 
study through assignment of a unique patient identification number.  This means that 
patient names are not included in data sets that are transmitted to any Sponsor location.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
132/Protocol GO29438 , Version 7Patient medical information obtained by [CONTACT_70177] (or separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].
Medical information may be given to a patient’s personal physician or other appropriate 
medical personnel responsible for the patient’s welfare, for treatment purposes.
Data generated by [CONTACT_70178], Sponsor 
monitors, representatives, and collaborators, and the IRB/EC for each study site, as 
appropriate.
8.[ADDRESS_76408] of 
the study to be fully documented, including but not limited to the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, including an audit trail c ontaining a complete record of all changes 
todata.
9.[ADDRESS_76409] on patient safety and 
data integ rity to the Sponsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures.   The Sponsor will review all protocol deviations and assess 
whether any represent a serious breach of Good Clinical Practice guidelines and require 
reporti ng to health authorities.  As per the Sponsor's standard operating procedures, 
prospective requests to deviate from the protocol, including requests to waive protocol 
eligibility criteria, are not allowed.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
133/Protocol GO29438 , Version 79.3 SITE INSPECTIONS
Site visits will be conducted by [CONTACT_26833], patients’ medical records, and eCRFs.  The investigator will 
permit national and local health authorities, Sponsor monitors, representatives, and 
collaborators, and the IRBs/ECs to i nspect facilities and records relevant to this study.
9.4 ADMINISTRA TIVE STRUC TURE
This study will be sponsored and managed by F. Hoffmann -La [COMPANY_002] Ltd.  
Approximately 225 sites globally will participate in the study and approximately 
568patients will be rand omized.  Additional patients will be enrolled in China to ensure a 
total of approximately 164 patients in the China cisplatin subpopulation, including those 
enrolled in China in the global enrollment phase and those enrolled in the China 
extension phase.
Randomization will occur through an IxRS.  Central facilities will be used for study 
assessments throughout the study (e.g., specified laboratory tests and PK analyses).  
Accredited local laboratories will be used for routine monitoring; local laboratory r anges 
will be collected.
9.5 PUBLICA TION OF DATA  AND PROTECTION OF 
TRADESECRETS
Regardless of the outcome of a study, the Sponsor is dedicated to openly providing 
information on the study to healthcare professionals and to the public, both at scientific 
congr esses and in peer -reviewed journals. The Sponsor will comply with all 
requirements for publication of study results.  For more information, refer to the [COMPANY_002] 
Global Policy on Sharing of Clinical Trials Data at the following W eb site:
http://www.roche.com /roche_global_polic y_on_sharing_of_clinical_study_information.pdf
The results of this study may be published or presented at scientific congresses.  For all 
clinical studies in patients involving an IMP for which a marketing authorization 
application has been filed or approved in any country, the Sponsor aims to submit a 
journal manuscript reporting primary clinical study results within [ADDRESS_76410] editorial and ethical practice, the Sponsor will generally 
support publication of multicenter studies only in their entirety and not as indiv idual 
center data.  In this case, a coordinating investigator [INVESTIGATOR_9231].
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
134/Protocol GO29438 , Version 7Authorship will be determined by [CONTACT_14346].  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by [CONTACT_26834].
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.
9.6 PROTOCOL A MENDMENTS
Any protocol amendments will be prepared by [CONTACT_1034].   Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any ch anges, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact [CONTACT_3031]).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
135/Protocol GO29438 , Version 710. REFERENCES
Aaronson NK, Ahmedzai S, Bergman B, et a l. The European Organization for Research 
and Treatment of Cancer QLQ -C30: a quality -of-life instrument for use in 
international clinical trials in oncology. J Natl Cancer Inst 1993;85:365 76.
ALIMTA®(pemetrexed for injection) U.S. Package Insert, Eli Lil ly and Company.
Antonia SJ, Brahmer JR, Gettinger S, et al.  Nivolumab (anti -PD-1; BMS -936558, 
ONO- 4538) in combination with platinum -based doublet chemotherapy (PT -DC) in 
advanced non -small cell lung cancer (NSCLC). J Clin Oncol 2014;32:abstract 8113.
Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll -like receptor 4- dependent contribution of 
the immune system to anticancer chemotherapy and radiotherapy. Nat Med 
2007;13:1050 1059.
Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin versus carboplatin -based chemotherapy in 
first-lin treatment of advanced non -small cell lung cancer: an individual patient data 
meta -analysis. J Natl Cancer Inst 2007;99: 84757.
AVASTIN®(bevacizumab) U.S. Package Insert, Genentech, Inc.
Azzoli CG, Baker Jr S, Temin S, et al. Amer ican Society of Clinical Oncology Clinical 
Practice Guideline update on chemotherapy for Stage IV non small -cell lung 
cancer. J Clin Oncol 2009;27:6251 66.
Bai S, Jorga K, Xin Y, et al. A guide to rational dosing of monoclonal antibodies. Clin 
Pharmacokine t 2012;51:119 35.
Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ -LC13: a modular 
supplement to the EORTC Core Quality of Life Questionnaire (QLQ -C30) for use in 
lung cancer clinical trials :EORTC study group on quality of l ife. Eur J Cancer 
1994;30A:635 42.
Besse B, Johnson M, Janne PA, et al. Phase II, single -arm trial (BIRCH) of atezolizumab 
as first -line or subsequent therapy for locally advanced or metastatic PD -L1-
selected non small cell lung cancer (NSCLC) [abstract]. Eur J Cancer 
2015; 51(Suppl 3):S717 18.
Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated 
with erlotinib: quality of life analysis of the National Cancer Institute of Canada 
Clinical Trials Group Study BR21. J Clin Oncol 2006;24:3831 7.
Blank C, Gajewski TF, Mackensen A. Interaction of PD -L1 on tumor cells with PD -1 on 
tumor -specific T cells as a mechanism of immune evasion: implications for tumor 
immunotherapy. Cancer Immunol Immunother 2005;54:307 14.
Blank C, Mackensen A. Contribution of the PD -L1/PD -[ADDRESS_76411] to T -cell exhaustion: 
anupdate on implications for chronic infections and tumor evasion. Cancer 
Immunol Immunother 2007;56:739 45.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
136/Protocol GO29438 , Version 7Bouzin C, Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to 
improve anti -cancer drug delivery. Drug Resist Updat 2007;10:109 20.
Brattström D, Bergqvist M, Hesselius P, et al. Serum VEGF and bFGF adds prognostic 
information in patients with normal platelet counts when sampled before, during 
and after treatment for locally advance d non -small cell lung cancer. Lung Cancer 
2004;43:55 62.
Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 
1982;38:29 41.
Butte MJ, Keir ME, Phamduy TB. Programmed death -1 ligand 1 interacts specifically 
with the B7- 1 costimulatory molecule to inhibit T cell responses. Immunity 
2007;27:111 22.
Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation 
of a simple formula based on renal function. JClinOncol 1989;7:1748 56.
Camidge DR, Bang Y, Kwak EL, et al. Activity and safety of crizotinib in patients with 
ALK-positive non -small cell lung cancer: updated results from a Phase 1 study. 
Lancet Oncol 2012;13:1011 9.
Cetin K, Ettinger DS, Hei YJ, et al. Survival by [CONTACT_33485], Epi[INVESTIGATOR_33407]. Clin Epi[INVESTIGATOR_5541] 2011;3:139 48.
Chen DS, Irving BA, Hodi FS. Molecular pathways: next -generation 
immunotherapy inhibiting programmed death -ligand 1 and progr ammed death -1. 
ClinCancer Res 2012;18:6580 7.
Chen TT. Milestone survival: a potential intermediate endpoint for immune checkpoint 
inhibit ors. J Natl Cancer Inst 2015;107: djv156.
Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus bes t 
supportive care versus placebo plus best supportive care for non -small -cell lung 
cancer: a randomised, double -blind, Phase 3 study. Lancet 2009;374:1432 40.
Cockcroft D W, Gault MH. Prediction of creatinine clearance from serum creatinine. 
Nephron 1976;16:31 41.
Crino L, Kim D, Riely GJ, et al. Initial Phase II results with crizotinib in advanced 
ALK-positive non -small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 
2011;29:abstract 7514.
D’Addario G, Fruh M, Reck M, et al. Metastatic non -small -cell lung cancer: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow -up. Ann Oncol 
2010;21:v115 –9.
De Marinis F, Rossi A, Di Maio M, et al. Treatment of advanced non -small -cell lung 
cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. 
Lung Cancer 2011;73:1 10.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
137/Protocol GO29438 , Version 7Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 
2009;136:260 71.
Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti CTLA -4 
antibodies across clinical indications. Semin Oncol 2010;37:499 507.
Dmitrienko A, Tamhane AC, Bretz F. Multiple testing problems in pharmaceutical 
statistics. Boca Raton: Chapman & Hall/CRC Biostatistics Series, 2010. 
Dunnett C W. A multiple comparison procedure for comparing several treatments with a 
control, J Am Stat Assoc 1955;50:1096 121.
Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology 
perspective: raising the bar for clinical trials by [CONTACT_70179]. J Clin Oncol 2014;32:1277 80.
European Medicines Agency Guideline on the evaluation of anticancer medicinal 
products in man.EMA/CHPM/205/95/Rev.4 (December 2012) .
Fehrenbacher L, Spi[INVESTIGATOR_20116] A, Ballinger M, et al., for the POPULAR Study Group. 
Atezolizumab versus docetaxel for patients with previously treated non small -cell 
lung cancer (POPLAR): a multicentre, open -label, Phase 2 randomised controlled 
trial. Lancet 2016; 387:1837 461.
Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality 
of life (QoL) questionnaire module to supplement the EORTC Core Cancer QoL 
questionnaire, the QLQ -C30 in patients with pancreatic cancer. EORTC Study 
Group on Quality of Life. Eur J Cancer 1999;35:939 41.
Fossella F, Pereira JR, von Pawel J, et al. Randomized, m ultinational, Phase III study of 
docetaxel plus platinum combinations versus vinorelbine plus cisplatin for 
advanced non -small -cell lung cancer: the TAX 326 study group. J Clin Oncol 
2003;21: 301624.
Fukuoka M, W u YL, Thongprasert S, et al. Biomarker analyses and final overall survival 
results from a Phase III, randomized, open -label, first -line study of gefitinib versus 
carboplatin/paclitaxel in clinically selected patients with advanced non -small -cell 
lung cancer in Asia (IPASS). J Clin Oncol 2011;29 :2866 74.
Giatromanolaki A. Prognostic role of angiogenesis in non -small cell lung cancer. 
Anticancer Res 2001;21:4373 82.
GLOBOCAN 2008. Estimated cancer incidence: mortality, prevalence and 
disability -adjusted life years (DALYs) worldwide in 2008.
Guidance for industry : clinical trial endpoints for the approval of c ancer drugs and 
biologics . May 2007. Available from: 
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071590.pdf .
Hales RK, Banchereau J, Ribas A, et al. Assessing oncologic benefit in clinical trials of 
immunotherapy agents. Ann Oncol 2010;21:1944 51.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
138/Protocol GO29438 , Version 7Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367 80.
Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology 
in advanced non- small cell lung cancer: a literature review. J Thorac Oncol 
2008;3:1468 81.
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipi[INVESTIGATOR_33410]. N Engl J Med 2010;363:711 23.
Hopwood P, Stephens RJ. Symptoms at presenta tion for treatment in patients with lung 
cancer: implications for the evaluation of palliative treatment. The Medical 
Research Council (MRC) Lung Cancer W orking Party. Br J Cancer 1995;71:633 6.
Horn L, Spi[INVESTIGATOR_43942], Gettinger SN, et al. Clinical activity, sa fety and predictive biomarkers 
of the engineered antibody MPDL3280A (anti -PDL1) in non -small cell lung cancer 
(NSCLC): update from a Phase Ia study. J Clin Oncol 2015;33:abstract 8029.
Hotta K, Matsuo K, Ueoka H, et al. Meta -analysis of randomized clinical trials comparing 
cisplatin to carboplatin in patients with advanced non- small cell lung cancer. J Clin 
Oncol 2004;22: 38529.
Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 19752011 , 
National Cancer Institute [based on November 2013 SEER data submission, 
posted to the SEER Web site April 2014 ].Available from: 
http://seer.cancer.gov/csr/1975_2011/.
Huang Y, Chen X, Dikov MM, et al. Distinct roles of VEGFR -1 and VEGFR -2 in the 
aberrant hematopoiesis associated wi thelevated levels of VEGF. Blood
2007;110:624 31.
Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest 1974;65:299 306.
Jain RK. Normalizing tumor vasculature with anti -angiogenic therapy: a new paradigm 
for combination therapy. Nat Med 2001;7:987 9.
Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. CA Cancer 
JClin2011;61:69 90.
Jiang L, Yang K, Mi D, et al. Safety of irinotecan/cisplatin versus etoposide/cisplatin for 
patients with extensive -stage small -cell lung cancer: a metaanaly sis. Clin Lung 
Cancer 2007;8: 497501.
Johnson DH, Fehrenbacher L, Novotny W F, et al. Randomized Phase II trial comparing 
bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone 
in previously untreated locally advanced or metastatic non -small -cell lung cancer. 
JClin Oncol 2004;22:2184 91.
Kantoff P W, Higano CS, Shore ND, et al. Sipuleucel -T immunotherapy for 
castration -resistant prostate cancer. N Engl J Med 2010;363:411 22.
Keir ME, Butte MJ, Freeman GJ, et al. PD -1 and i ts ligands in tolerance and immunity. 
Annual Rev Immunol 2008;26:677 704.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
139/Protocol GO29438 , Version 7Kelly K, Crowley J, Bunn PA, et al. Randomized Phase III trial of paclitaxel plus 
carboplatin versus vinorelbine plus cisplatin in the treatment of patients with 
advanced non -small -cell lung cancer: a southwest oncology group trial. J Clin 
Oncol 2001;19: 32108.
Koren E, Smith H W, Shores E, et al. Recommendations on risk -based strategies for 
detection and characterization of antibodies against biotechnology products. 
JImmuno Methods 2008;333:1 9.
Langer CJ, Besse B, Gualberto A, et al. The evolving role of histology in the 
management of advanced non –small -cell lung cancer. J Clin Oncol 
2010;28:5311 20.
Laporte S, Squifflet P, Baroux N, et al. Prediction of survival benefits from 
progression -free survival benefits in advanced non -small cell lung cancer: 
evidence from a meta -analysis of 2334 patients from 5 randomized trials. BMJ 
Open 2013;3:1 6.
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine 
release sy ndrome and neurologic toxicity associated with immune effector cells. 
Biol Blood Marrow Transplant 2019;25:625 38.
Liu SV, Powderly JD, Camidge DR, et al. Safety and efficacy of MPDL3280A (anti-PDL1) 
in combination with platinum -based doublet chemotherapy in patients with 
advanced non small cell lung cancer. J Clin Oncol 2015;33(suppl) :abstr act8030.
Merritt RE, Mahtabifard A, Yamada RE, et al. Cisplatin augments cytotoxic 
T-lymphocyte -mediated antitumor immunity in poorly immunogenic murine lung 
cancer. J Thorac Cardiovasc Surg 2003;126:1609 17.
Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, 
metastatic non -small -cell lung cancer after failure of erlotinib, gefitinib, or both, and 
one or two lines of chemotherapy ( LUX-Lung 1): a Phase 2b/3 randomised trial. 
Lancet Oncol 2012;12:528 38.
Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epi[INVESTIGATOR_623], risk 
factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584 94.
Mu CY, Huang JA, Chen Y, et al. High expression of PD -L1 in lung cancer may 
contribute to poor prognosis and tumor cells immune escape through suppressing 
tumor infiltrating dendritic cells maturation. Medical Oncol 2011;28: 6828.
National Comprehensive Cancer Network®(NCCN) .Guidelines for non-small cell lung 
cancer 2012.
NonSmall Cell Lung Cancer Collaborative Group. Chemotherapy in non -small cell lung 
cancer: a meta -analysis using updated data on individual patients from 52 
randomised clinical trials. BMJ 1995;311:899 909.
Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in 
health- related quality -of-life scores. J Clin Oncol 1998;16:139 44.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
140/Protocol GO29438 , Version 7Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance th erapy with pemetrexed plus 
best supportive care versus placebo plus best supportive care after induction 
therapy with pemetrexed plus cisplatin for advanced non -squamous non -small -cell 
lung cancer (PARAMOUNT): a doubl e-blind, Phase 3, randomised controlled trial. 
Lancet Oncol 2012;12:247 55.
Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology 
treatment of unresectable non -small -cell lung cancer guideline: update 2003. J Clin 
Oncol 2004;22:330 53.
Reck M, Crinò L. Advances in anti -VEGF and anti -EGFR therapy for advanced 
non-small cell lung cancer. Lung Cancer 2009;63:1 9.
Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin- gemcitabine and 
bevacizumab or placebo as first -line therapy for nonsquamous non -small -cell lung 
cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 
2010;21:1804 9.
Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with
either placebo or bevacizumab as first-line therapy for nonsquamous non -small 
cell lung cancer. AVAiL. J Clin Oncol 2009;27:1227 34.
Rosell R, Carcereny E, Gervais R , et al. Erlotinib versus standard chemotherapy as 
first-line treatment for European patients with advanced EGFR mutation -positive 
non-small -cell lung cancer (EURTAC): a multicentre, open -label, randomised
Phase 3 trial. Lancet Oncol 2012;13:239 46.
Rosenb erg AS, Worobec AS. A risk -based approach to immunogenicity concerns of 
therapeutic protein products. BioPharm Intl 2004; Nov:2226;Dec:34 42.
Sandler A, Gray R, Perry MC, et al. Paclitaxel –carboplatin alone or with bevacizumab for 
non– small -cell lung cance r. N Engl J Med 2006;355:2542 50.
Sarna L, Evangelista L, Tashkin D, et al. Impact of respi[INVESTIGATOR_70071] -term survivors of non -small cell lung cancer. 
Chest 2004;125:439 45.
Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three 
platinum -based doublets in advanced non -small -cell lung cancer. J Clin Oncol 
2002;20: 428591.
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin p lus 
gemcitabine with cisplatin plus pemetrexed in chemotherapy -naive patients with 
advanced -stage non– small -cell lung cancer. J Clin Oncol 2008;26:3543 51.
Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. 
Comparison of four chemotherapy regimens for advanced non –small -cell lung 
cancer. NEngl J Med 2002;346:92 8.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
141/Protocol GO29438 , Version 7Sequist LV, Yang J C -H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus 
pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutatio ns. 
J Clin Oncol 2013;31:3327 37.
Shaw AT, Engelman JA. Ceritinib in ALK -rearranged non -small -cell lung cancer. N Engl 
J Med; 2014;370: 25379.
Shaw AT, Kim D W, Nakagawa K, et al. Phase III study of crizotinib versus pemetrexed 
or docetaxel in patients with advanced ALK -positive non -small cell lung cancer 
(NSCLC). European Society of Medical Oncology Meeting 2012:abstract LBA1 PR.
Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3 -d]pyrimidine -based 
antifolate that inhibits multiple folate- requiring enzymes. Cancer Res 
1997;57: 111623.
Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte 
infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of 
cancer. Cancer Res 2010;70:6171 80.
Siegel R, Naishadham D, Jemal A. Cancer sta tistics, 2012. CA Cancer J Clin
2012;62:10 29.
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the 
use of white blood cell growth factors: an evidence -based clinical practice 
guideline. J Clin Oncol 2006;24:3187 205.
Spi[INVESTIGATOR_43942], Chaft JE, Gettinger SN, et al. Clinical activity and safety from a Phase II 
study (FIR) of MPDL3280A (anti -PDL1) in PD -L1selected patients with non small 
cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl; abstr 8028) .
Spi[INVESTIGATOR_33412], Park K, Mazières J, et al. Efficacy, safety and predictive biomarker results from 
a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L/3L 
NSCLC (POPLAR). J Clin Oncol 2015;33:abstract 8010.
Spi[INVESTIGATOR_26189], Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in 
advanced non -small cell lung cancer: improved survival without detriment to quality 
of life. Thorax 2004;59:828 –36.
Stinchcombe TE, Socinski MA, Lee CB, et al. Considerations for second -line therapy 
ofnon-small cell lung cancer. Oncologist 2008;13:128 36.
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with 
metastatic non-small -cell lung cancer. N Engl J Med 2010;363:733 42.
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and imm une correlates of 
antiPD-1 antibody in cancer. N Engl J Med 2012;366:2443 54.
Travis W D, Brambilla E, Noguchi M, et al. International association for the study of lung 
cancer/ American Thoracic Society/ European Respi[INVESTIGATOR_3764] I nternational 
multidisciplinary classification of lung adenocarcin oma. J Thorac Oncol 
2011;6:244 85.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
142/Protocol GO29438 , Version 7XALKORI®(crizotinib) U.S. Package Insert, [COMPANY_007].
Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX -Lung 3: a 
Phase III study of afatinib versus pemetrexed and cisplatin as first -line treatment 
afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma 
with EGFR mutations. J Clin Oncol 2013;31:3342 50.
Yang J, Riella LV, Chock S. The novel costimulatory programmed death ligand 1 /B7.[ADDRESS_76412] is functional in inhibiting alloimmune responses in vivo. J Immunol 
2011;187:1113 9.
Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and 
epi[INVESTIGATOR_70072] (LUX -Lung 2): a Phase 2 trial. Lancet 
Oncol 2012;13:539 48.
Ye, Y., Li, A., Liu, L., & Yao, B. (201 2). A group sequential Holm procedure with multiple 
primary endpoints. Statistics in medicine, 32(7), 1112 -1124.
ZYKADIA®(ceritinib) U.S. Package Insert, [COMPANY_001].
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
143/Protocol GO29438 , Version 7Appendix 1
Schedule of A ssessments
ProcedureScreening All Treatment Cycles aTreatment 
Discontinuation Visit Survival Follow -Up
Days 28
to 1Induction Phase
(Cycles 14or 6)Maintenance
Phase[ADDRESS_76413] 
Dose of Study 
TreatmentEvery 3 Months after 
Disease Progression 
or Loss of Clinical 
BenefitEvery 21 Days
(3 Days) bEvery 21 Days
(3 Days)
Informed consent x
Tumor tissue specimen (blocks or 10 or more FFPE slides 
preferred, if available).c
Fresh or archival tissue can be used.x
Demographic data x
Medical history and baseline conditions x
NSCLC cancer history x
Vital signsdx x x x
Weight x x x x
Height x
Complete physical examination x
Limited physical examination ex x x
ECOG performance status x x x x
12-Lead ECG x x fxfxf
Hematologygx x x x
Serum chemistryhx x x x
Coagulation test (aPTT or INR) x x
Appendix 1
Schedule of A ssessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
144/Protocol GO29438 , Version 7ProcedureScreening All Treatment Cycles aTreatment 
Discontinuation Visit Survival Follow -Up
Days 28
to 1Induction Phase
(Cycles 14or 6)Maintenance
Phase[ADDRESS_76414] 
Dose of Study 
TreatmentEvery 3 Months after 
Disease Progression 
or Loss of Clinical 
BenefitEvery 21 Days
(3 Days) bEvery 21 Days
(3 Days)
Pregnancy test (women of childbearing -potential ONLY) xixjxjxj
TSH, freeT3, free T4kx x x x
ALK and/or EGFR assessment if status is unknown (may 
be done locally or centrally)x
HIV, HBV, HCV serologylx
Urinalysismx
Determination of duration of induction treatment x
Induction treatment administration
Arm A:  a tezolizumab carboplatin or 
cisplatin pemetrexed
Arm B:  carboplatin or cisplatin pemetrexedxn
Maintenance treatment administration
Arm A:  a tezolizumab pemetrexed
Arm B:  p emetrexedxn
Tumor response assessment xoxpxpxq
Serum sample for atezolizumab ATA assessment 
(atezolizumab -treat edpatients only)rx x x120 ( 30)days after 
last dose of 
atezolizumab
Appendix 1
Schedule of A ssessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
145/Protocol GO29438 , Version 7ProcedureScreening All Treatment Cycles aTreatment 
Discontinuation Visit Survival Follow -Up
Days 28
to 1Induction Phase
(Cycles 14or 6)Maintenance
Phase[ADDRESS_76415] 
Dose of Study 
TreatmentEvery 3 Months after 
Disease Progression 
or Loss of Clinical 
BenefitEvery 21 Days
(3 Days) bEvery 21 Days
(3 Days)
Serum sample for PK sampling (atezolizumab -treated 
patients only)rx x x120 ( 30)days after 
last dose of 
atezolizumab
Carboplatin, cisplatin, and pemetrexed PK sampling 
(20patients in Arm A) rx
Optional tumor biopsysOptional at time of radiographic 
progression
Blood samples for biomarkers r
x x x x120 ( 30)days after 
last dose of 
atezolizumab
Optional blood for DNA extraction (RCR only) r, tx
Informed consent to continue treatment beyond 
radiographic progression (atezolizumab -treated patients)At time of radiographic progression
Optional tumor biopsy at other timepoints (RCR only) Any time during study treatment or during survival follow -up
Adverse events x x x xuxu
Concomitant medications x vx x x
Patient -reported outcomes ( EORTC QLQ -C30, EORTC 
QLQ -LC13, SILC, and EQ -5D-5L) vx wx wx w
Survival and anti -cancer therapy follow -up x x xx
Appendix 1
Schedule of A ssessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
146/Protocol GO29438 , Version 7ATAanti-therapeutic antibody; CT computed tomography; ECOG Eastern Cooperative Oncology Group; EORTC European Organization for Research and 
Treatment of Cancer; ePRO electronic Patient -Reported Outcome; EQ-5D -5LEuroQoL 5 Dimensions 5 -Level Version; FFPE formalin-fixed paraffin -embedded; 
HBcAb hepatitis B core antibody; HBVhepatitis B virus; HCV hepatitis C virus; IV intravenous; MRI magnetic resonance imaging; NSCLC nonsmall ce ll 
lung cancer; PCRpolymerase chain reaction; PDpharmacodynamic ; PD-L1programmed death ligand 1; PK pharmacokinetic; PROPatient -Reported 
Outcome; QLQ -C30Quality -of-Life Questionnaire Core 30; QLQ -LC13 Quality -of-Life Questionnaire Lung Cancer module; RCR [COMPANY_002] Clinical Repository; 
RECIST Response Evaluation Criteria in Solid Tumors; SILC Symptoms in Lung Cancer; TSH thyroid -stimulating hormone.
aAssessments should be performed before study drug infusion unless otherwise noted.
bCycle [ADDRESS_76416] be performed within 5 days after the patient is randomized. Screening assessments performed 96hours before Cycle 1 ,Day 1 are not 
required to be repeated for Cycle 1, Day 1. In addition, ECOG performance status, limited physical examination, and local laboratory tests may be performed 
96 hours before Day 1 of each cycle as specified in Section [IP_ADDRESS] .
cAny available tumor tissue sample can be submitted before or within 4 weeks after enrollment. It is strongly encouraged that the sites submit representative 
tumor specimens preferably in paraffin blocks o r as 10 (or more) serial, freshly cut, unstained slides for biomarker analysis.  See Section 4.1.1 , Inclusion Criteria, 
and Section [IP_ADDRESS] .
dVital signs include pulse rate, respi[INVESTIGATOR_697], blood pressures, and temperature. Vital signs should be recorded as des cribed in Section 4.5.4 .
eSymptom -directed physical examinations; see Section 4.5.3 for details.
fECG recordings will be obtained when clinically indicated.
gHematology consists of CBC, including RBC count, hemoglobin, hematocrit, WBC count with differential (neutrophils, lymphocytes, eosinophils, monocytes, 
basophils, and other cells), and platelet count.
hSerum chemistry includes BUN or urea, creatinine, sodium, potassium, magnesium, chloride, bicarbonate or total CO 2, calcium, phosphorus, glucose, 
total bilirubin, ALT, AST, alkaline phosphatase, LDH, total protein, and albumin.
iSerum pregnancy test within 14 days before Cycle 1, Day 1.
jUrine pregnancy tests; if a urine pregnancy test result is positive, it must be confirmed by a serum pregnancy test.
kThyroid function testing (TSH, free T3, free T4) collected at Cycle 1, Day 1 and every fourth cycle thereafter.  Note:  Total T3 will be tested only at sites where 
free T3 testing cannot be performed.
lAll patients will be tested for HIV prior to the incl usion into the study and HIV -positive patients will be excluded from the clinical study .  HBV DNA must be 
collected prior to randomization in patients who have negative serology for hepatitis B surface antigen and positive serology for HBcAb .
mUrinalysis by [CONTACT_5230] (specific gravity, pH, glucose, protein, ketones, and blood) should be obtained at screening and when clinically indicated throughout the 
study.

Appendix 1
Schedule of A ssessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
147/Protocol GO29438 , Version 7nFor atezolizumab, the initial dose will be delivered over 60 ( 15) minutes.  If the first infusion is well tolerated, all subsequent infusions may be delivered over 
30(10)minutes until disease progression per RECIST v1.1 or loss of clinical benefit.  For carboplatin or cisplatin and pemetrexed, study drug will be 
administered according to t he local prescribing information, including premedication with steroids (see Section 4.3.2 ).
oCT scans (with oral/IV contrast unless contraindicated) or MRI scans of the chest and abdomen.  A CT scan of the pelvis is required at screening and as 
clinically ind icated or as per local standard of care at subsequent response evaluations.  A CT (with contrast) or MRI scan of the head must be done at screening 
to evaluate CNS metastasis in all patients.  See Section 4.5.5 for details.
pPerform every 6 weeks ( 7 days) (ap proximately every two cycles) for 12 months following Cycle 1, Day 1 , and then every 9 weeks ( 7 days) thereafter after 
completion of the W eek 48 tumor assessment , regardless of treatment delays, until radiographic disease progression (loss of clinical benefit for patients 
assigned to atezolizumab who continue treatment with atezolizumab after disease progression according to RECIST v1.1), withdrawal of consent, death, or 
study termination by [CONTACT_1034], whichever occurs first.  See Section 4.5.[ADDRESS_76417] v1.1 (e.g., toxicity, symptomatic deterioration) , 
tumor assessments will continue at the same frequency aswould have been followed if the patient had remained on study treatment until radiographic diseas e 
progression (loss of clinical benefit for patients treated with atezolizumab who continue treatment after disease progression according t o RECIST v1.1), 
withdrawal of consent, death, or study termination by [CONTACT_1034] , whichever occurs first, even if patient starts another anti -cancer therapy after study treatment 
discontinuation, unless consent is withdrawn.
rSee Appendix 2for detailed schedule.
sOptional tumor biopsy at radiographic disease progression, if clinically feasible, preferably within [ADDRESS_76418] that is 
believed to be related to prior exposure to study treatment (see Section 5.6).
vFrom 7 days before screening.

Appendix 1
Schedule of A ssessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
148/Protocol GO29438 , Version 7wEORTC QLQ -C30, EORTC QLQ -LC13, and the EQ -5D-5L questionnaires will be completed by [CONTACT_70180](s).  SILC will be completed usin g an ePRO device at the patient’s home on a 
weekly basis.  During survival follow -up, the EORTC QLQ -C30, EORTC QLQ -LC13, and EQ -5D- 5L questionnaires will be completed at 3 and 6 months 
following disease progression.  The SILC will be completed monthly dur ing survival follow -up for 6 months following disease progression or loss of clinical benefit 
(for atezolizumab -treated patients who continue after disease progression according to RECIST v1.1).  Patients who discontinue study treatment for any reason 
other than radiographic progressive disease or loss of clinical benefit will complete the EORTC QLQ -C30, EORTC QLQ -LC13, and EQ -5D-5Lat each tumor 
assessment visit and will complete the SILC at home on a weekly basis, until radiographic disease progression pe r RECIST v1.1 (or for atezolizumab -treated 
patients who continue treatment after radiographic disease progression) or loss of clinical benefit as determined by [CONTACT_20603] (unless the patient withdraws 
consent or the Sponsor terminates the study).   Study personnel should review all questionnaires for completeness before the patient leaves the investigational 
site.
xSurvival follow -up information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every [ADDRESS_76419].  All patients will be periodically contact[CONTACT_70181] d new anti -cancer therapy 
information unless the patient requests to be withdrawn from follow -up(this request must be documented in the source documents and signed by [CONTACT_1275]).  If the patient withdraws from the study , study staff may use a public information source (e.g., county records), when permissible, to obtain 
informat ion about survi val status only.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
149/Protocol GO29438, Version 7Appendix 2
Schedule of Pharmacokinetic, Biomarker, and A nti-Therapeutic 
Antibody  Assessments
Study Visit TimeArm A
(Atezolizumab 
Carboplatin or Cisplatin 
Pemetrexed)Arm B
(Carboplatin or 
Cisplatin 
Pemetrexed)
Screening N/A Biom arkersaBiom arkersa
Cycle 1, Day 1 Pre-dose (same day as 
treatment administration) Atezolizumab ATA
Atezolizumab 
pharmacokinetics
Biom arkers b
Carboplatin or cisplatin 
pharmacokineticsc
Pemetrexed 
pharmacokineticscBiom arkersb
30 (10) minutes after 
end of atezolizumab 
infusionAtezolizumab 
pharmacokineticsNA
510minutes before the 
end of carboplatin or 
cisplatin infusion bCarboplatin or cisplatin 
pharmacokinetics cNA
1 hour after end of 
carboplatin or cisplatin 
infusion bCarboplatin or cisplatin 
pharmacokinetics cNA
510 minutes before the 
end of pemetrexed 
infusion bPemetrexed 
pharmacokinetics cNA
1 hour after end of 
pemetrexed infusion bPemetrexed 
pharmacokinetics cNA
Cycle 2, Day 1 Pre-dose (same day as 
treatment administration)Atezolizumab ATA
Atezolizumab 
pharmacokinetics
Biom arkersbBiom arkersb
Cycle3, Day 1 Pre-dose (same day as 
treatment administration)Atezolizumab ATA
Atezolizumab 
pharmacokinetics
Biom arkers b
Carboplatin or cisplatin 
pharmacokinetics c
Pemetrexed 
pharmacokinetics cBiom arkers b
Appendix 2
Schedule of Pharmacokinetic, Biomarker, and A nti-Therapeutic 
Antibody  Assessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
150/Protocol GO29438, Version 7Study Visit TimeArm A
(Atezolizumab 
Carboplatin or 
Cisplatin 
Pemetrexed)Arm B
(Carboplatin or 
Cisplatin 
Pemetrexed)
510minutes before the 
end of carboplatin or 
cisplatin infusionbCarboplatin or 
cisplatin 
pharmacokinetics cNA
1 hour after end of 
carboplat in or cisplatin 
infusion bCarboplatin or 
cisplatin 
pharmacokinetics cNA
510 minutes before the 
end of pemetrexed 
infusion bPemetrexed 
pharmacokinetics cNA
1 hour after end of 
pemetrexed infusion bPemetrexed 
pharmacokinetics cNA
Cycles 4, 8, and 
16,Day 1Pre-dose (same day as 
treatment administration)Atezolizumab ATA
Atezolizumab 
pharmacokinetics
Biom arkers bBiom arkersb
After Cycle 16, 
every eighth c ycle, 
Day1 (3 day s)Pre-dose (same day as 
treatment administration)Atezolizumab ATA
Atezolizumab 
pharmacokinetics
Biom arkers bBiom arkersb
At time of fresh 
biopsy 
(on-treatment or at 
progression, 
including during 
follow -up)At visit Biom arkersbBiom arkersb
Treatment 
discontinuation 
visitAt visit Atezolizumab ATA
Atezolizumab 
pharmacokinetics
Biom arkers bBiom arkersb
120(30 days) 
after last dose of 
atezolizumabAt visit Atezolizumab ATA
Atezolizumab 
pharmacokinetics
Biom arkersbBiom arkersb
Appendix 2
Schedule of Pharmacokinetic, Biomarker, and A nti-Therapeutic 
Antibody  Assessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
151/Protocol GO29438, Version 7Study Visit TimeArm A
(Atezolizumab 
Carboplatin or Cisplatin 
Pemetrexed)Arm B
(Carboplatin or 
Cisplatin 
Pemetrexed)
At any time during 
the study (RCR 
consent required)At visit Optional RCR blood 
(DNA extraction) dOptional RCR blood 
(DNA extraction)d
ATAanti-therapeutic antibody; NA not applicable; PKpharmacokinetic; RCR [COMPANY_002] Clinical 
Repository.
Note:  Serum PK samples for atezolizumab; plasma PK samples for carboplatin or cisplatin and 
pemetrexed.
aWhole blood for biomarkers.
bPlasma and serum for biomarkers.
cAt selected centers, 20patients in Arm A will undergo the additional PK assessments for 
carboplatin or cisplatin and pemetrexed where applicable.
dThe optional RCR blood sample (for DNA extraction) requires an additional informed consent 
and can be collected at any time during the course of the study.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
152/Protocol GO29438, Version 7Appendix 3
American Joint Committee on Cancer
Non Small Cell Lung Cancer Staging, 7th Edition

Appendix 3
American Joint Committee on Cancer 
Non Small Cell Lung Cancer Staging, 7th Edition (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
153/Protocol GO29438, Version 7Reference:  Lung. In: Edge S, By[CONTACT_3238], Compton CC, et al, editors. AJCC Cancer Staging 
Manual, Seventh Edition. Chicago: Springer, 2010:267 –70.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
154/Protocol GO29438, Version 7Appendix 4
Response Evaluation Criteria in Solid Tumors:  
Modified Excerpt from Original Publication
Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST), 
Version 1.11are presented below, with slight modifications and the ad dition of 
explanatory text as needed for clarity.2
MEA SURA BILITY OF TUM OR AT BASELINE
DEFINITIONS
At baseline, tumor lesions/lymph nodes will be categorized measurable or 
non-measurable as follows.
a.Measurable Tumor Lesions
Tumor Lesions.   Tumor lesions must be accurately measured in at least one dimension 
(longest diameter in the plane of measurement is to be recorded) with a minimum size of:
10 mm by [CONTACT_20420] (CT) or magnetic resolution imaging (MRI) scan 
(CT/MRI scan slice th ickness/interval no greater than 5mm)
10-mm caliper measurement by [CONTACT_12148] (lesions that cannot be 
accurately measured with calipers should be recorded as non- measurable)
[ADDRESS_76420] be 15 mm in the short axis when assessed by [CONTACT_70182] (CT scan 
slice thickness recommended to be no greater than 5 mm).  At baseline and in follow -up, 
only the short axis will be measured and followed.  See also notes below on “Baseline 
Documentation of Target and Non -Target Lesions” for information on lymph node 
measurement.
b.Non- Measurable Tumor Lesions
Non-measurable tumor lesions encompass small lesions (longest diameter 10 mm or 
pathological lymph n odes with 10 to 15 mm short axis), as well as truly 
non-measurable lesions.  Lesions considered truly non -measurable include 
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal 
masses/abdominal organomegaly identified by [CONTACT_33486].
                                           
1Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: 
Revised RECIST guideline (Version 1.1). Eur J Cancer 2009; 45:22847.
2For consistenc ywithin this document, the section numbers and cross -references to other 
sections within the article have been deleted and minor formatting changes have been made.

Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
155/Protocol GO29438, Version 7c.Special Considerations Regarding Lesion Measurability
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment, as outlined below.
Bone lesions:
Bone scan, positron emission tomography (PET) scan, or plain films are not 
considered adequate imaging techniques to measure bone lesions.  However , these 
techniques can be used to confirm the presence or disappearance of bone lesions.
Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue 
components , that can be evaluated by [CONTACT_12783] -sectional imaging techniques such 
asCTor MRI can be considered measurable lesions if the soft tissue component 
meets the definition of measurability described above.
Blastic bone lesions are non -measurable.
Cystic lesions:
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered malignant lesions (neither measurable nor non- measurable) since they 
are, by [CONTACT_108], simple cysts.
Cystic lesions thought to represent cystic metastases can be considered 
measurable lesions if they meet the definition of measur ability described above.  
However, if non -cystic lesions are present in the same patient, these are preferred 
for selection as target lesions.
Lesions with prior local treatment:
Tumor lesions situated in a previously irradiated area or in an area subjected to 
other loco -regional therapy are usually not considered measurable unless there has 
been demonstrated progression in the lesion.  Study protocols should detail the 
conditions under which such lesions would be considered measurable.
TARGET LESIONS:  SPECIFICA TIONS BY [CONTACT_70183] M EASUREMENTS
a.Measurement of Lesions
All measurements should be recorded in metric notation, using calipers if clinically 
assessed.  All baseline evaluations should be performed as close as possible to the 
treatment start and never more than 4 weeks before the beginning of the treatment.
b.Method of Assessment
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline and during study.  
Imaging -based evaluation should always be the preferred option.
Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
156/Protocol GO29438, Version 7Clinical Lesions.   Clinical lesions will be considered measurable only when they are 
superficial and 10 mm in diameter as assessed using calipers (e.g., skin nodules).  
Chest X -Ray.   Chest CT scan is preferred over chest X -ray, particularly when 
progression is an important endpoint, since CT is more sensitive than X -ray, particularly 
in identifying new lesions.  However, lesions on chest X- ray may be considered 
measurable if they are clearly defined and surrounded by [CONTACT_6776].
CT, MRI.   CT is the best currently available and reproducible method to measure lesions 
selected for response assessment.  This guideline has defined measurability of lesions 
on CT scan on the basis of the assumption that CT slice thickness is [ADDRESS_76421] scans with 
intravenous (IV) contrast because of allergy or renal insufficiency, the decision as to 
whether a non- contrast CT scan or MRI scan (without IV contrast) will be used to 
evaluate the patient at baseline and during the study should be guided by [CONTACT_70184].  For patients who develop 
contraindications to contrast after a baseline contrast CT scan is done, the decision as to 
whether non- contrast CT or MRI (enhanced or non -enhanced) scan will be performed 
should also be based on the tumor type and the anatomic location of the disease 
andshould be optimized to allow for comparison with the prior studies if possible.  
Each case should be discussed with the radiologist to determine if substitution of these 
other approaches is possible and, if not, the patient should be considered not evaluable 
from that point forward .  Care must be taken in measurement of target lesions on a 
different modality and interpretation of non -target dise ase or new lesions since the same 
lesion may appear to have a different size using a new modality.
Ultrasound.   Ultrasound is not useful in assessment of lesion size and should not be 
used as a method of measurement.
Endoscopy , Laparoscopy , Tumor Markers, Cytology , Histology .  The utilization of 
these techniques for objective tumor evaluation cannot generally be advised.
Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
157/Protocol GO29438, Version 7TUMOR RESPONSE EVA LUATION
ASSESSMENT OF OVERA LL TUMOR BURDEN A ND M EASURA BLE 
DISEA SE
To assess objective response or future progression, it is necessary to estimate the 
overall tumor burden at baseline and to use this as a comparator for subsequent 
measurements.  Measurable disease is defined by [CONTACT_70185], as detailed above.
BASELINE DOCUMENTA TION OF TA RGE T AND NON -TARGET LESIONS
When more than one measurable lesion is present at baseline, all lesions up to a 
maximum of five lesions total (and a maximum of two lesions per organ) representative 
of all involved organs should be identified as target lesions an d will berecorded and 
measured at baseline.  This means in instances where patients have only one or two 
organ sites involved, a maximum of two lesions (one site) and fourlesions (two sites), 
respectively, will be recorded.  Other lesions (albeit measurable) in those organs will be 
recorded as non-target lesions (even if the size is 10mm by [CONTACT_3610]).
Target lesions should be selected on the basis of their size (lesions with the longest 
diameter) and be representative of all involved organs but in addition should lend 
themselves to reproducible repeated measurements .  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement, in which 
circumstance the next largest lesion that can be measured reproducib ly should be 
selected.
Lymph nodes merit special mention since they are normal anatomical structures that 
may be visible by [CONTACT_33490].  As noted above, pathological 
nodes that are defined as measurable and may be identified as t arget lesions must meet 
the criterion of a short axis of [ADDRESS_76422] in which the image is obtained (for CT scan, this 
is almost always the axial plane; for MRI scan the plane of acquisition may be axial, 
sagittal, or coronal).  The smaller of these measures is the short axis.  For example, an 
abdominal node that is reported as being 20 mm30 mm has a short axis of 20 mm and 
qualifies as a malignant, measurable node.  In this example, 20 mm should be recorded 
as the node measurement.  All other pathological nodes (those with short axis 10mm 
but 15mm) should be considered non- target lesions.  Nodes that have a short axis 
10 mm are considered non -pathological and should not be recorded or followed.
Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
158/Protocol GO29438, Version 7Lesions irradiated within 3 weeks prior to Cycle 1 ,Day 1 may not be counted as target 
lesions.
A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all 
target lesions will be calculated and reported as the baseline sum of diameters.  If lymph 
nodes are to be in cluded in the sum, then, as noted above, only the short axis is added 
into the sum.  The baseline sum of diameters will be used as a reference to further 
characterize any objective tumor regression in the measurable dimension of the disease.
All other lesi ons (or sites of disease), including pathological lymph nodes, should be 
identified as non -target lesions and should also be recorded at baseline.  Measurements 
are not required and these lesions should be followed as “present,” “absent,” or in rare 
cases “unequivocal progression.”
In addition, it is possible to record multiple non- target lesions involving the same organ 
as a single item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph 
nodes” or “multiple liver metastases”).
RESPONSE CRI TERIA
a.Evaluation of Target Lesions
This section provides the definitions of the criteria used to determine objective tumor 
response for target lesions.
Complete response (CR):  disappearance of all target lesions
Any pathological lymph nodes (whether target or non -target) must have 
reduction in short axis to 10 mm.
Partial response (PR):  at least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum of diameters
Progressi ve disease (PD):  at least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (nadir), including baseline
In addition to the relative increase of 20%, the sum must also demonstrate 
anabsolute increase o f at least 5 mm.
The appearance of one or more new lesions is also considered progression.
Stable disease (SD):  neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum on study
b.Spec ial Notes on the A ssessment of Target Lesions
Lymph Nodes.   Lymph nodes identified as target lesions should always have the actual 
short axis measurement recorded (measured in the same anatomical plane as the 
Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
159/Protocol GO29438, Version 7baseline examination), even if the nodes regres s to 10 mm on study.  This means that 
when lymph nodes are included as target lesions, the sum of lesions may not be zero 
even if CR criteria are met since a normal lymph node is defined as having a short axis 
10 mm.
Target Lesions That Become Too Smal l to Measure.   While on study, all lesions 
(nodal and non -nodal) recorded at baseline should have their actual measurements 
recorded at each subsequent evaluation, even when very small (e.g., 2 mm).  However, 
sometimes lesions or lymph nodes that are recor ded as target lesions at baseline 
become so faint on CT scan that the radiologist may not feel comfortable assigning an 
exact measure and may report them as being too small to measure.  W hen this occurs, it 
is important that a value be recorded on the CRF as follows:
If it is the opi[INVESTIGATOR_26191], 
themeasurement should be recorded as 0 mm.
If the lesion is believed to be present and is faintly seen but too small to measure, a 
default value of 5 mm should be assigned and BML (below measurable limit) should 
be ticked.  (Note:  It is less likely that this rulewill be used for lymph nodes since 
they usually have a definable size when normal and are frequently surrounded by 
[CONTACT_12156]; how ever, if a lymph node is believed to be 
present and is faintly seen but too small to measure, a default value of 5 mm should 
beassigned in this circumstance as well and BML should also be ticked.)
To reiterate, however, if the radiologist is able to provide an actual measure, that should 
be recorded, even if it is below [ADDRESS_76423] diameter for the coalesced lesion.
Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
160/Protocol GO29438, Version 7c.Evaluation of Non -Target Lesions
This section provides the definitions of the criteria used to determine t he tumor response 
for the group of non -target lesions.  Although some non -target lesions may actually be 
measurable, they need not be measured and, instead, should be assessed only 
qualitatively at the timepoints specified in the protocol.
CR:  disappearan ce of all non- target lesions and (if applicable) normalization of 
tumor marker level)
All lymph nodes must be non- pathological in size ( 10 mm short axis).
Non-CR/Non -PD:  persistence of one or more non- target lesion(s) and/or 
(ifapplicable) maintenance of tumor marker level above the normal limits
PD:  unequivocal progression of existing non -target lesions
The appearance of one or more new lesions is also considered progression.
d.Special Notes on A ssessment of Progression of Non -Target Disease
When th e Patient A lso Has Measurable Disease.   In this setting, to achieve 
unequivocal progression on the basis of the non -target disease, there must be an overall 
level of substantial worsening in non -target disease in a magnitude that, even in the 
presence of S Dor PR in target disease, the overall tumor burden has increased 
sufficiently to merit discontinuation of therapy.  A modest increase in the size of one or 
more non -target lesions is usually not sufficient to qualify for unequivocal progression 
status.  T he designation of overall progression solely on the basis of change in 
non-target disease in the face of SD or PR of target disease will therefore be extremely 
rare.
When the Patient Has Only  Non -Measurable Disease.   This circumstance arises in 
some Phase III studies when it is not a criterion of study entry to have measurable 
disease.  The same general concepts apply here as noted above; however, in this 
instance, there is no measurable disease assessment to factor into the interpretation of 
an increase in non-measurable disease burden.  Because worsening in non -target 
disease cannot be easily quantified (by [CONTACT_108]:  if all lesions are truly non -measurable), 
auseful test that can be applied when assessing patients for unequivocal progression 
isto cons ider if the increase in overall disease burden based on the change in 
non-measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease; that is, an increase in tumor burden 
representing an additi onal 73% increase in volume (which is equivalent to a 
20% increase in diameter in a measurable lesion).  Examples include an increase in 
apleural effusion from “trace” to “large” or an increase in lymphangitic disease from 
localized to widespread or may b e described in protocols as “sufficient to require a 
Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
161/Protocol GO29438, Version 7change in therapy.”  If unequivocal progression is seen, the patient should be considered 
to have had overall PD at that point.  Although it would be ideal to have objective criteria 
toapply to non -measurable disease, the very nature of that disease makes it impossible 
todo so; therefore, the increase must be substantial.
e.New Lesions
The appearance of new malignant lesions denotes disease progression; therefore, some
comments on detection of new lesi ons are important.  There are no specific criteria for 
theidentification of new radiographic lesions; however, the finding of a new lesion 
should be unequivocal, that is, not attributable to differences in scanning technique, 
change in imaging modality, or findings thought to represent something other than tumor 
(for example, some “new” bone lesions may be simply healing or flare of preexisting 
lesions).  This is particularly important when the patient’s baseline lesions show PR or 
CR.  For example, necros is of a liver lesion may be reported on a CT scan report as a
“new” cystic lesion, which it is not.
A lesion identified during the study in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progres sion.
If a new lesion is equivocal, for example because of its small size, continued therapy and 
follow -up evaluation will clarify if it represents truly new disease.  If repeat scans confirm 
there is definitely a new lesion, then progression should be dec lared using the date of 
the initial scan.
EVALUATION OF RESPON SE
a.Timepoint Response ( Overall Response)
It is assumed that at each protocol -specified timepoint, a response assessment occurs.  
Table [ADDRESS_76424] non- measurable (therefore non -target) disease only, Table 2 is to 
be used.

Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
162/Protocol GO29438, Version 7Table 1  Timepoint Response:   Patients with Target Lesions
(with or without Non -Target Lesions)
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/non -PD No PR
CR Not evaluated No PR
PR Non-PD or not all 
evaluatedNo PR
SD Non-PD or not 
allevaluatedNo SD
Not all evaluated Non-PD No NE
PD Any Yes or no PD
Any PD Yes or no PD
Any Any Yes PD
CRcomplete response; NE not evaluable; PD progressive disease; 
PRpartial response; SD stable disease.
Table 2  Timepoint Response: Patients with Non -Target 
Lesions Only
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non -PD No Non-CR/non -PDa
Not all evaluated No NE
Unequivocal PD Yes or no PD
Any Yes PD
CRcomplete response; NE not evaluable; PD progressive disease.
a“Non -CR/non -PD” is preferred over “stable disease” for non -target 
disease since stable disease is increasingly used as an endpoint for 
assessment of efficacy  in some studies; thus, assigning “stable disease” 
when no lesions can be me asured is not advised.
b.Missing A ssessments and Not -Evaluable Designation
When no imaging/measurement is done at all at a particular timepoint, the patient is not 
evaluable at that timepoint.  If only a subset of lesion measurements are made at an 
asse ssment, usually the case is also considered not evaluable at that timepoint, unless a 
Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
163/Protocol GO29438, Version 7convincing argument can be made that the contribution of the individual missing lesion(s) 
would not change the assigned timepoint response.  This would be most likely to happen 
in the case of PD.  For example, if a patient had a baseline sum of [ADDRESS_76425] 
a sum of 80 mm; the patient will have achieved PD status, regardless of the contribution 
of the missing lesion.
If one or more target lesions were not assessed either because the scan was not done 
or the scan could not be assessed because of poor image quality or obstructed view, the 
response for target lesions should be “unable to assess” since the patient is not 
evaluable.  Similarly, if one or more non -target lesions are not assessed, the response 
for non -target lesions should be “unable to assess” except where there is clear 
progression.  Overall response would be “unable to ass ess” if either the target response 
or the non -target response is “unable to assess,” except where this is clear evidence of 
progression as this equates with the case being not evaluable at that timepoint.
Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
164/Protocol GO29438, Version 7Table [ADDRESS_76426] Overall Response
CR CR CR
CR PR SD, PD, or PRa
CR SD SD, provided minimum duration 
for SD was met; otherwise, PD
CR PD SD, provided minimum duration 
for SD was m et; otherwise, PD
CR NE SD, provided minimum duration 
for SD was met; otherwise, NE
PR CR PR
PR PR PR
PR SD SD
PR PD SD, provided minimum duration 
for SD was met; otherwise, PD
PR NE SD, provided minimum duration 
for SD was met; otherwise, NE
NE NE NE
CRcomplete response; NE not evaluable; PD progressive disease; PR partial response; 
SDstable disease.
aIf a CR is truly met at the first timepoint, any disease seen at a subsequent timepoint, 
even disease meeting PR criteria relative to baseline, qualifies as PD at that point 
(since disease must have reappeared after CR).  Best response would depend on whether 
the minimum duration for SD was met.  However, sometimes CR may  be claimed when 
subsequent scans suggest small lesions were li kely still present and in fact the patient had 
PR, not CR, at the first timepoint.  Under these circumstances, the original CR should be 
changed to PR and the best response is PR.
c.Special Notes on Response A ssessment
When nodal disease is included in the sum of target lesions and the nodes decrease to 
“normal” size ( 10 mm), they may still have a measurement reported on scans.  This 
measurement should be recorded even though the nodes are normal in order not to 
overstate progression should it be based on increase in size of the nodes.  As noted 
earlier, this means that patients with CR may not have a total sum of “zero” on the CRF.
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
“symptomatic deterioration.”  Every effort should be made to document objective 
Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
165/Protocol GO29438, Version 7progression even after discontinuation of treatment.  Symptomatic deterioration is not a 
descriptor of an objective resp onse; it is a reason for stoppi[INVESTIGATOR_12003].  The 
objective response status of such patients is to be determined by [CONTACT_70186]- target disease as shown in Tables 1 3.
For equivocal fi ndings of progression (e.g., very small and uncertain new lesions; cystic 
changes or necrosis in existing lesions), treatment may continue until the next scheduled 
assessment.  If at the next scheduled assessment progression is confirmed, the date of 
progr ession should be the earlier date when progression was suspected.
If a patient undergoes an excisional biopsy or other appropriate approach (e.g., multiple 
passes with large core needle) of a new lesion or an existing solitary progressive lesion 
that follo wing serial sectioning and pathological examination reveals no evidence of 
malignancy (e.g., inflammatory cells, fibrosis, etc.), then the new lesion or solitary 
progressive lesion will not constitute disease progression.
In studies for which patients with advanced disease are eligible (i.e., primary disease still 
or partially present), the primary tumor should also be captured as a target or non target 
lesion, as appropriate.  This is to avoid an incorrect assessment of CR if the primary 
tumor is still present but not evaluated as a target or non -target lesion.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
166/Protocol GO29438, Version 7Appendix [ADDRESS_76427] been 
developed that account for the possible appearance of new lesions and allow 
radiological progression to be confirmed at a subsequent assessment.
Modified Response Evaluation Criteria in Solid Tumors (RECIST) is derived from 
RECIST, Version 1.1 (v1.1) conventions1and immune- related response criteria2(irRC).  
When not otherwise specified, RECIST v1.[ADDRESS_76428] v1.1:  Summary  of Changes
RECIST v1.1Modified RECIST
New lesions after baseline Define progression New measurable lesions are 
added into the total tumor burden 
and followed.
Non-target lesions May contribute to the 
designation of overall 
progressionContribute only in the assessment 
of a complete response
Radiographic progression First instance of 20% 
increase in the sum of 
diam eters or unequivocal 
progression in non -target 
diseaseDetermined only on the basis of 
measurable disease
RECIST Response Evaluation Criteria in Solid Tumors.
A.DEFINITIONS OF MEA SURABLE/NON -MEA SURA BLE LESIONS
All measurable and non -measurable lesions should be assessed at Screening and at the 
protocol -specified tumor assessment timepoints.  Additional assessments may be 
performed, as clinically indicated for suspi[INVESTIGATOR_55519].  
1Eisenhauer et al. Eur J Cancer 2009;45: 228 47; Topalian et al. N E ngl J Med
2012;366:2443 54; and W olchok et al. Clin Can Res 2009;15:7412 20.
2Wolchok et al. Clin C an Res 2009;15:7412 20; Nishino et al. J Immunother Can 2014;2:17; 
Nishino et al. Clin Can Res 2013;19: 393643.

Appendix 5
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
167/Protocol GO29438, Version 7A.[ADDRESS_76429] one dimension 
(longest diameter in the plane of measurement is to be recorded) with a minimum size 
as follows:
10 mm by [CONTACT_20420] (CT) or magnetic re sonance imaging (MRI) scan 
(CT/MRI scan slice thickness/interval no greater than 5 mm)
10-mm caliper measurement by [CONTACT_12148] (lesions that cannot be 
accurately measured with calipers should be recorded as non- measurable)
Malignant Ly mph Nodes.   To be considered pathologically enlarged and measurable, 
alymph node must be [ADDRESS_76430] scan (CT scan 
slice thickness recommended to be no greater than 5 mm).  At baseline and follow -up, 
only the short axis will be measured and followed.
A.2 NON- MEASURA BLE LESIONS
Non-measurable tumor lesions encompass small lesions (longest diameter 10mmor 
pathological lymph nodes with short axis 10 but 15 mm), as well as truly 
non-measurable lesions.  Lesions considered truly non-measurable include 
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal 
mass/abdominal organomegaly identified by [CONTACT_70187].
A.3 SPECIA L CONSIDERA TIONS REG ARDING LESION 
MEA SURA BILITY
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment, as outlined below.
Bone Lesion s
Bone scan, positron emission tomography (PET) scan, or plain films are not considered 
adequate imaging techniques for measuring bone lesions.  However, these techniques 
can be used to confirm the presence or disappearance of bone lesions.
Lytic bone lesi ons or mixed lytic –blastic lesions, with identifiable soft tissue components, 
that can be evaluated by [CONTACT_12783] -sectional imaging techniques such as CT or MRI can be 
considered as measurable lesions if the soft tissue component meets the definition of 
measura bility described above.
Blastic bone lesions are non -measurable.
Appendix 5
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
168/Protocol GO29438, Version 7Cystic Lesions
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non -measurable) since they 
are, by [CONTACT_108], simple cysts.
Cystic lesions thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above.  However, if 
non-cystic lesions are present in the same patient, these are preferred for selection as 
target lesions.
Lesions with Prior Local Treatment
Tumor lesions situated in a previously irradiated area or in an area subjected to other 
loco-regional therapy are usually not considered measurable unless there has been 
demonstrated progression in the lesion.  Study protocols should detail the conditions 
under which such lesions would be considered measurable.
B.TUMOR RESPONSE EVA LUATION
B.1DEFINITIONS OF T ARGET/NON -TARGET LESIONS
Target Lesions
When more than one measurable lesion is present at baseline, all lesions up to a 
maximum of five lesions total (and a maximum of two lesions per organ) representative 
of all involved organs should be identified as target lesions and will be recorded and 
measured at baseline.  This means that, for instances in which patients have only one 
ortwo organ sites involved, a maximum of two lesions (one site) and four lesions 
(two sites), respectively, will be recorded.  Other lesions (albeit measurable) in those 
organs will be recorded as non-target lesions (even if the size is 10mm by [CONTACT_3610]).
Target lesions should be selected on the basis of their size (lesions with the longest 
diameter) and be representative of all involved organs, but in addition, should lend 
themselves to reproducible repeated measurements .  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement, in which 
circumstance, the next largest lesion that can be measured reproducibly should be 
selected.
Lymph nodes merit special mention since they are normal anatomical structures 
thatmay be visible by [CONTACT_33490].  As noted above, 
pathological nodes that are defined as measurable and may be identified as target 
lesions must meet the criterion of a short axis of [ADDRESS_76431] scan.  Only the short 
axis of these nodes will contribute to the baseline sum.  The short axis of the node is the 
diameter normally used by [CONTACT_48861] a node is involved by [CONTACT_70188].  
Appendix 5
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
169/Protocol GO29438, Version 7Nodal size is normally reported as two dimensions in the plane in which the image is 
obtained (for CT, this is almost always the axial plane; for MRI, the plane of acquisition 
may be axial, sagittal, or coronal).  The smaller of these measures is the short axis.  For 
example, an abdominal node that is reported as being 20 mm30 mm has a short axis 
of 20mm and qualifies as a malignant, measurable node.  In this example, 20 mm 
should be recorded as the node measurement.  All other pathological nodes (those with 
short axis 10 mm but 15mm) should be considered non -target lesions.  Nodes that 
have a short axis of 10 mm are considered non- pathological and should not be 
recorded or followed.
Lesions irradiated within 3 weeks prior to Cycle 1 Day 1 may not be counted as target 
lesions.
Non- Target Lesions
All other lesions (or sites of disease), including pathological lymph nodes, should be 
identified as non -target lesions and should also be recorded at baseline.  Measurements 
are not required.
It is possible to record multiple non- target lesions involving the same organ as a single 
item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph nodes” or 
“multiple liver metastases”).
After baseline, changes in non -target lesions will contribute only in the assessment 
ofCR (i.e. , a CR is attained only with the complete disappearance of all tumor lesions, 
including non- target lesions) and will not be used to assess progressive disease.
New Lesions
During the study, all new lesions identified and recorded after baseline must be 
assessed at all tumor assessment timepoints.  New lesions will also be evaluated for 
measurability with use of the same criteria applied to prospective target lesions at 
basel ine per RECIST, (e.g., non lymph node lesions must be 10mm; see note for new 
lymph node lesions below).  Up to a maximum of five new lesions total (and a maximum 
of two lesions per organ), all with measurements at all timepoints, can be included in the 
tumor response evaluation.  New lesion types that would not qualify as target lesions per 
RECIST cannot be included in the tumor response evaluation.
New lesions that are not measurable at first appearance but meet measurability criteria 
at a subsequent ti mepoint will be measured from that point on and contribute to the sum 
of longest diameters (SLD), if the maximum number of 5 measurable new lesions being 
followed has not been reached. 
Appendix 5
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
170/Protocol GO29438, Version 7B.2CALCULA TION OF S UM OF THE DIA METERS
A sum of the diameters (longes t for non -nodal lesions, short axis for nodal lesions) for all 
target lesions will be calculated as a measure of tumor burden.
The sum of the diameters is calculated at baseline and at each tumor assessment for 
the purpose of classification of tumor respon ses.
Sum of the Diameters at Baseline :  The sum of the diameters for all target lesions 
identified at baseline prior to treatment on Day 1.
Sum of the Diameters at Tumor A ssessment :  For every on -study tumor assessment 
collected per protocol or as clinical ly indicated the sum of the diameters at tumor 
assessment will be calculated using tumor imaging scans.  All target lesions selected at 
baseline and up to five new measurable lesions (with a maximum of two new lesions per 
organ) that have emerged after bas eline will contribute to the sum of the diameters at 
tumor assessment.  Hence, each net percentage change in tumor burden per 
assessment with use of modified RECIST accounts for the size and growth kinetics of 
both old and new lesions as they appear.
Note:   In the case of new lymph nodes, RECIST v1.1 criteria for measurability 
(equivalent to baseline target lesion selection) will be followed.  That is, if at first 
appearance the short axis of a new lymph node lesion 15 mm, it will be considered a 
measureable new lesion and will be tracked and included in the SLD.  Thereafter, the 
lymph node lesion will be measured at subsequent timepoints and measurements will be 
included in the SLD, even if the short axis diameter decreases to 15 mm (or even 
10mm).  However, if it subsequently decreases to 10 mm, and all other lesions are 
no longer detectable (or have also decreased to a short axis diameter of 10 mm if 
lymph nodes), then a response assessment of CR may be ass igned.
If at first appearance the short axis of a new lymph node is 10 mm and 15 mm, the 
lymph node will not be considered measurable but will still be considered a new lesion. It 
will not be included in the SLD unless it subsequently becomes measurabl e (short axis 
diameter 15 mm).
The appearance of new lymph nodes with diameter 10 mm should not be considered 
pathological and not considered a new lesion.
Appendix 5
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
171/Protocol GO29438, Version 7B.3RESPONSE CRITERI A
Timepoint Response
It is assumed that at each protocol -specified timepoint, a response assessment occurs.  
Table [ADDRESS_76432] measurable disease at baseline.
Complete Response (CR) :  Disappearance of all target and non -target lesions.  Lymph 
nodes that shrink to 10 mm short axis are considered normal.
Partial Response (PR) :  At least a 30% decrease in the sum of the diameters of all 
target and all new measurable lesions, taking as reference the baseline sum of 
diameters, in the absence of CR.
Note: the appearance of new measurable lesions is factored into the overall tumor 
burden, but does not automatically qualify as progressive disease until the sum of the 
diameters increases by 20% when compared with the sum of the diameters at nadir.
Stable Disease (SD) :  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum of the diameters while 
onstudy.
Progressive Disease (PD) :  At least a 20% increase in the sum of diameters of all 
target and selected new measurable lesions, taking as reference the smallest sum on 
study (nadir SLD; this includes the baseline sum if that is the smallest on study) .  In 
addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least [ADDRESS_76433] tumor response.
Missing A ssessments and Not Evaluable Designation
When no imaging/measurement is done at all at a particular timepoint, the patient is
considered not evaluable (NE) at that timepoint.  If only a subset of lesion 
measurements are made at an assessment, usually the case is also considered NE at 
that timepoint, unless a convincing argument can be made that the contribution of the 
individual missing lesion(s) would not change the assigned timepoint response.  This 
would only happen in the case of PD.  For example, if a patient had a baseline sum of 
50mm with three measured lesions and at follow -up only two lesions were assessed but 

Appendix 5
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
172/Protocol GO29438, Version 7those gav e a sum of [ADDRESS_76434] Timepoint Response Definitions
% Change in Sum of the DiametersaNon-Target Lesion 
Response 
AssessmentOverall Modified RECIST 
Timepoint Response
100% from baselinebCR CR
100% from baselinebNon-CR or not all 
evaluatedPR
 30% from baseline Any PR
 30% to 20% Any SD
Not all evaluated Any NE
 20%from nadir SLD Any PD
CRcomplete response; NEnot evaluable; PD progressive disease; PR partial response; 
RECIST Response Evaluation Criteria in Solid Tumors; SD stable disease; SLD sum of the 
longest diameter.
aPercent change in sum of the diameters (including me asurable new lesions when present).
bWhen lymph nodes are included as target lesions, the % change in the sum of the 
diam eters may not be 100% even if CR criteria are met, since a normal ly mph node is 
defined as having a short axis of 10 mm.  Any path ological ly mph nodes (whether target or 
non-target) must have reduction in short axis to 10 mm in order to meet the definition of 
CR.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
173/Protocol GO29438, Version 7Appendix 6
AntiPD-L1 Immunohistochemistry
OVERVIEW
The Ventana antiPD-L1 (SP142) rabbit monoclonal primary antibody 
immunohistochemistry (IHC) assay will be used to determine 
programmed death ligand 1 (PD -L1) IHC status.  The anti PD-L1 (SP142) rabbit 
monoclonal antibody IHC assay is currently being developed by [CONTACT_70189] a companion diagnostic to atezolizumab.  For Study GO29438, the 
antiPD-L1 (SP142) IHC assay will be used for investigational purposes only.
The V entana antiPD-L1 (SP142) rabbit monoclonal primary antibody is intended for 
laboratory use in the semi -quantitative immunohistochemical assessment of the PD -L1 
protein in formalin -fixed paraffin -embedded non small cell lung carcinoma (NSCLC) 
tissue stained on a Ventana BenchMark ULTRA automated slide stainer.  It is indicated 
as an aid in the selection of NSCLC patients with locally advanced or metastatic disease 
who might benefit from treatment with atezolizumab.
This assay is for investigational use only .  The performance characteristics of this 
product have not been established.
DEVICE DESCRIPTION
The Ventana antiPD-L1 (SP142) rabbit monoclonal primary antibody is a pre -dilute, 
ready -to-use antibody product optimized for use with the Ventana Medical Sys tems 
OptiView DAB IHC Detection Kit and the OptiView Amplification Kit on Ventana Medical 
Systems automated BenchMark ULTRA platforms.  One 5- mL dispenser of anti PD-L1 
(SP142) rabbit monoclonal primary antibody contains approximately 36 g of rabbit 
monoc lonal antibody directed against the PD -L1 protein and contains sufficient reagent 
for 50 tests.  The reagents and the IHC procedure are optimized for use on the 
BenchMark ULTRA automated slide stainer, utilizing Ventana System Software (VSS). 
SCORING SYST EM
PD-L1 staining with anti PD-L1 (SP142) rabbit monoclonal primary antibody in NSCLC 
can be observed in both tumor cells and tumor -infiltrating immune cells.
Details of the criteria for PD -L1 diagnostic assessment are described in the IDI 
document.
Atezolizumab —F.Hoffmann- La [COMPANY_002] Ltd
174/Protocol GO29438 , Version 7Appendix 7
EORTC QLQ -C30

Appendix 7
EORTC QLQ -C30 (cont.)
Atezolizumab —F.Hoffmann- La [COMPANY_002] Ltd
175/Protocol GO29438 , Version 7

Atezolizumab —F.Hoffmann- La [COMPANY_002] Ltd
176/Protocol GO29438 , Version 7Appendix 8
EORTC QLQ -LC13

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
177/Protocol GO29438, Version 7Appendix 9
EQ-5D -5L

Appendix 9
EQ-5D -5L(cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
178/Protocol GO29438, Version 7

Appendix 9
EQ-5D -5L(cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
179/Protocol GO29438, Version 7

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
180/Protocol GO29438, Version 7Appendix 10
Eastern Cooperative Oncology  Group Performance Status Scale
Grade Description
0Fully active, able to carry  on all predisease performance without restriction
1Restricted in phy sically  strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature; e.g., light housework or office work
2Ambulator y and capable of all self -care but unable to carry out any work activities; up 
and about 50% of waking hours
3Capable of only limited self -care, confined to a bed or chair 50% of waking hours
4Completely disabled; cannot carry on any self-care; totally confined to bed orchair
5Dead
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
181/Protocol GO29438, Version 7Appendix 11
Anaphy laxis Precautions
EQUIPMENT NEEDED
Oxygen
Epi[INVESTIGATOR_33414], intravenous, and/or endotracheal use in accordance 
with standard practice
Antihistamines
Corticosteroids
Intravenous infusion solutions, tubing, catheters, and tape
PROCEDURES
In the event of a suspected anaphylactic reaction during study drug infusion, 
thefollowing procedures should be performed:
1.Stop the study drug infusion.
2.Maintain an adequate airway.
3.Administer antihistamines, epi[INVESTIGATOR_238], or other medications as required by [CONTACT_27964].
4.Continue to observe the patient and document observations .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
182/Protocol GO29438, Version 7Appendix 12
Preexisting A utoimmune Diseases
Patients should be carefully questioned regarding their history of acquired or congenital 
immune deficiencies or autoimmune disease.  Patients with any history of immune 
deficiencies or autoimmune disease listed in the table below are excluded from 
participating in the study.  Possible exceptions to this exclusion could be patients with a 
medical history of such entities as atopic disease or childhood arthralgias for whom the 
clinical s uspi[INVESTIGATOR_33415].  Patients with a history of autoimmune-
related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible 
for this study.  In addition, transient autoimmune manifestations of an acute infectious 
disease that resolved upon treatment of the infectious agent are not excluded 
(e.g., acute Lyme arthritis).  Contact [CONTACT_70190].
Autoimmune Diseases andImmune Deficiencies
Acute disseminated 
encephalomyelitis
Addison’s disease
Ankylosing spondylitis
Antiphospholipid antibody syndrome
Aplastic anemia
Autoimmune hemolytic anemia
Autoimmune hepatitis
Autoimmune hypoparathyroidism
Autoimmune hypophysitis
Autoimmune myocarditis
Autoimmune oophoritis
Autoimmune orchitis
Autoimmune thrombocytopenic 
purpura
Behcet’s disease
Bullous pemphigold
Chronic fatigue syndrome
Chronic inflammatory demyelinating
    polyneuropathy
Chung -Strauss syndrome
Crohn’s disease 
Dermatomyositis
Diabetes mellitus type 1
Dysa utonomiaEpi[INVESTIGATOR_33416]’s syndrome
Graves’ disease
Guillain -Barré syndrome
Hashimoto’s disease
IgA nephropathy
Inflammatory bowel disease
Interstitial cystitis
Kawasaki’s disease
Lambe rt-Eaton myasthenia 
syndrome
Lupus erythematosus
Lyme disease -chronic
Meniere’s syndrome
Mooren’s ulcer
Morphea
Multiple sclerosis
Myasthenia gravis
Neuromyotonia
Opsoclonus myoclonus syndrome
Optic neuritisOrd’s thyroiditis
Pemphigus
Pernicious anemia
Polyarteritis nodusa
Polyarthritis
Polyglandular autoimmune 
syndrome
Primary biliary cirrhosis
Psoriasis
Reiter’s syndrome
Rheumatoid arthritis
Sarcoidosis
Scleroderma
Sjögren’s syndrome
Stiff-Person syndrome
Takayasu’s arteritis
Ulcerative colitis
Vitilig o
Vogt-Kovanagi -Harada disease
Wegener’s granulomatosis
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
183/Protocol GO29438, Version 7Appendix 13
Symptoms in Lung Cancer

Appendix 13
Symptoms in Lung Cancer (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
184/Protocol GO29438, Version 7

Appendix 13
Symptoms in Lung Cancer (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
185/Protocol GO29438, Version 7

Appendix 14
Additional Guidance on Chemotherapy  Administration (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
187/Protocol GO29438, Version 7Within a [ADDRESS_76435] the site on how to open the appropriate visits and electronic Case Report Form 
(eCRF) so that the site can then record the interruption and reintroduction accordingly on 
the eCRF.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
188/Protocol GO29438, Version 7Appendix [ADDRESS_76436], and in severe cases, immune -mediated
toxicities may require acute management with topi[INVESTIGATOR_70073], systemic 
corticosteroids, or other immunosuppressive agents. 
The investigator should consider the benefit risk balance a given patient may be 
experiencing prior to further administration of atezolizumab.  In patients who have 
metthe criteria for permanent discontinuation, resumption of atezolizumab 
may beconsidered if the patient is deriving benefit and has fully recovered from the 
immune -mediated event.  Patients can be re -challenged with atezolizumab only after 
approval has been do cumented by [CONTACT_33494] (or an appropriate delegate) and 
the Medical Monitor. 
MANAGEMENT GUIDELINE S
PULMONA RY EVENTS
Dyspnea, cough, fatigue, hypoxia, pneumonitis, and pulmonary infiltrates have been 
associated with the administration of atezolizumab.  Patients will be assessed for 
pulmonary signs and symptoms throughout the study and will also have computed 
tomography ( CT) scans of the chest performed at every tumor assessment.  
All pulmonary events should be thoroughly evaluated for other commonly reported 
etiologies such as pneumonia or other infection, lymphangitic carcinomatosis, pulmonary 
embolism, heart failure, c hronic obstructive pulmonary disease, or pulmonary 
hypertension.   Management guidelines for pulmonary events are provided in Table 1 .

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
189/Protocol GO29438, Version 7Table 1Management Guidelines for Pulmonary  Events, Including 
Pneumonitis
Event Management
Pulm onary 
event, Grade 1 Continue atezolizumab andmonitor closely.
Re-evaluate on serial imaging.
Consider patient referral to pulmonary specialist.
Pulm onary 
event, Grade 2Withhold atezolizumab for up to 12 weeks after event onset.a
Refer patient to pulmonary and infectious disease specialists and 
consider bronchoscopy or BAL.
Initiate treatment with 1 2 mg/kg/day oral prednisone or equivalent.
If event resolves to Grade 1 or better, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76437] 
Medical Monitor.c
For recurrent events, treat as a Grade 3 or 4 event.
Pulm onary 
event, Grade 3 
or 4Permanently discontinue atezolizumab and contact [CONTACT_25290].c
Bronchoscopy or BAL is recommended.
Initiate treatment with 1 2 mg/kg/day oral prednisone or equivalent.
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.
If event resolves to Grade 1 or better, taper corticosteroids over 
1month.
BALbronchoscopic alveolar lavage.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to 10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 10mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor. 
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
190/Protocol GO29438, Version 7HEPA TIC EVENTS
Immune -mediated hepatitis has been associated with the administration of atezolizumab.  
Eligible patients must have adequate liver function, as manifested by [CONTACT_33496], and liver function will be monitored throughout 
study treatment.  Management guidelines for hepatic events are provided in Table 2 .
Patients with right upper -quadrant abdominal pain and/or unexplained nausea or 
vomiting should have liver function tests (LFTs) performed immediate ly and reviewed 
before administration of the next dose of study drug.
For patients with elevated LFTs, concurrent medication, viral hepatitis, and toxic or 
neoplastic etiologies should be considered and addressed, as appropriate.
Table 2Management Guideli nes for Hepatic Events
Event Management
Hepatic event, 
Grade 1Continue atezolizumab.
Monitor LFTs until values resolve to within normal limits. 
Hepatic event, 
Grade 2All events:
Monitor LFTs more frequently until return to baseline values. 
Events of 5 days’ duration:
Withhold atezolizumab for up to 12 weeks after event onset.a
Initiate treatment with 1 2 mg/kg/day oral prednisone or 
equivalent.
If event resolves to Grade 1 or better, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76438] Medical Monitor.c
LFTliver function test.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day 
oral prednisone or equivalent.  The acceptable length of the extended period of time 
must be agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 
10mg/day oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving 
benefit and have fully recovered from the immune -mediated event.  Patients can be 
re-challenged with atezolizumab only after approval has been documented by [CONTACT_33497] (or an appropriate delegate) and the Medical Monitor. 

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
191/Protocol GO29438, Version 7Table 2Management Guidel ines for Hepatic Events (cont.)
Event Management
Hepatic event, 
Grade 3 or 4Permanently discontinue atezolizumab and contact [CONTACT_31807].c
Consider patient referral to gastrointestinal specialist for 
evaluation and liver biopsy to establish etiology of hepatic 
injury. 
Initiate treatment with 1 2 mg/kg/day oral prednisone or 
equivalent.
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.
If event resolves to Grade 1 or better, taper corticosteroids over 
1 month.
LFTliver function test.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks a fter 
event onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day 
oral prednisone or equivalent.  The acceptable length of the extended period of time 
must be agreed upon by [CONTACT_33495].
bIf corticoste roids have been initiated, they must be tapered over 1 month to 
10mg/day oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving 
benefit and have fully recovered from the immune -mediated event.  Patients can be 
re-challenged with atezolizumab only after approval has been documented by [CONTACT_33497] (or an appropriate delegate) and the Medical Monitor. 
GASTROINTESTINA L EVE NTS
Immune -mediated colitis has been associated with the administration of atezolizumab.  
Management guidelines for diarrhea or colitis are provided in Table 3 .
All events of diarrhea or colitis should be thoroughly evaluated for other more common 
etiologies.  For events of significant duration or magnitude or associated with signs of 
systemic inflammation or acute -phase reactants (e.g., increased C -reactive protein, 
platelet count, or bandemia):  Perform sigmoidoscopy (or colonos copy, if appropriate) 
with colonic biopsy, with three to five specimens for standard paraffin block to check for 
inflammation and lymphocytic infiltrates to confirm colitis diagnosis. 

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
192/Protocol GO29438, Version 7Table 3Management Guidelines for Gastrointestinal E vents 
(Diarrhea orColitis)
Event Management
Diarrhea or 
colitis, Grade 1Continue atezolizumab.
Initiate sy mptomatic treatment.
Endoscopy is recommended if sy mptoms persist for 7days.
Monitor closely.
Diarrhea or 
colitis, Grade 2Withhold atezolizumab for up to 12 weeks after event onset.a
Initiate sy mptomatic treatment.
Patient referral to GI specialist is recommended.
For recurrent events or events that persist 5 day s, initiate treatment 
with 1 2 mg/kg/day oral prednisone or equivalent. 
If event resolves to Grade 1 or better, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76439] 
Medical Monitor.c
Diarrhea or 
colitis, Grade 3Withhold atezolizumab for up to 12 weeks after event onset.a
Refer patient to GI specialist for evaluation and confirmatory  biops y.
Initiate treatment with 1 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 12 mg/kg/day oral prednisone or equivalent
upon improvement.
If event resolves to Grade 1 or better, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76440] 
Medical Monitor.c
GIgastrointestinal.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to 10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 10mg/day 
oral prednisone or equivalent before atezolizumab can be res umed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by [CONTACT_70191] (or an 
appropriate delegate) and the Medical Monitor. 
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
193/Protocol GO29438, Version 7Table 3 Management Guidelines for Gastrointestinal Events 
(Diarrhea orColitis) (cont.)
Event Management
Diarrhea or 
colitis, Grade 4Permanently discontinue atezolizumab and contact [CONTACT_25290].c
Refer patient to GI specialist for evaluation and confirmation biopsy.
Initiate treatment with 1 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1 2 mg/kg/day oral prednisone or 
equivalent upon improvement.
If eve nt does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.
If event resolves to Grade 1 or better , taper corticosteroids over 
1month.
GIgastrointestinal.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to 10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 10mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor. 
ENDOCRINE EVENTS
Thyroid disorders, adrenal insufficiency, diabetes mellitus, and pi[INVESTIGATOR_33417].  Management guidelines for 
endocrine events are provided in Table [ADDRESS_76441] if an endocrinopathy is suspected.  Thyroid -stimulating hormone (TSH) 
and free triiodothyronine and thyroxine levels should be measured to determine whether 
thyroid abnormalities are present.  Pi[INVESTIGATOR_33418] (e.g., TSH, 
growth hormone, luteinizing hormone, follicle -stimulating hormone, testosterone, 
prolactin, adrenocorticotropic hormone [ACTH] levels, and ACTH stimulation test) and 
magnetic resonance imaging (MRI) of the brain ( with detailed pi[INVESTIGATOR_33419]) may 
help to differentiate primary pi[INVESTIGATOR_33420].

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
194/Protocol GO29438, Version 7Table 4 Management Guidelines for Endocrine Events
Event Management
Asymptomatic 
hypothy roidismContinue atezolizumab.
Initiate treatment with thyroid replacement hormone.
Monitor TSH weekly.
Symptomatic 
hypothy roidismWithhold atezolizumab.
Initiate treatment with thyroid replacement hormone.
Monitor TSH weekly.
Consider patient referral to endocrinologist.
Resume atezolizumab when sy mptoms are controlled and 
thyroid function is improving.
Asymptomatic 
hyperthy roidismTSH 0.1 mU/L and 0.5 mU/L:
Continue atezolizumab.
Monitor TSH ever y 4 weeks.
TSH 0.1 mU/L:
Follow guidelines for sy mptomatic hyperthyroidism.
Symptomatic 
hyperthy roidismWithhold atezolizumab.
Initiate treatment with anti -thyroid drug such as methimazole 
or carbimazole as needed.
Consider patient referral to endocrinologist.
Resume atezolizumab when sy mptoms are controlled and 
thyroid function is improving.
Permanently discontinue atezolizumab and contact [CONTACT_33499] -threatening immune -mediated hyperthy roidism.c
MRImagnetic resonance imaging; TSH thyroid-stimulating hormone.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to 10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 10 mg/day  
oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  Patients can be re -challenged 
with atezolizumab only after approval has been documented by [CONTACT_33494] 
(oran appropriate delegate) and the Medical Monitor. 
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
195/Protocol GO29438, Version 7Table 4 Management Guidelines for Endocrine Events (cont.)
Event Management
Symptomatic adrenal 
insufficiency, 
Grade 24 Withhold atezolizumab for up to 12 weeks after event onset .a
Refer patient to endocrinologist.
Perform appropriate imaging.
Initiate treatment with 1 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 12mg/kg/day oral prednisone or 
equivalent upon improvement .
If event resolves to Grade 1 or better and patient is stable on 
replacement therapy, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76442] Medical 
Monitor.c
Hyperglycemia, 
Grade 1 or 2 Continue atezolizumab.
Initiate treatment with insulin if needed.
Monitor for glucose control.
Hyperglycemia, 
Grade 3 or 4Withhold atezolizumab.
Initiate treatment with insulin.
Monitor for glucose control.
Resume atezolizumab when sy mptoms resolve and glucose 
levels are stable.
MRImagnetic resonance imaging; TSH thyroid-stimulating hormone.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to 10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 10mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have fully rec overed from the immune -mediated event.  Patients can be re -challenged 
with atezolizumab only after approval has been documented by [CONTACT_33494] 
(oran appropriate delegate) and the Medical Monitor. 
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
196/Protocol GO29438, Version 7Table 4 Management Guidelines for Endocrine Events (cont.)
Event Management
Hypophy sitis 
(pan-hypopi[INVESTIGATOR_297]), 
Grade 2 or 3 Withhold atezolizumab for up to 12 weeks after event onset .a
Refer patient to endocrinologist.
Perform brain MRI (pi[INVESTIGATOR_33421]).
Initiate treatment with 1 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 12mg/kg/day oral prednisone or 
equivalent upon improvement.
Initiate hormone replacement if clinically indicated.
If event resolves to Grade 1 or better, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76443] Medical Monitor.c
For recurrent hypophysitis, treat as a Grade 4 event.
Hypophy sitis 
(pan-hypopi[INVESTIGATOR_297]), 
Grade 4 Permanently discontinue atezolizumab and contact [CONTACT_31807].c
Refer patient to endocrinologist.
Perform brain MRI (pi[INVESTIGATOR_33421]).
Initiate treatment with 1 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 12mg/kg/day oral prednisone or 
equivalent upon improvement.
Initiate hormone replacement if clinically indicated.
MRImagnetic resonance imaging; TSH thyroid-stimulating hormone.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to 10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 10mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have fully rec overed from the immune -mediated event.  Patients can be re -challenged 
with atezolizumab only after approval has been documented by [CONTACT_33494] 
(oran appropriate delegate) and the Medical Monitor. 
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
197/Protocol GO29438, Version 7OCULA R EVENTS
An ophthalmologist should evaluate visual complaints (e.g., uveitis, retinal events).  
Management guidelines for ocular events are provided in Table 5 .
Table 5 Management Guidelines for Ocular Events
Event Management
Ocular event, 
Grade 1 Continue atezolizumab.
Patient referral to ophthalmologist is strongly recommended.
Initiate treatment with topi[INVESTIGATOR_33422].
If symptoms persist, treat as a Grade 2 event.
Ocular event, 
Grade 2Withhold atezolizumab for up to 12 weeks after event onset .a
Patient referral to ophthalmologist is strongly recommended.
Initiate treatment with topi[INVESTIGATOR_33422].
If event resolves to Grade 1 or better, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76444] 
Medical Monitor.c
Ocular event, 
Grade 3 or 4Permanently discontinue atezolizumab an d contact [CONTACT_31807].c
Refer patient to ophthalmologist.
Initiate treatment with 1 2 mg/kg/day oral prednisone or equivalent.  
If event resolves to Grade 1 or better, taper corticosteroids over 
1month.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to 10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 
10mg/day oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  Patients can be re -challenged 
with atezolizumab only after approval has been documented by [CONTACT_33494] 
(oran appropriate delegate) and the Medical Monitor. 

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
198/Protocol GO29438, Version 7IMMUNE -MEDIATED MYOC ARDITIS
Immune -mediated myocarditis has been associated with the administration of 
atezolizumab.  Immune -mediated myocarditis should be suspected in any patient 
presenting with signs or symptoms suggestive of myocarditis, including, but not limited to, 
laboratory (e.g., B -type natriuretic peptide) or cardiac imaging abnormalities, 
dyspnea, chest pain, palpi[INVESTIGATOR_814], f atigue, decreased exercise tolerance, or syncope.  
Immune -mediated myocarditis needs to be distinguished from myocarditis resulting from 
infection (commonly viral, e.g., in a patient who reports a recent history of 
gastrointestinal illness), ischemic event s, underlying arrhythmias, exacerbation of 
preexisting cardiac conditions, or progression of malignancy.  
All patients with possible myocarditis should be urgently evaluated by [CONTACT_40913], an ECG, a chest X -ray, an echocardiogram , and a cardiac 
MRI as appropriate per institutional guidelines.  A cardiologist should be consulted.  
Anendomyocardial biopsy may be considered to enable a definitive diagnosis and 
appropriate treatment, if clinically indicated.
Patients with signs and s ymptoms of myocarditis, in the absence of an identified 
alternate etiology, should be treated according to the guidelines in Table 6.

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
199/Protocol GO29438, Version 7Table 6Management Guidelines for Immune -Mediated Myocarditis
Event Mana gement
Immune -mediated
myocarditis, Grade 1Refer patient to cardiologist.
Initiate treatment as per institutional guidelines.
Immune -mediated
myocarditis, Grade 2Withhold atezolizumab for up to [ADDRESS_76445] Medical Monitor.
Refer patient to cardiologist.
Initiate treatment as per institutional guidelines and consider 
antiarrhythmic drugs, temporary pacemaker, ECMO, or VAD as 
appropriate.
Consider treatment with 1 2mg/kg/day IV methylprednisolone or 
equivalent and convert to 12mg/kg/day oral prednisone or 
equivalent upon improvement.a
If event resolves to Grade 1 or better, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76446] 
Medical Monitor.c
Immune -mediated
myocarditis, Grade 3 -4Permanently discontinue atezolizumab and contact [CONTACT_31807].c
Refer patient to cardiologist.
Initiate treatment as per institutional guidelines and consider 
antiarrhythmic drugs, temporary pacemaker, ECMO, or VAD as 
appropriate.
Initiate treatment with 1 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1 2mg/kg/day oral prednisone or 
equivalent upon improvement.a,b
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.
If event resolves to Grade 1 or better , taper corticosteroids 
over1month.
ECMO extracorporeal membrane oxygenation; VAD ventricular assist device.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event onset) to 
allow for corticosteroids (if initiated) to be reduced to 10 mg/day oral prednisone or equivalent.  
The acceptable length of the extended period of time must be agreed upon by [CONTACT_33501].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 10mg/day oral 
prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and have 
fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor.
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
200/Protocol GO29438, Version 7INFUSION -RELA TED REA CTIONS AND CYTOKINE -RELEAS E 
SYNDROME
No premedication is indicated for the administration of Cycle 1 of atezolizumab.  
However, patients who experience an infusion -related reaction (IRR) or cytokine -release 
syndrome (CRS) with atezolizumab may receive premedication with antihistamines ,
anti-pyretics , and/ or analgesics (e.g., acetaminophen) for subsequent infusions.  
Metamizole (dipyrone) is prohibited in treating atezolizumab -associated IR Rs because of 
its potential for causing agranulocytosis.
IRRs are known to occur with the administration of monoclonal antibodies and have 
been reported with atezolizumab.  These reactions, which are thought to be due to 
release of cytokines and/or other c hemical mediators, occur within 24 hours of 
atezolizumab administration and are generally mild to moderate in severity.
CRS is defined as a supraphysiologic response following administration of any immune 
therapy that results in activation or engagement of endogenous or infused T cells 
and/or other immune effector cells.  Symptoms can be progressive, always include fever 
at the onset, and may include hypotension, capi[INVESTIGATOR_7946] (hypoxia), and end -organ 
dysfunction (Lee et al. 2019).  CRS has been well docum ented with chimeric antigen 
receptor T -cell therapi[INVESTIGATOR_70074] T -cell engager antibody therapi[INVESTIGATOR_70075] -1 or PD -L1 (Rotz et al. 2017; 
Adashek and Feldman 2019), including atezolizumab.
There may be significant overlap in signs and symptoms of IRRs and CRS, and in 
recognition of the challenges in clinically distinguishing between the two, consolidated 
guidelines for medical management of IRRs and CRS are provided in Table 7.

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
201/Protocol GO29438, Version 7Table 7Management Guidelines for Infusion- Related Reactions and 
Cytokine -Release Syndrome
Event Management
Grade 1a
Feverbwith or 
without 
constitutional 
symptomsImmediately interrupt infusion.
Upon symptom resolution, wait for 30 minutes and then restart 
infusion at half the rate being given at the time of event onset.
If the infusion is tolerated at the reduced rate for 30 minutes, the 
infusion rate may be increased to the original rate.
If sym ptoms recur, discontinue infusion of this dose.
Administer symptomatic treatment,cincluding maintenance of 
IV fluids for hydration.
In case of rapid decline or prolonged CRS ( 2 days) or in 
patients with significant symptoms and/or comorbidities, 
consider managing as per Grade 2.
For subsequent infusions, consider administration of oral 
premedication with antihistamines, anti -pyretics, and/or 
analgesics, and monitor closely for IRRs and/or CRS.
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
202/Protocol GO29438, Version 7Table 7 Management Guidelines for Infusion -Related Reactions and 
Cytokine -Release Syndrome (cont.)
Grade 2a
Feverbwith 
hypotension not 
requiring 
vasopressors
and/or
Hypoxia requiring 
low- flow oxygend
by [CONTACT_70192] -byImmediately i nterrupt infusion.
Upon symptom resolution, wait for 30 minutes and then restart 
infusion at half the rate being given at the time of event onset.
If symptoms recur, discontinue infusion of this dose.
Administer symptomatic treatment.c
For hypotension, administer IV fluid bolus as needed.
Monitor c ardiopulmonary and other organ function closely (in the 
ICU, if appropriate).  Administer IV fluids as clinically indicated, and 
manage constitutional symptoms and organ toxicities as per 
institutional practice.
Rule out other inflammatory conditions that can mimic CRS 
(e.g., sepsis).  If no improvement within 24 hours, initiate workup and 
assess for signs and symptoms of HLH or MAS as described in this 
appendix.
Consider IV corticosteroids (e.g., methylprednisolone 2 mg/kg/day or 
dexamethasone 10 mg every 6 hours).
Consider anti -cytokine therapy.e
Consider hospi[INVESTIGATOR_70076].  If no 
improvement within 24 hours, manage as per Grade 3, that 
is,hospi[INVESTIGATOR_28068] (monitoring in the ICU is recommended), 
permanently disconti nue atezolizumab, and contact [CONTACT_25290] .
If symptoms resolve to Grade 1 or better for 3 consecutive days, the 
next dose of atezolizumab may be administered.  
For subsequent infusions, consider administration of oral premedication 
with antihistamines, anti -pyretics, and/or analgesics and monitor closely 
for IRRs and/or CRS .
If symptoms do not resolve to Grade [ADDRESS_76447] Medical Monitor.
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
203/Protocol GO29438, Version 7Table 7 Management Guidelines for Infusion -Related Reactions and 
Cytokine -Release Syndrome (cont.)
Grade 3a
Feverbwith 
hypotension 
requiring a 
vasopressor (with 
or without 
vasopressin)
and/or
Hypoxia requiring 
high -flow oxygend
by [CONTACT_21294], 
face mask, 
non-rebreather 
mask, or Ventu ri 
maskPermanently discontinue atezolizumab and contact [CONTACT_25290].f
Administer symptomatic treatment.c
For hypotension, administer IV fluid bolus and vasopressor as needed.
Monitor cardiopulmonary and other organ function closely; monitoring 
in the ICU is recommended.  Administer IV fluids as clinically 
indicated, and manage constitutional symptoms and organ toxicities as 
per institutional practice.
Rule out other inflammatory conditions that can mimic CRS 
(e.g., sepsis).  If no improvement withi n 24 hours, initiate workup and 
assess for signs and symptoms of HLH or MAS as described in this 
appendix.
Administer IV corticosteroids (e.g., methylprednisolone 2 mg/kg/day or 
dexamethasone 10 mg every 6 hours).
Consider anti -cytokine therapy.e
Hospi[INVESTIGATOR_70077].  If no 
improvement within 24 hours, manage as per Grade 4, that is, admit 
patient to ICU and initiate hemodynamic monitoring, mechanical 
ventilation, and/or IV fluids and vasopressors as needed; for patien ts 
who are refractory to anti -cytokine therapy, experimental treatments 
may be considered at the discretion of the investigator and in 
consultation with the Medical Monitor .
Grade 4a
Feverbwith 
hypotension 
requiring multiple 
vasopressors 
(excluding 
vasopressin)
and/or
Hypoxia requiring 
oxygen by [CONTACT_70193] (e.g., 
CPAP, BiPAP, 
intubation and 
mechanical 
ventilation)Permanently discontinue atezolizumab and contact [CONTACT_25290].f
Administer symptomatic treatment.c
Admit patient to ICU and initiate hemodynamic monitoring, 
mechanical ventilation, and/or IV fluids and vasopressors as needed.  
Monitor other organ function closely.  Manage constitutional 
symptoms and organ toxicities as per institutional practice.
Rule out other inflammatory conditions that can mimic CRS 
(e.g., sepsis).  If no improvement within 24 hours, initiate workup and 
assess for signs and symptoms of HLH or MAS as described in this 
appendix.
Administer IV corticost eroids (e.g., methylprednisolone 2 mg/kg/day or 
dexamethasone 10 mg every 6 hours).
Consider anti -cytokine therapy.e  For patients who are refractory to 
anti-cytokine therapy, experimental treatmentsgmay be considered at 
the discretion of the investigat or and in consultation with the Medical 
Monitor.
Hospi[INVESTIGATOR_70078].
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
204/Protocol GO29438, Version 7Table 7 Management Guidelines for Infusion- Related Reactions and 
Cytokine -Release Syndrome (cont.)
ASTCT American Society for Transplantation and Cellular Therapy; BiPAP bi-level 
positive airway pressure; CAR chimeric antigen receptor; CPAP continuous positive airway 
pressure; CRScytokine -release syndrome; CTCAE Common Terminology Criteria for 
Adverse Events; eCRF electronic Case Report Form; HLH hemophagocytic 
lymphohistiocytosis; ICUintensive care unit; IRRinfusion -related reaction ; 
MAS macrophage activation syndrome; NCCN National Cancer Comprehensive Network; 
NCINational Cancer Institute .
Note:  The management guidelines have been adapted from NCCN guidelines for management 
of CAR T -cellrelated toxicities (Version 2.2019).
aGrading system for management guidelines is based on ASTCT consensus grading for CRS.  
NCI CTCAE v4.0 should be used when reporting severity of IRRs, CRS, or organ toxicities 
associated with CRS on the Adverse Event eCRF.  Organ toxicities associated with CRS 
should not influence overall CRS grading.
bFever is defined as temperature 38C not attributable to any other cause.  In pati ents who 
develop CRS and then receive anti -pyretic, anti -cytokine, or corticosteroid therapy, fever is 
no longer required when subsequently determining event severity (grade).  In this case, the 
grade is driven by [CONTACT_70194]/or hypoxia .
cSymptomatic treatment may include oral or IV antihistamines, anti -pyretics, analgesics, 
bronchodilators, and/or oxygen.  For bronchospasm, urticaria, or dyspnea, additional 
treatment may be administered as per institutional practice.
dLow flow is defi ned as oxygen delivered at 6 L/min, and high flow is defined as oxygen 
delivered at 6 L/min.
eThere are case reports where anti -cytokine therapy has been used for treatment of CRS with 
immune checkpoint inhibitors (Rotz et al. 2017; Adashek and Feldman 2019), but data are 
limited, and the role of such treatment in the setting of antibody -associated CRS has not 
been established.
fResumption of atezolizumab may  be considered in patients who are deriving benefit and have 
fully recovered from the event.  Patients can be re -challenged with atezolizumab only after 
approval has been documented by [CONTACT_33494] (or an appropriate delegate) and the 
Medical Monitor.  For subsequent infusions, administer oral premedication with 
antihistamines, anti -pyreti cs, and/or analgesics, and monitor closely for IRRs and/or CRS.  
Premedication with corticosteroids and extending the infusion time may also be considered 
after consulting the Medical Monitor and considering the benefit risk ratio.
gRefer to Riegler et al. (2019) for information on experimental treatments for CRS.
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
205/Protocol GO29438, Version 7PANCRE ATIC EVENTS
Symptoms of abdominal pain associated with elevations of amylase and lipase, 
suggestive of pancreatitis, have been associated with the administration of atezolizumab.  
The differential diagnosis of acute abdominal pain should include pancreatitis.  
Appropr iate work -up should include an evaluation for ductal obstruction, as well as 
serum amylase and lipase tests.  Management guidelines for pancreatic events, 
including pancreatitis, are provided in Table 8 .
Table 8 Management Guidelines for Pancreatic Events, Including 
Pancreatitis 
Event Management
Amylase and/or lipase 
elevation, Grade 2Continue atezolizumab.
Monitor am ylase and lipase weekly.
For prolonged elevation (e.g., 3 weeks), consider treatment 
with 10 mg /day oral prednisone or equivalent.
Amylase and/or lipase 
elevation, Grade 3 or 4Withhold atezolizumab for up to 12 weeks after event onset .a
Refer patient to GI specialist.
Monitor am ylase and lipase every other day.
If no improvement, consider treat ment with 1 2mg/kg/day 
oral prednisone or equivalent.
If event resolves to Grade 1 or better, resume 
atezolizumab.b
If event does not resolve to Grade [ADDRESS_76448] Medical Monitor.c
For recurrent events, p ermanently discontinue atezolizumab 
and contact [CONTACT_25290].c
GIgastrointestinal.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event onset) 
to allow for corticosteroids (if in itiated) to be reduced to  10 mg/day oral prednisone or 
equivalent.  The acceptable length of the extended period of time must be agreed upon by 
[CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 10 mg/day  
oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor. 

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
206/Protocol GO29438, Version 7Table 8Management Guidelines for Pancreatic Events, Including 
Pancreatitis (cont.)
Event Management
Immune -mediated
pancreatitis, Grade 2 or 3Withhold atezolizumab for up to 12 weeks after event onset .a
Refer patient to GI specialist.
Initiate treatment with 1 2 mg/kg/day IV methylprednisolone 
or equivalent and convert to 1 2mg/kg/day oral prednisone 
or equivalent upon improvement.
If event resolves to Grade 1 or better, resume 
atezolizumab.b
If event does not resolve to Grade [ADDRESS_76449] Medical Monitor.c
For recurrent events, p ermanently discontinue atezolizumab 
and contact [CONTACT_25290].c
Immune -mediated
pancreatitis, Grade 4Permanently discontinue atezolizumab and contact [CONTACT_31807].c
Refer patient to GI specialist.
Initiate treatment with 1 2 mg/kg/day IV methylprednisolone 
or equivalent and convert to 1 2mg/kg/day oral prednisone 
or equivalent upon improvement.
If event does not improve within 48 hours after initiating 
corticosteroids, consider ad ding an immunosuppressive 
agent.
If event resolves to Grade 1 or better , taper corticosteroids 
over  1 month.
GIgastrointestinal.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to 10 mg/day oral prednisone or 
equivalent.  The acceptable length of the extended period of time must be agreed upon by 
[CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 10mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have fully rec overed from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor. 
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
207/Protocol GO29438, Version 7DERMA TOLOGIC EVENTS
Treatment -emergent rash has been associated with atezolizumab.  The majority 
ofcases of rash were mild in severity and self limited, with or without pruritus.  
Adermatologist should evaluate persistent and/or severe rash or pruritus.  A biopsy 
should be considered unless contraindicated.  Management guidelines for dermatologic 
events are provided in Table 9.
Table 9Management Guidelines for Dermatologic Events
Event Management
Dermatologic 
event, Grade 1 Continue atezolizumab.
Consider treatment with topi[INVESTIGATOR_33423]/or other 
symptomatic therapy (e.g., antihistamines).
Dermatologic 
event, Grade 2 Continue atezolizumab.
Consider patient referral to dermatologist.
Initiate treatment with topi[INVESTIGATOR_33424].
Consider treatment with higher -potency topi[INVESTIGATOR_33425].
Dermatologic 
event, Grade 3 Withhold atezolizumab for up to 12 weeks after event onset .a
Refer patient to dermatologist.
Initiate treatment with 10 mg/da y oral prednisone or equivalent, 
increasing dose to 1 2 mg/kg/day if event does not improve 
within 48 72 hours.
If event resolves to Grade 1 or better, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76450] Medical Monitor.c
Dermatologic 
event, Grade 4Permanently discontinue atezolizumab and contact [CONTACT_31807].c
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day 
oral prednisone or equivalent.  The acceptable length of the extended period of time 
must be agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 
10mg/day oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving 
benefit and have fully recovered from the immune -mediated event.  Patients can be 
re-challenged with atezolizumab only after approval has been documented by [CONTACT_33497] (or an appropriate delegate) and the Medical Monitor. 

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
208/Protocol GO29438, Version 7NEUROLOGIC DISORDERS
Myasthenia gravis and Guillain -Barré syndrome have been observed with single -agent 
atezolizumab.  Patients may present with signs and symptoms of sensory and/or motor 
neuropathy.  Diagnostic work -up is essential for an accurate charact erization to 
differentiate between alternative etiologies.  Management guidelines for neurologic 
disorders are provided in Table 10 .
Table 10Management Guidelines for Neurologic Disorders
Event Management
Immune -mediated
neuropathy, 
Grade 1Continue atezolizumab.
Investigate etiology.
Immune -mediated
neuropathy, 
Grade 2 Withhold atezolizumab for up to 12 weeks after event onset .a
Investigate etiology.
Initiate treatment as per institutional guidelines.
If event resolves to Grade 1 or better, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76451] Medical Monitor.c
Immune -mediated
neuropathy, 
Grade 3 or 4Permanently discontinue atezolizumab and contact [CONTACT_31807].c 
Initiate treatment as per institutional guidelines.
Myasthenia gravis 
and Guillain- Barré 
syndrome 
(any grade)Permanently discontinue atezolizumab and contact [CONTACT_31807].c
Refer patient to neu rologist.
Initiate treatment as per institutional guidelines.
Consider initiation of 1 2 mg/kg/day oral or IV prednisone or 
equivalent.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to 10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must 
be agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to 
10mg/day oral prednisone or equivalent before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving 
benefit and have fully rec overed from the immune -mediated event.  Patients can be 
re-challenged with atezolizumab only after approval has been documented by [CONTACT_33497] (or an appropriate delegate) and the Medical Monitor. 

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
209/Protocol GO29438, Version 7IMMUNE -MEDIATED MENINGOENCEPHA LITIS
Immune -mediated meningoencephalitis is an identified risk associated with the 
administration of atezolizumab.  Immune -mediated meningoencephalitis should be 
suspected in any patient presenting with signs or symptoms suggestive of meningitis or 
encephalitis, including, but not limited to, headache, neck pain, confusion, seizure, motor 
or sensory dysfunction, and altered or depress ed level of consciousness.  
Encephalopathy from metabolic or electrolyte imbalances needs to be distinguished from 
potential meningoencephalitis resulting from infection (bacterial, viral, or fungal) or 
progression of malignancy, or secondary to a paraneoplastic process.  
All patients being considered for meningoencephalitis should be urgently evaluated with 
a CT scan and/or MRI scan of the brain to evaluate for metastasis, inflammation, or 
edema.  If deemed safe by [CONTACT_1963], a lumbar punctur e should be 
performed and a neurologist should be consulted.
Patients with signs and symptoms of meningoencephalitis, in the absence of an 
identified alternate etiology, should be treated according to the guidelines in Table 11.
Table 11Management Guidelines for Immune -Mediated
Meningoencephalitis
Event Management
Immune -mediated
meningoencephalitis, 
all gradesPermanently discontinue atezolizumab and contact [CONTACT_25290].a
Refer patient to neurologist.
Initiate treatment with 1 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1 2mg/kg/day oral prednisone or 
equivalent upon improvement.
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.
If event resolves to Grade 1 or better , taper corticosteroids over 
1month.
aResumption of atezolizumab may  be considered in patients who are deriving benefit and have 
fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor.
RENA L EVENTS
Immune -mediated nephritis has been associated with the administration of atezolizumab.  
Eligible patients must have adequate renal function .Renal function, including serum 
creatinine, should be monitored throughout study treatment.  Patients with abnormal 
renal function should be evaluated and treated for other more common etiologies 

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
210/Protocol GO29438, Version 7(including prerenal and postrenal causes, and concomitant medications such as 
non-steroidal anti -inflammatory drugs).  Refer the patient to a renal specialist if clinically 
indicated.  A re nal biopsy may be required to enable a definitive diagnosis and 
appropriate treatment.
Patients with signs and symptoms of nephritis, in the absence of an identified alternate 
etiology, should be treated according to the guidelines in Table 12 .
Table 12Management Guidelines for Renal Events 
Event Management
Renal event, 
Grade 1Continue atezolizumab.
Monitor kidney function, including creatinine, closely until 
values resolve to within normal limits or to baseline values. 
Renal event, 
Grade 2Withhold atezolizumab for up to 12 weeks after event onset. a
Refer patient to renal specialist.
Initiate treatment with corticosteroids equivalent to 
12mg/kg/day oral prednisone.
If event resolves to Grade 1 or better, resume atezol izumab.b
If event does not resolve to Grade [ADDRESS_76452] Medical Monitor.c
Renal event, 
Grade 3 or 4Permanently discontinue atezolizumab and contact [CONTACT_31807]. 
Refer patient to renal specialist and consider renal biopsy.
Initiate treatment with corticosteroids equivalent to 
12mg/kg/day oral prednisone.
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.
If event resolves to Grade 1 or better, taper corticosteroids over 
1 month.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to the equivalen t 
of 10mg/day oral prednisone.  The acceptable length of the extended period of 
time must be agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to the 
equivalent of 10mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving 
benefit and have fully recovered from the immune -mediated event.  Patients can be 
re-challenged with atezolizumab only after approval has been documented by [CONTACT_33497] (or an appropriate delegate) and the Medical Monitor. 

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
211/Protocol GO29438, Version 7IMMUNE -MEDIATED MYOS ITIS
Immune -mediated myositis has been associated with the administration of atezolizumab.  
Myositis or inflammatory myopathies are a group of disorders sharing the common 
feature of inflammatory muscle injury; dermatomyositis and polymyositis are among 
the most common disorders.  Initial diagnosis is based on clinical (muscle weakness, 
muscle pain, skin rash in dermatomyositis), biochemical (serum creatine kinase 
increase), and imaging (electromyography/MRI) features, and is confirmed with a 
muscle biopsy.
Patients with signs and symptoms of myositis, in the absence of an identified alternate 
etiology, should be treated according to the guidelines in Table 13.
Table 13Management Guidelines for Immune -Mediated Myositis
Event Management
Immune -mediated 
myositis, Grade 1Continue atezolizumab.
Refer patient to rheumatologist or neurologist. 
Initiate treatment as per institutional guidelines.
Immune -mediated 
myositis, Grade 2Withhold atezolizumab for up to [ADDRESS_76453] Medical Monitor.
Refer patient to rheumatologist or neurologist.
Initiate treatment as per institutional guidelines.
Consider treatment with corticosteroids equivalent to 
12mg/kg/day IV methylprednisolone and convert to 
12mg/kg/day oral prednisone or equivalent upon improvement.
If cor ticosteroids are initiated and event does not improve within 
48hours after initiating corticosteroids, consider adding an 
immunosuppressive agent.
If event resolves to Grade 1 or better, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76454] 
Medical Monitor.c
aAtezolizumab may be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to the equivalent of 
10mg/day oral prednisone.  The acceptable length of the extended period of time must 
be agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to the 
equivalent of 10mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor. 

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
212/Protocol GO29438, Version 7Table 13Management Guidelines for Imm une-Mediated Myositis (cont.)
Immune -mediated 
myositis, Grade 3Withhold atezolizumab for up to [ADDRESS_76455] Medical Monitor.
Refer patient to rheumatologist or neurologist.
Initiate treatment as per institutional guidelines.
Respi[INVESTIGATOR_70079].
Initiate treatment with corticosteroids equivalent to 1 2mg/kg/day 
IV methylprednisolone, or higher -dose bolus if patient is severely 
compromised (e.g., cardiac or respi[INVESTIGATOR_1856], dysphagia, or 
weakness that severely limits mobility); convert to 1 2mg/kg/day 
oral prednisone or equivalent upon improvement.
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.
If event resolves t o Grade 1 or better, resume atezolizumab.b
If event does not resolve to Grade [ADDRESS_76456] 
Medical Monitor.c
For recurrent events, treat as a Grade 4 event.
Immune -mediated 
myositis, Grade 4Permanently discontinue atezolizumab and contact [CONTACT_31807].c
Refer patient to rheumatologist or neurologist.
Initiate treatment as per institutional guidelines.
Respi[INVESTIGATOR_70079].
Initiate tre atment with corticosteroids equivalent to 1 2mg/kg/day 
IV methylprednisolone, or higher -dose bolus if patient is severely 
compromised (e.g., cardiac or respi[INVESTIGATOR_1856], dysphagia, or 
weakness that severely limits mobility); convert to 1 2mg/kg/day 
oral prednisone or equivalent upon improvement.
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.
If event resolves to Grade 1 or better, taper corticosteroids over 
1month.
aAtezolizumab may be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to the equivalent of 
10mg/day oral prednisone.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].
bIf corticosteroids have been initiated, they must be tapered over 1 month to the 
equivalent of 10mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor. 
Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
213/Protocol GO29438, Version 7HEMOPHAGOCYTIC LYMPH OHISTIOCYTOSIS AND M ACROPHAGE 
ACTIVATION SYNDROME
Immune -mediated reactions may involve any organ system and may lead to 
hemophagocytic lymphohistiocytosis (HLH) and macrophage activation sy ndrome 
(MAS), which are considered to be potential risks for atezolizumab.  
Patients with suspected HLH should be diagnosed according to published criteria by 
[CONTACT_70195] (2014).  A patient should be classified as having HLH if five of 
the following eight criteria are met:
 Fever 38.5°C
 Splenomegaly
 Peripheral blood cytopenia consisting of at least two of the following:
– Hemoglobin 90g/L (9 g/dL) ( 100 g/L [10 g/dL] for infants 4 weeks old)
– Platelet count 100109/L (100,000/ L)
– ANC 1.0109/L (1000/ L)
 Fasting triglycerides 2.992 mmol/L (265 mg/dL) and/or fibrinogen 1.5g/L 
(150 mg/dL)
 Hemophagocytosis in bone marrow, spleen, lymph node, or liver
 Low or absent natural killer cell activity
 Ferritin 500 mg/L (500 ng/mL)
 Soluble interleukin 2 (IL -2) receptor (soluble CD25) elevated [ADDRESS_76457] 
deviations above age -adjusted laboratory -specific norms
Patients with suspected MAS should be diagnosed according to published criteria for 
systemic juvenile idiopathic arthritis by [CONTACT_70196]. (2016).  A febrile patient should 
be classified as having MAS if the following criteria are met:
 Ferritin 684 mg/L (684 ng/mL)
 At least two of the following:
– Platelet count 181109/L (181,000/ L)
– AST 48U/L
– Triglycerides 1.761 mmol/L (156 mg/dL)
– Fibrinogen 3.6g/L (360 mg/dL)
Patients with suspected HLH or MAS should be treated according to the guidelines in 
Table 14.

Appendix 15
Risks A ssociated with A tezolizumab and Guidelines for Management 
of Adverse Events A ssociated w ith A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
214/Protocol GO29438, Version 7Table 14Management Guidelines for Suspected Hemophagocytic 
Lymphohistiocytosis or Macrophage Activation Syndrome
Event Management
Suspected HLH 
or MASPermanently discontinue atezolizumab and contact [CONTACT_31807].
Consider patient referral to hematologist.
Initiate supportive care, including intensive care monitoring if 
indicated per institutional guidelines.
Consider initiation of IV corticosteroids and/or an 
immunosuppressive agent.
If event does not improve withi n 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.
If event resolves to Grade 1 or better, taper corticosteroids over 
1month.
HLH hemophagocytic lymphohistiocytosis; MAS macrophage activation syndrome.
REFERENCES
Adashek ML, Feldman M. Cytokine release syndrome resulting from anti programmed 
death -1 antibody: raising awareness among community oncologist. J Oncol 
Practice 2019;15:502 4.
McClain KL, Eckstein O. Clinical features and diagnosis of hemophagocytic 
lymphohistiocytosis. Up to Date [resource on the Internet]. 2014 [updated 
29October 2018; cited: 17 May 2019]. Available from: 
https://www.uptodate.com/contents/clinical -features -and- diagnosis -of-
hemophagocytic -lymphohistiocytosis .
Ravelli A, Minoia F, Davi S, et al. 2016 classification criteria for macrophage 
activ ation syndrome complicating systemic juvenile idiopathic arthritis: a 
European League Against Rheumatism/American College of 
Rheumatology/Paediatric Rheumatology International Trials Organisation 
Collaborative Initiative. Ann Rheum Dis 2016;75:481 9.
Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of 
cytokine release syndrome after chimeric antigen receptor T -cell therapy. Ther 
Clin Risk Manag 2019;15:323 35.
Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndr ome in a patient 
receiving PD -1-directed therapy. Pediatr Blood Cancer 2017;64:e26642.